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Cardiovascular diseases are the leading cause of death worldwide, accounting 
for 30.5 percent of total deaths [1]. In the European Union alone, the economic 
burden of cardiovascular disease is about €192 billion annually considering both 
direct and indirect healthcare costs [2]. Adequate prediction and efficient treat-
ment of cardiovascular diseases are therefore important health issues. It is well 
appreciated that cardiovascular diseases are multifactorially determined [3]. Some 
factors such as age and gender are unmodifiable in contrast to lifestyle factors such 
as tobacco consumption, poor dietary habits and low levels of exercise, as well as 
dyslipidaemia and hypertension.
In the early 1950s the Framingham Heart Study was the first to show that a 
high serum total cholesterol results is associated with an increased risk of cardio-
vascular events [4]. Many other prospective studies have been carried out aimed 
at evaluating the relationship of incident cardiovascular disease with specific lipo-
proteins and apolipoproteins (apo’s) [5-7]. Moreover, when Friedewald described 
a formula to estimate the low density lipoprotein (LDL) cholesterol concentration, 
which is calculated by using the total cholesterol, high density lipoprotein (HDL) 
cholesterol and the triglyceride concentration, it became possible to determine the 
risk attributable to this specific lipoprotein fraction without the use of laborious 
and expensive procedures such as separation of lipoproteins by ultracentrifugation 
[8]. In this regard it is also important that the apparently cardioprotective effect of 
a high HDL cholesterol was described for the first time in 1977 [9].
In 1984 the Lipid Research Clinics Coronary Primary Prevention trial was the 
first to demonstrate that lowering LDL cholesterol with colestyramine decreased 
the risk of coronary heart disease, thereby supporting the so-called cholesterol 
hypothesis [10]. Since then, many large scale studies have demonstrated vascular 
benefit of hydroxymethylglutaryl coenzyme A (HMGCoA) reductase inhibitors, also 
known as statins. As a consequence, statin therapy is considered as first line drug 
treatment in subjects at high risk of (recurrent) cardiovascular disease, although 
international and national guidelines are still changing [3, 11-13]. It is important 
to note that only 30-70% of patients reach target lipid levels according to current 
guidelines [3,11-14]. Furthermore, there is a clear need for additional pharma-
cological therapies to optimize cardiovascular protection, since there remains a 
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considerable residual cardiovascular risk even during intensive statin treatment 
[15]. As a consequence, much effort is still being paid to the development of new 
drugs which are either aimed either at further lowering LDL cholesterol or at rais-
ing HDL cholesterol, in the expectation that higher HDL cholesterol levels would 
translate in cardiovascular benefit [16-18]. Of special interest in this area is the role 
of cholesteryl ester transfer protein (CETP). This lipid transfer protein has the abil-
ity to transfer neutral lipids (cholesteryl esters and triglycerides) between plasma 
lipoproteins. As a consequence, CETP decreases cholesteryl esters in HDL and 
increases the cholesteryl ester content in apoB-containing lipoproteins. Whether 
plasma CETP levels infer or associate with cardiovascular risk has not been un-
equivocally established [19-21]. In addition, a better identification of individuals 
who are still at high-risk of (recurrent) cardiovascular disease despite lipid lowering 
drug treatment would help to identify those who would most benefit from ad-
ditional pharmacological intervention.
It is increasingly recognized that besides LDL, other apoB100-containing li-
poproteins, such as intermediate density lipoproteins (IDL) and very low density 
lipoproteins (VLDL) bear atherogenic potential [22-25]. This would imply that for 
an appropriate assessment of cardiovascular risk these lipoproteins should also be 
considered together with LDL cholesterol and HDL cholesterol. Thus, the choles-
terol content of atherogenic lipoproteins is reflected by the non-HDL-cholesterol-
concentration, which is calculated as the total cholesterol concentration minus the 
HDL cholesterol concentration. In addition, the level of atherogenic lipoproteins 
can be estimated by measuring the apoB concentration (LDL, IDL or VLDL particles 
contain one apoB100 molecule each [7, 26]), whereas HDL particles contain a vari-
able number of apoA-I molecules [7, 27]. In reducing the risk of cardiovascular 
disease it is paramount to appropriately identify the individuals at high risk of 
developing cardiovascular disease. To this end several risk stratification systems 
and scores have been developed [28, 29]. Areas of uncertainty include i) whether 
cardiovascular risk is better predicted by apoB, non-HDL cholesterol or LDL choles-
terol concentrations and ii) whether the ratio of total cholesterol/HDL cholesterol, 
being equivalent to the non-HDL cholesterol/HDL cholesterol ratio, or the apoB/




Aims of this thesis
The central objectives of this thesis are i) to determine cardiovascular risk in the 
context of lipid and non-lipid risk markers, and ii) to establish the extent to which 
lipid and (apo)lipoprotein risk markers, and their proposed treatment targets are 
modified in response to lipid lowering treatment.
outline of this thesis
Part A will consider lipoproteins, apolipoproteins their ratios and the risk of cardio-
vascular disease they infer. In this section, we will also consider the association of 
(genetic variation in) CETP, and of adipokines with (sub)clinical atherosclerosis. Part 
B will focus on the effects of lipid lowering treatment on various (apo)lipoproteins.
PArt A
(Apo)lipoproteins, cholesteryl ester transfer protein, adipokines and risk of 
cardiovascular disease: prospective and cross sectional studies
In chapter 2 we investigate whether the ratios of total cholesterol/HDL cholesterol 
and apoB/ apoA-I are superior markers for predicting cardiovascular events, com-
pared to traditional lipid markers. We hypothesized that these ratios of pro-ath-
erogenic to anti-atherogenic (apo)lipoproteins would perform better than single 
measures of atherogenic lipoproteins. We also investigate whether this prediction 
of risk would be influenced by other novel risk markers such as albuminuria and 
C-reactivity protein. This study is performed among participants of the population-
based prevention of renal and vascular end-stage disease (PREVEND) cohort.
In chapter 3 we review the CETP pathway in lipid metabolism and discuss 
pharmacological inhibition of CETP. CETP has the ability to transfer cholesteryl 
esters from HDL toward apoB-containing lipoproteins, thereby decreasing HDL 
cholesteryl esters and increasing the cholesteryl ester content in apoB-containing 
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lipoproteins. Despite a robust rise of the HDL cholesterol concentration the first 
CETP inhibitor, torcetrapib, failed to reduce cardiovascular risk in patients at high 
cardiovascular risk [32]. In this chapter we discuss the possible explanations for the 
failure of torcetrapib, and review two other CETP inhibitors that are being tested in 
order to determine whether raising HDL cholesterol by inhibiting CETP translates 
in cardiovascular risk reduction.
In chapter 4 we investigate whether common genetic variations in CETP modify 
the predictive value of the aforementioned total cholesterol/HDL cholesterol and 
apoB/apoA-I ratios. These common variations are known to be consistently associ-
ated with CETP mass and activity [33]. We tested whether common variations in 
CETP may influence the association of the total cholesterol/ HDL cholesterol and 
the apoB/apoA-I ratio with prospectively determined first major cardiovascular 
events. These analyses are performed in the PREVEND study population.
In chapter 5 we set out to determine whether it is the plasma CETP mass or the 
plasma cholesteryl ester transfer rate which may predict cardiovascular disease 
risk. In view of the previous data [34-36], we hypothesized that plasma cholesteryl 
ester transfer would be more closely associated with cardiovascular disease risk 
than CETP mass.
In chapter 6 we explore the prognostic value of two adipocyte derived hormones, 
leptin and adiponectin for cardiac events in men. Leptin is primarily involved in 
the regulation of food intake and energy expenditure. Leptin is considered to have 
important atherogenic effects, and its plasma concentration is elevated in obese 
individuals [37]. In contrast, adiponectin is known to have effects on pathways 
that may inhibit the development of atherosclerosis. Levels of adiponectin are 
decreased in obesity and diabetes mellitus [38]. High leptin levels are known to be 
associated with increased risk of first cardiac events, whereas adiponectin is known 
to have a cardioprotective effect. We hypothesized that the leptin to adiponectin 
ratio would predict cardiac events better than these separate adipokine measures.
Chapter 7 describes the relation of carotid intima media thickness, a well-known 
predictor of cardiovascular disease with adiponectin and the leptin/adiponectin 





Lipid lowering intervention studies
Lipid lowering treatment is an important measure in cardiovascular disease pre-
vention. Several guideline targets have been proposed for total cholesterol, LDL 
cholesterol, HDL cholesterol, non-HDL-cholesterol and apoB [2, 39, 40]. Whether 
the relationships between these separate predictors change and to which extent 
when therapy is initiated is of great clinical relevance in determining the optimal 
dosage of lipid lowering treatment.
In chapter 8 we investigate the relationship of LDL cholesterol and non-HDL 
cholesterol with apoB and the extent to which this relationship changes after ator-
vastatin administration. This study is conducted among participants of the DALI 
study cohort comprising hypertriglyceridaemic individuals with type 2 diabetes 
mellitus, a population at high risk of developing cardiovascular disease.
In chapter 9 we study LDL size and remnant particles in the same population 
as in the previous chapter. Small dense LDL particles and remnant particles have 
been linked to increased risk of atherosclerosis [41-44]. We investigate the effect 
of atorvastatin treatment on LDL particle size and remnant-like particle cholesterol.
Chapter 10 describes a study concerning apolipoprotein M. ApoM is mainly 
expressed in the liver and kidney [45]. In human plasma it is located predominantly 
in the HDL fraction and to a lesser extent in LDL [46]. In murine models apoM may 
retard atherosclerosis development [45, 47-49]. Although apoM regulation may be 
intricately related to cholesterol metabolism, little is known about the effects of 
lipid lowering treatment on plasma apoM. We hypothesize that the plasma level 
of apoM might be decreased upon administration of statins or fibrates in patients 
with type 2 diabetes mellitus.
In Chapter 11 we investigate the relationship between apoM and proprotein 
subtilisin-kexin type 9 (PCSK9). PCSK9 has a key role in LDL receptor regulation. 
PCSK9 binds to the LDL receptor, the primary conduit for the removal of LDL from 
the circulation, and directs it towards intracellular degradation. The PCSK9 pathway 
thus prevents LDL receptor recycling to the cell surface, and contributes to higher 
circulating LDL cholesterol [50]. Accordingly, plasma apoB-containing lipoproteins 
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levels are correlated positively with the PCSK9 concentration [50, 51]. Against this 
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Apolipoprotein B/A-I and total cholesterol/HDL 
cholesterol ratios both predict cardiovascular events 
in the general population independently of non-lipid 
risk factors, albuminuria and CRP
P.J.W.H. Kappelle, R.T. Gansevoort, J.L. Hillege, B.H.R. Wolffenbuttel, R.P.F. Dullaart
on behalf of the PREVEND study group




Background The total cholesterol/HDL cholesterol and apolipoprotein B/A-I ratio 
predict major adverse cardiovascular events (MACE). The extent to which these 
associations are modified by high sensitivity C-reactive protein (hs-CRP) and 
albuminuria is largely unknown. We compared the strength of these ratios with 
first MACE in the general population, and determined whether these associations 
remain when taking account of these risk markers.
subjects and methods A prospective case-cohort study was performed among 
6948 subjects (PREVEND cohort) without previous cardiovascular disease and who 
did not use lipid lowering drugs initially. Fasting serum total cholesterol (TC), LDL 
cholesterol, HDL cholesterol (HDL-C), non-HDL cholesterol, apoB, apoA-I, triglycer-
ides, hs-CRP and albuminuria were measured at baseline. The composite endpoint 
was incident MACE.
results 362 first cardiovascular events occurred during 7.9 years of follow-up. All 
pro- and anti-atherogenic measures of lipoproteins and apos predicted MACE in 
age-and sex-adjusted Cox proportional hazard analyses (p=0.018 to p<0.001). The 
age-and sex-adjusted hazard ratio (HR) was 1.37 (95 % CI, 1.26-1.48) for the apoB/
apoA-I ratio and 1.24 (95 %, 1.18-1.29) for the TC/HDL-C ratio (both p<0.001). These 
relationships were essentially unaltered after additional triglyceride adjustment. 
Pair-wise comparison revealed that these ratios performed similar in age- and 
sex-adjusted analysis (p=0.397). The HRs of apoB/apoA-I (p<0.001) and TC/HDL-C 
(p<0.001) were only marginally attenuated by additional controlling for traditional 
risk factors (hypertension, diabetes, obesity, smoking), hs-CRP and albuminuria.
Conclusions First MACE is associated with both the fasting serum apoB/apoA-I ratio 
and the TC/HDL-C ratio in the general population, independently of triglycerides, 
hs-CRP and albuminuria.
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Apolipoprotein B/A-I and total cholesterol/HDL cholesterol ratios both predict cardiovascular events
2
introduCtion
Cardiovascular diseases represent major causes of morbidity and mortality world 
wide [1], and lipoprotein abnormalities play a central role in its multifactorial 
pathogenesis [2]. Guidelines have traditionally advocated that the low density 
lipoprotein cholesterol (LDL-C) concentration represents the primary target for 
lipid lowering intervention [2]. However, there is growing awareness that all apoli-
poprotein B (apoB)-containing lipoproteins bear atherogenic potential [3-6]. Thus 
besides LDL-C, the cholesterol concentration in the combined LDL, intermediate 
density lipoprotein (IDL) and very low density lipoprotein (VLDL) fractions, collec-
tively measured as non-HDL cholesterol (non-HDL-C), as well as the serum apoB 
concentration are now considered as equivalent rather than a secondary target 
to initiate lipid lowering treatment [7-9]. In addition, it is well appreciated that 
the risk of cardiovascular disease is inversely related to high density lipoprotein 
cholesterol (HDL-C) of which apolipoprotein A-I (apoA-I) is the most abundant 
apolipoprotein [2,10].
Several cross-sectional and prospective studies have evaluated the strength 
of the relationships of prevalent and incident cardiovascular disease with single 
pro-atherogenic (apo)lipoprotein measures, as well as with ratios of lipoprotein 
cholesterol, such as the non-HDL-C/HDL-C ratio (equivalent to the total choles-
terol (TC)/HDL-C ratio), and the apoB/apoA-I ratio [1,3-6,11-16]. The ratios of 
pro-atherogenic to anti-atherogenic (apo)lipoproteins are likely to perform better 
than single measures of atherogenic lipoprotein cholesterol [1,3,4,12-14,16], but 
it is uncertain whether the apoB/apoA-I ratio is to be preferred over lipoprotein 
cholesterol ratios in cardiovascular disease prediction in the general population. A 
recent meta-analysis by the Emerging Risk Factors Collaboration showed a similar 
hazard of cardiac and cerebral vascular events attributable to the non-HDL-C/HDL-
C ratio compared to the apoB/apoA-I ratio [17], in apparent contrast with other 
studies [3,14]. Both earlier reports have accounted for traditional risk factors and 
serum triglycerides, whereas in the EPIC-Norfolk study high sensitive C-reactive 
protein (hs-CRP)] was also taken into consideration [14,17]. Importantly, it is un-
known whether the relationship of incident cardiovascular disease with lipoprotein 
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cholesterol and apolipoprotein ratios is affected by other novel risk markers, such 
as elevated urinary albumin excretion [18,19].
The present study was initiated to determine the strength of associations of 
major adverse cardiovascular events (MACE) with fasting serum lipoprotein cho-
lesterol, apolipoproteins and their ratios in the population-based Prevention of 
Renal and Vascular End-stage Disease (PREVEND) cohort. The focus of PREVEND on 
the role of elevated urinary albumin excretion and inflammation for progression of 
renal and cardiovascular disease, gave us the opportunity to examine the extent 
to which the relationship of MACE with (apo)lipoprotein measures is modified by 
serum hs-CRP and albuminuria.
2 mAteriAls And methods
2.1 Study population
This study was carried out among subjects who participated in the PREVEND study. 
This prospective cohort study started in 1997. This prospective cohort study in-
vestigates the natural course of urinary albumin excretion and its relation to renal 
and cardiovascular disease in a predominantly Caucasian population. Details of the 
study protocol have been published elsewhere [20]. In summary, all inhabitants of 
the city of Groningen aged 28 to 75 years were sent a questionnaire and a vial to 
collect a first-morning-void urine sample (prescreening). Of these subjects, 40,856 
responded (47.8%) and returned a vial to a central laboratory for urinary albumin 
and creatinine assessment. After exclusion of patients with insulin-treated diabetes 
mellitus and pregnant women, all subjects with a urinary albumin concentration 
of ≥10 mg/l (n = 7,768) were invited, and 6,000 participated. Furthermore, 3,394 
randomly selected subjects with a urinary albumin concentration of <10 mg/l were 
invited, and 2,592 participated. These 8,592 subjects participated in the baseline 
screening and constitute the actual PREVEND cohort. For the present study, we first 
excluded participants who were non-fasting at first blood draw (n=428), subjects 
with a prior history of cardiovascular disease (n=426) and those who used lipid 
lowering drugs (n=238). Finally, we excluded those remaining subjects with missing 
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values of one of the following variables: cholesterol, triglycerides, HDL-C, apoA-I, 
apoA-II or apoB (n=552), eventually leaving 6,948 subjects for present analysis. The 
PREVEND study was approved by the institutional review board of our institution 
and is conducted in accordance with the guidelines of the declaration of Helsinki. 
All participants signed informed consent.
2.2 Baseline measurements and definitions
Participants underwent two visits at the outpatient research unit for the baseline 
survey. They completed a questionnaire on demographics, cardiovascular disease 
history, smoking habits, alcohol consumption and medication use prior to their first 
visit. Height and weight were measured on the first visit; body mass index (BMI) 
was calculated as the ratio between weight and height squared (in kg m-2). Obesity 
was defined as BMI ≥30 kg/m2. During both visits blood pressure was measured, in 
supine position, every min for 10 min with an automatic device (Dinamap XL Model 
9300, Johnson-Johnson Medical, Tampa, FL). Blood pressure values are given as 
the mean of the last two recordings of both visits; hypertension was defined as 
systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at least 
90 mm Hg or the use of antihypertensive drugs [21]. The participants collected two 
24h urine samples for measurement of albumin excretion. Microalbuminuria and 
macroalbuminuria were defined as mean urinary albumin excretion between 30 
and 300 mg/24h, and >300 mg/24h, respectively [22]. Participants were instructed 
to remain fasting for at least 8 hr before blood sampling which was done at the sec-
ond visit. Diabetes mellitus was diagnosed by fasting plasma glucose ≥7.0 mmol/l, 
according to 1997 American Diabetes Association criteria [23] or use of glucose 
lowering drugs. Furthermore, information on medication use was checked using 
pharmacy-dispensing data from all community pharmacies in the city of Groningen, 
which covers complete information on drug use in 80% of PREVEND participants.
2.3 Outcome
The primary endpoint of this analysis was first major adverse cardiovascular events 
(MACE), which was defined as the combined endpoint of incident cardiovascular 
morbidity and mortality that occurred during the follow-up of the study. Informa-
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tion (on hospitalization) for cardiovascular morbidity was obtained from PRISMANT, 
the Dutch national registry of hospital discharge diagnoses. Data on mortality were 
received from the municipal register, and cause of death was obtained by linking 
the number of the death certificate to the primary cause of death as coded by the 
Dutch Central Bureau of Statistics. Data were coded according to the International 
Classification of Diseases, 9th revision and the classification of interventions. MACE 
was defined as the following: acute myocardial infarction (ICD-code 410), acute 
and subacute ischemic heart disease (411), occlusion or stenosis of the precere-
bral (433) or cerebral arteries (434) and the following procedures: coronary artery 
bypass grafting or percutaneous transluminal coronary angioplasty, and other 
vascular interventions namely percutaneous transluminal angioplasty or bypass 
grafting of aorta and peripheral vessels. Survival time was defined as the period 
from the baseline survey to the date of a first MACE. Subjects who did not develop 
MACE were censored on December 31st 2005. In case a person moved to an un-
known destination (n=396, overall cohort), census date was date of removal from 
the municipal registry.
2.4 Laboratory Methods
Blood samples were taken after 15 min rest. Plasma glucose was measured shortly 
after blood sampling. Serum samples for lipid and apolipoprotein measurements 
were stored at –80 °C until analysis. Serum total cholesterol (TC) and plasma glucose 
were assessed using Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, 
NY). HDL-C was measured with a homogeneous method (direct HDL, no. 7D67, 
AEROSET System; Abbott Laboratories, Abbott Park, IL) [24]. Serum triglycerides 
were measured enzymatically. LDL-C was calculated with the Friedewald formula 
[25]. Non-HDL-C was calculated as the difference between total cholesterol and HDL 
cholesterol. Serum apoB, apoA-I and apoA-II were determined by nephelometry 
applying commercially available reagents for Dade Behring nephelometer systems 
(BN II; Dade Behring, Marburg, Germany; apo A-I test kit, code no. OUED, apo A-II 
test kit, code no. OQBA, apo B test kit, code no. OSAN) [25]. Reference preparations 
for apoB, apoA-I and apoA-II were IRP SP3-07, BCR-393 and BCR-394, respectively. 
Urinary albumin concentration was determined by nephelometry (Dade Behring 
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Diagnostic). hs-CRP was measured by nephelometry with a threshold of 0.18 mg/l 
(BNII, Dade Behring, Marburg, Germany). The inter- and intra-assay coefficients of 
variations (CVs) of all these assays were well below 5% except for the inter-assay 
CV of hs-CRP which was 5.7%.
2.5 Statistical methods
Analyses were performed using SPSS version 16.0.2 (SPSS Inc., Chicago, IL, USA) 
and Stata SE 11 (StataCorp, College Station, Tx, USA). Normally distributed values 
are presented as mean ± SD with between group differences being tested with 
Student’s t-tests. Variables with a skewed distribution are presented as median 
(inter-quartile range) and between group differences were tested with Mann–
Whitney U-tests. Differences between categorical variables were tested using a 
χ-square test.
Event-free survival time for participants was defined as the period between 
inclusion in the study and MACE. The associations between incidence of MACE 
and (apo)lipoprotein(s) (ratios) were analyzed by Cox proportional hazard analy-
ses. The proportional hazard assumption was assessed for every predictor using 
graphical approaches. Proportional hazard was assumed when the log–log-survival 
curve was found constant over time. The proportional hazards assumption was not 
violated in any model. Hazard ratios (HRs) were reported per SD change for each 
variable with 95% confidence intervals (95% CI). Additional models were also made 
by further controlling for triglycerides, conventional risk factors (hypertension, 
diabetes, obesity and smoking), hs-CRP and albuminuria. Interactions between 
(apo)lipoprotein ratios, hs-CRP and albuminuria on cardiovascular risk were also 
determined. To this end the mean value was subtracted from the measured value 
in order to obtain a distribution centered on the mean, and product terms were 
calculated. These product terms were then included in the models. If a variable had 
a skewed distribution, logarithmically transformed values were used, which was 
the case for triglycerides, hs-CRP and albuminuria. We tested the crude and age- 
and sex- adjusted contributions of different sets of (apo)lipoprotein parameters on 
MACE. Variables were entered pair-wise in the models in order to directly compare 
differences in HR’s by means of Wald statistics.
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Because of the design of the PREVEND study with preferential inclusion of sub-
jects with elevated urinary albumin excretion, sensitivity analyses were performed. 
Analyses were re-done using a complex sample design procedure. In addition, 
sensitivity analyses were performed on the data-set of subjects derived from the 
random sample making part of the PREVEND cohort ([20] and www.PREVEND.org). 
A two-sided p <0.05 indicated statistical significance.
3 results
Total follow up was 52,112 person-years. During a median follow up of 7.9 (inter-
quartile range, 7.5-8.1) years 362 first cases of MACE were documented (6.9 per 
1,000 person-years). Table 1 provides the numbers of first MACE with respect to 
the composite endpoint, and the separate cardiovascular domains in the whole 
cohort, specified for sex.
Table 1. Major adverse cardiovascular events (MACE) by cardiovascular domain and sex
All Men Women
total events 362 255 107
Cardiac event 253 (69.9%) 185 (72.5%) 68 (63.6%)
Cerebrovascular event 85 (23.5%) 51 (20.0%) 34 (31.7%)
Peripheral vascular event 24 (6.6%) 19 (7.5%) 5 (4.8%)
Cardiac events include fatal/non-fatal myocardial infarction, ischemic heart disease, coronary 
artery bypass grafting and percutaneous transluminal coronary angioplasty. Cerebrovascular 
events include fatal/non-fatal occlusion of cerebral arteries, occlusion or stenosis of precere-
bral arteries, subarachnoidal hemorrhage, intracranial hemorrhage, other intracranial hemor-
rhages and carotic artery desobstruction. Peripheral vascular events include aortic peripheral 
bypass surgery and percutaneous transluminal femoral angioplasty (see Methods).
Subjects who experienced an event (cases) were older, more likely to be male and 
smoked more frequently compared to subjects who did not experience an event 
during follow-up (controls) (Table 2). Obesity, diabetes mellitus, hypertension as 
well as micro- and macroalbuminuria were more prevalent among cases. Serum 
TC, LDL-C, non-HDL-C, apoB, the TC/HDL-C and the apoB/apoA-I ratio, as well as 
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triglycerides and hs-CRP levels were higher, whereas HDL-C, apoA-I and apoA-II 
were lower in cases (Table 2). When cases and controls were split by gender, similar 
differences in clinical features, lipids apolipoproteins and their ratios were found 
except for smoking, apoA-I and apoA-II which did not differ significantly between 
female cases and controls (supplementary Table).








men (%) 47.8 70.4 46.6 <0.001
Age (years) 48 +12 60 +11 48 +12 <0.001
obesity (%) 15.2 25.0 14.7 <0.001
hypertension (%) 29.9 64.6 28.0 <0.001
microalbuminuria (%) 12.0 26.5 11.1 <0.001
macroalbuminuria (%) 1.4 4.4 1.2 <0.001
diabetes (%) 2.8 5.3 2.1 <0.001
Alcohol use (%) 25.7 26.7 25.6 0.657
smoking status(%) never 30.3 16.0 31.0 <0.001
former smoker 35.8 39.0 35.5
Current 33.9 45.0 33.2
tC (mmol/l) 5.64 +1.13 6.18 +1.11 5.62 +1.12 <0.001
ldl-C (mmol/l) 3.69 +1.06 4.23 +1.07 3.66 +1.05 <0.001
non-hdl-C (mmol/l) 4.31 +1.22 5.01 +1.18 4.27 +1.21 <0.001
hdl-C (mmol/l) 1.34 +0.40 1.18 +0.38 1.34 +0.40 <0.001
ApoA-i (g/l) 1.39 +0.28 1.33 +0.27 1.40 +0.28 <0.001
ApoB (g/l) 1.04 +0.30 1.20 +0.31 1.03 +0.30 <0.001
ApoA-ii (g/l) 0.34 +0.06 0.33 +0.06 0.34 +0.06 <0.001
tC/ hdl-C 4.64 +1.84 5.78 +2.12 4.57 +1.81 <0.001
ApoB/apoA-i 0.77 +0.27 0.94 +0.31 0.76 +0.27 <0.001
triglycerides (mmol/l) 1.12 (0.82-1.64) 1.47 (1.02-2.06) 1.11 (0.81-1.61) <0.001
hs-CrP (mg/l) 1.24 (0.55-2.86) 2.46 (1.12-5.34) 1.20 (0.53-2.77) <0.001
TC, Total Cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipopro-
tein cholesterol; non-HDL-C, TC-HDL cholesterol; apo, apolipoprotein; hs-CRP, high sensitivity 
C-reactive protein. Values are given as mean ± SD, except for triglycerides and hs-CRP which 
are given in median (interquartile range).
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Age- and sex adjusted HRs for individual (apo)lipoprotein measures (TC, LDL-C, non-
HDL-C, HDL-C and apos) and their ratios with incident MACE are given in Table 3. 
MACE was associated with all pro- and anti-atherogenic lipoprotein variables, apos 
and their ratios (p=0.018 to p<0.001). Of the pro-atherogenic variables, the highest 
age- and sex-adjusted HR point estimates were found for non-HDL-C and the apoB/
apoA-I ratio. Of the anti-atherogenic measures the highest point estimate was 
found for HDL-C. All HRs for MACE were only marginally altered after additional 
adjustment for triglycerides (Table 3). The relationship of incident MACE with the 
apoB/apoA-I ratio and the TC/HDL-C ratio according to quartiles is illustrated in Fig. 
1. The HRs for MACE of the apoB/apoA-ratio and the TC/HDL-C ratio in the upper 
quartile compared to the combined 3 lower quartiles were 1.95 (95 % CI, 1.58-2.40, 
p<0.001) and 2.13 (95 % CI, 1.72-2.63, p<0.001), respectively. Furthermore, risk was 
associated with hypertension (HR: 1.88; 95% CI, 1.48-2.38, p<0.001), obesity (HR: 
1.48; 95% CI, 1.16-1.88, p=0.002), diabetes (HR: 1.54; 95% CI, 1.04-2.27, p=0.03), 
smoking (former smoker HR:1.29 ; 95% CI 0.95-1.77, p=0.108, current smoker HR 
2.44 95% CI 1.80-3.31 p<0.001), hs-CRP (HR: 1.40; 95% CI, 1.27-1.54, p<0.001) and 
UAE (HR: 1.25; 95% CI, 1.15-1.35, p<0.001) in age- and sex-adjusted analyses.
Direct pair-wise comparisons between the various pro- and anti-atherogenic 
lipoproteins, apos and their ratios were made in order to compare the strength 
of their associations with MACE (Table 4). Of single pro-atherogenic measures, 
non-HDL cholesterol was the strongest single predictor of MACE in age- and sex 
adjusted analysis. Of the anti-atherogenic measures, the strongest relationship was 
found with HDL-C. ApoA-I performed better than apoA-II in age- and sex-adjusted 
analysis. When ratios were compared with single measures, the apoB/apoA-I ratio 
performed better than apo B and LDL-C. The TC/HDL-C ratio was not significantly 
better than LDL-C, whereas both the TC/HDL-C ratio and the apoB/apoA-I ratio 
were not superior to non-HDL-C in age-and sex-adjusted analyses. The relationship 
of incident MACE with the apoB/apoA-I ratio was stronger than that with the TC/
HDL-C ratio in unadjusted analysis (HR: 1.43; 95 % CI, 1.31-1.56) vs (1.12 (1.05-
1.18), p<0.001), but the apoB/apoA-I ratio was not statistically superior in age- and 
sex-adjusted analysis (Table 4).
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Figure 1 Unadjusted and age- and sex-adjusted relationships of first major adverse cardio-
vascular event with the total cholesterol/ HDL cholesterol (TC/HDLC) ratio and the apolipo-
protein B/apolipoprotein A-I (apoB/apoA-I). Ratios are presented in quartiles with the first 
quartile as reference category. The vertical bars represent the point estimate of the hazard 
ratio (HR) and 95% confidence intervals. * p<0.001, **p for trend <0.001
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Table 3. Hazard ratios (HRs) of serum total cholesterol, lipoprotein cholesterol, apolipopro-
teins and their ratios for major adverse cardiovascular events (MACE)
Age- and sex-adjusted Age-, sex- and triglyceride-adjusted
hr (95%Ci) p-value hr (95% Ci) p-value
tC 1.27 (1.15-1.41) <0.001 1.16 (1.04-1.30) 0.007
ldl-C 1.30 (1.17-1.45) <0.001 1.24 (1.12-1.38) <0.001
non-hdl-C 1.36 (1.23-1.50) <0.001 1.25 (1.11-1.41) <0.001
hdl-C 0.69 (0.60-0.79) <0.001 0.77 (0.66-0.90) 0.001
ApoB 1.24 (1.13-1.35) <0.001 1.13 (1.01-1.26) 0.028
ApoA-i 0.78 (0.70-0.88) <0.001 0.82 (0.73-0.92) <0.001
ApoA-ii 0.88 (0.78-0.98) 0.018 0.86 (0.77-0.95) 0.005
TC/HDL-C ratio 1.24 (1.18-1.29) <0.001 1.19 (1.11-1.27) <0.001
ApoB/apoA-I ratio 1.37 (1.26-1.48) <0.001 1.30 (1.18-1.43) <0.001
TC, Total Cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipopro-
tein cholesterol; non-HDL-C, TC-HDL-C; apo, apolipoprotein. All hazard ratios are given per 1 
SD increase.
The extent to which the relationship of MACE with the apoB/apoA-I ratio and the 
TC/HDL-ratio were modified by traditional cardiovascular risk factors (hyperten-
sion, diabetes, obesity, smoking), albuminuria and hs-CRP was determined next. 
In age-, sex- and triglyceride-adjusted analyses, further controlling for traditional 
risk factors (model 1), albuminuria and hs-CRP (model 2) or both sets of variables 
(model 3) only marginally diminished the relationship of MACE with the apoB/
apoA-I ratio (Table 5). Likewise, the relationship of MACE with the TC/HDL-C 
ratio remained essentially unaltered after adjustment for traditional risk factors, 
albuminuria and hs-CRP. When the apoB/apoA-I ratio and the TC/HDL-C ratio were 
included together in the same model (model 3), both ratios were related to risk 
(HR: 1.16 (95% CI, 1.02-1.31, p=0.020 and HR: 1.13 (95% CI, 1.03-1.24, p=0.011, 
respectively). No significant interactions of the apoB/apoA-I ratio and the TC/HDL-
C ratio with albuminuria and CRP on incident MACE were observed (p > 0.10 for all, 
data not shown). In the subgroup of subjects with elevated urinary albumin excre-
tion (>30 mg/24h; n=918) both the apoB/apoA-I ratio (HR: 1.28: 95% CI, 1.08-1.50, 
p=0.003) and the TC/HDL-C ratio predicted MACE. (HR: 1.28; 95% CI, 1.08-1.51, 
p=0.004)
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Table 4. Direct pair-wise comparisons of the relationships of lipoprotein cholesterol, apoli-
poproteins and their ratios with major adverse cardiovascular events (MACE)
Age- and sex-adjusted
hr (95% Ci) p-value
Comparison of single variables
non-hdl-C 1.43 (1.21-1.70) 0.016
ldl-C 0.94 (0.77-1.13)
non-hdl-C 1.39 (1.20-1.63) 0.015
ApoB 0.97 (0.83-1.13)
ldl-C 1.22 (1.04-1.43) 0.418
ApoB 1.08 (0.94-1.26)
ApoA-i 0.95 (0.81-1.12) 0.069
hdl-C 0.72 (0.60-0.86)
ApoA-ii 0.98 (0.87-1.11) 0.002
hdl-C 0.70 (0.60-0.81)
ApoA-i 0.74 (0.62-0.87) 0.015
ApoA-ii 1.08 (0.92-1.27)
Comparison of single variables with ratios
non-hdl-C 1.13 (0.97-1.32) 0.832
TC/HDL-C Ratio 1.16 (1.06-1.27)
ApoB 0.85 (0.73-0.99) <0.001
ApoB/ApoA-I Ratio 1.57 (1.34-1.83)
ApoB 1.09 (0.98-1.22) 0.147
TC/HDL-C Ratio 1.21 (1.15-1.28)
non-hdl-C 1.13 (0.98-1.30) 0.299
ApoB/ApoA-I Ratio 1.28 (1.14-1.44)
ldl-C 1.15 (1.03-1.29) 0.476
TC/HDL-C ratio 1.21 (1.15-1.28)
ldl-C 1.07 (0.94-1.22) 0.047
ApoB/ApoA-I ratio 1.32 (1.20-1.47)
Comparison of ratios
TC/HDL-C Ratio 1.15 (1.07-1.24) 0.397
ApoB/ApoA-I Ratio 1.24 (1.11-1.38)
HR, hazard ratio; TC, Total Cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high 
density lipoprotein cholesterol, non-HDL-C, total cholesterol-HDL-C; apo, apolipoprotein. All 
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Because of the design of the PREVEND study with enrichment of subjects with 
urinary albumin excretion >10 mg/l, the analyses were repeated using a complex 
sample design procedure. These analyses yielded essentially similar results. The 
age- and sex-adjusted HRs of MACE with the apoB/apoA-I and with the TC/HDL-C 
ratio were 1.37 (95% CI, 1.21-1.56, p<0.001) and 1.19 (95% CI, 1.09-1.29, p<0.001), 
respectively. Finally, sensitivity analyses were carried out on the data-set of sub-
jects recruited from the random sample of the PREVEND cohort [20] (n = 2819). 
The age- and sex-adjusted relationship of MACE with the apoB/apoA-I ratio (HR: 
1.37; 95% CI, 1.17-1.63, p<0.001) was similar compared to that observed in the 
whole study population (Table 3), whereas the HR of the TC/HDL-C ratio was 1.13 
(95% CI, 0.96-1.24, p=0.19).
disCussion
This prospective case-cohort study shows that the association of first MACE with 
the serum TC/HDL-C and the apoB/apoA-I ratio is at least as strong as that at-
tributable to single pro-atherogenic (apo)lipoprotein measures. Direct pair-wise 
comparison of the strength of the relationship of MACE with these ratios showed a 
higher hazard attributable to the apoB/apoA-I ratio, but this measure was not sta-
tistically superior to the TC/HDL-C ratio after sex and age adjustment. Of relevance, 
both ratios predicted first MACE after additional adjustment for triglycerides, as 
well as for non-lipid risk factors and for hs-CRP and albuminuria. The present study, 
therefore, suggests that incident cardiovascular risk is determined by both the TC/
HDL-C and the apoB/apoA-I ratio in the general population even when taking ac-
count of novel risk markers.
Our findings agree with a recent meta-analysis showing similar age- and sex-
adjusted hazards for incident coronary heart disease of the apoB/apoA-I compared 
to the TC/HDL-C ratio [17]. In comparison, the INTERHEART case-control study [1], 
as well as the prospective Amoris and EPIC-Norfolk studies showed preference 
of the apoB/apoA-I ratio over the TC/HDL-C ratio with respect to their relation 
with incident CVD [3,14]. The present observation that non-HDL-C rather than 
Chapter 2
40
apoB is the strongest single pro-atherogenic measure is also in keeping with the 
meta-analysis [17], and contrasts with the Amoris report [3]. One methodologi-
cal point of that study is that HDL-C was not directly measured [3]. Instead both 
HDL-C and LDL-C were estimated using a mathematical formula based on apoA-I, 
triglycerides and TC. A potentially important difference between the EPIC Norfolk 
study [14] and the current report is that we included fasting individuals only. The 
serum apoB/apoA-I is supposed to be unaffected by the non-fasting state [11], but 
the interpretation of non-fasting non-HDL-C may be confounded by cholesterol 
contained in chylomicrons [11,27]. The Friedewald formula is originally reported 
to be inaccurate using non-fasting samples [25]. Therefore, it is possible that 
non-fasting conditions of study participants may to some extent have affected the 
interpretation of the EPIC-Norfolk report [14] and the meta-analysis [17]. Although 
the relationship of incident coronary heart disease with serum triglycerides was 
found to be unaffected by the non-fasting state [17], it is obvious that collecting 
fasting serum samples likely reduces potential bias due to postprandial triglyceride 
variations. Thus, the present study, in which we directly compared cardiovascular 
hazard attributable to the fasting serum apoB/apoA-I ratio with that of the TC/
HDL-C ratio, is complementary to these reports [14,17]. Of further interest, lower 
apoA-II was found in cases, but did not predict MACE independently of apoA-I and 
HDL-C. In comparison, coronary risk was inversely related to apoA-II even after con-
trolling for HDL-C, apoA-I and conventional risk factors [28], although no difference 
in apoA-II levels between cases and controls was observed in another prospective 
study [29]. Collectively, these findings suggest that the value of additional apoA-II 
measurement is limited.
Microalbuminuria is an independent predictor of cardiovascular disease [18,30] 
and diabetes mellitus [31], and coincides with endothelial dysfunction and chronic 
inflammation [30,32-34]. Microalbuminuria is also associated with unfavour-
able lipoprotein changes, as evidenced by lower HDL-C, higher triglycerides and 
increased small LDL particle concentration [35]. Furthermore, hs-CRP associates 
positively with obesity, insulin resistance and negatively with HDL-C [16,36-38]. In 
view of these interrelationships, we consider our finding that the association of in-
cident MACE with the apoB/apoAI ratio and the TC/HDL-C ratio was not relevantly 
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attenuated by the degree of urinary albumin excretion and hs-CRP levels of clinical 
interest. This result supports the hypothesis that lipid factors, micro-albuminuria 
and enhanced chronic inflammation are at least in part independent predictors 
of clinically manifest atherosclerosis. Of further relevance, both ratios also signifi-
cantly predicted events in subjects with elevated urinary albumin excretion, sup-
porting the validity of these (apo)lipoprotein measures in these high risk subjects.
Comparison of the strength of the relationships of the apoB/apoA-I ratio and the 
TC/HDL-C ratio with incident cardiovascular disease needs to be interpreted from a 
pathophysiological perspective. The pro-atherogenic potential of apoB-containing 
lipoproteins is neither integratively reflected by their cholesterol concentration as 
such, nor by the serum apoB level, but there is general agreement that all apoB-
containing lipoprotein particles are implicated in the atherosclerotic process [39]. 
In this respect it is of interest that non-HDL-C also performed better than LDL-C in 
the current study. Of further relevance, evidence is accumulating that not all HDLs 
are equally atheroprotective and that these particles can become dysfunctional 
[40-44]. It has been suggested that this problem can at least in part be circumvented 
by apoA-I measurement [40]. Nonetheless, modification of apoA-I, e.g. by oxida-
tion and chlorination of amino-acid residues, may attenuate its anti-atherogenic 
properties [45]. This could possibly explain why the inverse relationship of incident 
MACE with apoA-I was weaker than that with HDL-C. Taken together, it is obvious 
that routinely available lipoprotein cholesterol and apolipoprotein measures are 
still suboptimal in cardiovascular risk prediction.
Several methodological aspects of our study need to be outlined. Firstly, we 
carried out a prospective analysis in a population-based cohort. Consequently, the 
number of events in women and in each separate cardiovascular domain was not 
large enough to allow for meaningful sex- and domain-specific analyses. Secondly, 
as in other studies [4-6,12,14,15,17], we only included subjects without clinically 
manifest cardiovascular disease at baseline. Thirdly, we reliably excluded prescrip-
tion of lipid lowering drugs at baseline, but did not include information regarding 
its use during follow-up in the present analyses. However, statin treatment shifts 
the relation of LDL-C and non-HDL-C with apoB towards lower concentrations of 
these measures that correspond to similar apoB levels [46, 47]. Thus, if statin 
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treatment was started during follow-up this may have underestimated possible 
superiority of the apoB/apoA-I ratio. It has indeed been suggested that the apoB/
apoA-I ratio is better than the TC/HDL-C ratio in predicting recurrent events during 
statin treatment [13]. Additionally it should be noted that relevant bias due to 
overrepresentation of subjects with microalbuminuria consequent to the design of 
the PREVEND study is very unlikely, because both a complex design procedure and 
a sensitivity analysis yielded similar results. Therefore, we consider our findings to 
be representative for the general population.
Of note, it should be appreciated that our study was not aimed to address the 
discriminative power of the various (apo)lipoprotein variables in predicting risk. 
The magnitude of HRs of the (apo)lipoprotein measures as documented in our 
study in keeping with those reported previously [17]. Importantly, much higher 
hazards are required to be able to demonstrate significant improvement in risk pre-
diction upon addition of the risk factor/marker under study to a set of established 
risk factors [14, 48, 49]. Finally, continuous effort is still needed to further optimize 
standardization of HDL cholesterol and apolipoprotein measurement worldwide. 
Assay availability and costs remain relevant issues that determine preference of 
their use in clinical practice. Our study suggests that calculated LDL cholesterol 
does not add to total cholesterol and HDL cholesterol measurement.
In conclusion, this case-cohort study supports the contention that the fasting 
serum apoB/apoA-I ratio and the TC/HDL-C ratio are both important determinants 
of first MACE in the general population. The relationships of events with these 
ratios are only marginally affected by triglycerides, non-lipid risk factors, hs-CRP 
and albuminuria.
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Age (years) 49.3±12.7 60.8±10.1 48.4±12.4 <0.001
Obesity (%) 14.1 19.7 13.6 0.011
Hypertension (%) 35.0 64.7 32.5 <0.001
Microalbuminuria (%) 15.4 31.0 14.1 <0.001
Macroalbuminuria (%) 1.9 5.5 1.6 <0.001
Diabetes (%) 3.4 7.8 3.0 <0.001
Alcohol use (%) 35.0 31.2 35.3 0.11
Smoking status(%) Never 25.8 9.8 27.2 <0.001
Former smoker 39.3 43.9 38.9
Current 34.8 46.3 33.9
TC (mmol/l) 5.70±1.11 6.11±1.10 5.66±1.10 <0.001
LDL-C (mmol/l) 3.83±1.01 4.22±1.04 3.80±1.01 <0.001
Non-HDL-C (mmol/l) 4.54±1.16 5.01±1.16 4.50±1.16 <0.001
HDL-C (mmol/l) 1.16±0.31 1.10±0.33 1.17±0.31 <0.001
ApoA-I (g/l) 1.30±0.24 1.27±0.25 1.30±0.24 0.038
ApoB (g/l) 1.09±0.30 1.21±0.32 1.08±0.30 <0.001
ApoA-II (g/l) 0.34±0.06 0.32±0.06 0.34±0.06 <0.001
TC/ HDL-C 5.29±1.95 6.06±2.13 5.22±1.93 <0.001
ApoB/apoA-I 0.86±0.27 0.99±0.31 0.85±0.26 <0.001
Triglycerides (mmol/l) 1.25(0.90-1.88) 1.50(1.05-2.14) 1.24(0.89-1.85) <0.001
hs-CRP (mg/l) 1.17(0.54-2.60) 2.38(1.12-5.03) 1.11(0.51-2.45) <0.001
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Age (years) 47.4±12.1 59.0±11.2 47.1±11.9 <0.001
Obesity (%) 16.3 37.7 15.6 <0.001
Hypertension (%) 25.3 64.5 24.1 <0.001
Microalbuminuria (%) 8.8 15.9 8.6 0.017
Macroalbuminuria (%) 0.9 1.9 0.9 0.255
Diabetes (%) 2.4 7.6 2.3 0.004
Alcohol use (%) 17.1 15.9 17.2 0.796
Smoking status(%) Never 34.4 30.8 34.5 0.122
Former smoker 32.6 27.1 32.8
Current 33.0 42.1 32.7
TC (mmol/l) 5.60±1.15 6.36±1.15 5.57±1.14 <0.001
LDL-C (mmol/l) 3.55±1.09 4.26±1.13 3.53±1.08 <0.001
Non-HDL-C (mmol/l) 4.10±1.23 4.99±1.23 4.07±1.22 <0.001
HDL-C (mmol/l) 1.50±0.40 1.37±0.42 1.50±0.40 <0.001
ApoA-I (g/l) 1.48±0.29 1.47±0.27 1.48±0.29 0.72
ApoB (g/l) 0.99±0.30 1.17±0.29 0.98±0.30 <0.001
ApoA-II (g/l) 0.35±0.07 0.34±0.07 0.35±0.07 0.41
TC/ HDL-C 4.04±1.51 5.11±1.95 4.01±1.48 <0.001
ApoB/apoA-I 0.69±0.24 0.82±0.26 0.68±0.24 <0.001
Triglycerides (mmol/l) 1.04(0.77-1.43) 1.39(0.98-1.97) 1.03(0.76-1.42) <0.001
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As delineated in this review, CETP contributes to an atherogenic lipoprotein profile 
by redistributing cholesteryl esters from HDL towards apolipoprotein B-containing 
lipoproteins, especially when the concentration of acceptor triglyceride-rich lipo-
proteins is elevated. However, this lipid transfer protein may have anti-atherogenic 
proprerties as well. Experimental evidence is accumulating which suggests that 
the atheroprotective reverse cholesterol transport pathway, whereby cholesterol 
is removed from peripheral macrophages to the liver for metabolism and biliary 
excretion, is stimulated by CETP in vivo. CETP could also play a role in host defense 
against infection and inflammatory processes. Moreover, recently published obser-
vational studies show that higher CETP levels may confer cardiovascular protection, 
whereas reported associations of CVD with CETP gene variations are equivocal.
The concept that HDL cholesterol raising through inhibition of cholesteryl ester 
transfer protein (CETP) may ameliorate cardiovascular disease (CVD) risk has been 
challenged by the failure of the CETP inhibitor, torcetrapib. Adverse clinical out-
come associated with the use of this CETP inhibitor has been attributed to off-target 
effects, which relate to stimulation of aldosterone. Other CETP inhibitors, such as 
dalcetrapib and anacetrapib, are unlikely to increase blood pressure. Dalcetrapib 
is less potent than anacetrapib, which doubles HDL cholesterol. Both inhibitors 
considerably lower LDL cholesterol.
Serious concerns remain about the validity of the concept that HDL cholesterol 
raising by means of CETP inhibition is a viable strategy. Results of ongoing clini-
cal trials with these drugs will have to be awaited before making up the balance 
between possible benefits and harms related to pharmacological CETP inhibition.
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introduCtion
Observational studies have demonstrated that high levels of high density lipopro-
tein (HDL) cholesterol confer a lower risk for cardiovascular disease (CVD) [1,2]. 
The inverse relation of HDL cholesterol with CVD risk is graded, continuous and 
holds true for both younger and older individuals [2]. Low HDL cholesterol remains 
predictive of high CVD risk during statin treatment [3]. These observations have 
contributed to the general belief that HDL particles have cardioprotective prop-
erties [4-6]. Since there remains a high residual cardiovascular risk during statin 
treatment [4], there is a clear need for additional pharmacological therapies to 
optimize cardiovascular protection.
One such novel approach is directed towards cholesteryl ester transfer protein 
(CETP), a plasma lipid transfer protein that has the ability to transfer cholesteryl 
esters from HDL towards apolipoprotein B-containing lipoproteins [7,8]. Although 
the pro-atherogenic properties of CETP have not been unequivocally demonstrated 
in animal experiments [9], several pharmaceutical companies are engaged in 
developing drugs that inhibit the activity of CETP in plasma. One of these agents, 
torcetrapib (Pfizer Inc. USA), was the first HDL-targeted drug that was launched into 
large scale clinical studies in humans. As of December 2006, it was decided to stop 
the torcetrapib development program, because interim analysis in one of these tri-
als indicated excess death in subjects treated with torcetrapib on top of atorvastatin 
compared to subjects receiving atorvastatin alone [10]. The failure of torcetrapib 
has greatly intensified the discussion about the concept that HDL cholesterol raising 
through CETP inhibition is a valid approach to reduce the burden of CVD.
The pros and cons of CETP inhibitor treatment in humans have been discussed 
in several recent papers [9,11-19]. In this review, we will update observational 
studies with respect to the relation of CVD with circulating CETP levels, reports on 
associations of CVD risk with common CETP gene variations. We will also delineate 
potential mechanisms responsible for the failure of torcetrapib, and review two 
CETP inhibitors that are currently under clinical evaluation (dalcetrapib (JTT-705/
R04607381) and anacetrapib (MK-0859)).
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what is CetP and what does it do?
In contrast to mice, rats and pigs which lack CETP by nature, human plasma contains 
CETP, a highly hydrophobic glycoprotein with an molecular mass of about 74,000 
[7,20]. Human CETP comprises 476 amino acid residues, and belongs to the lipid 
transfer/lipopolysaccharide-binding protein family [7,20]. Liver, adipose tissue and 
macrophages are considered to be important sources of CETP in human plasma [7]. 
Its gene is located in chromosome 16 (16q12-16q21), and consists of 16 exons and 
15 introns [21]. The CETP promoter contains several regulatory elements which are 
activated via sterol regulatory element binding protein-1 [22] and via liver X-receptors 
[23]. Partial and complete CETP deficiency is rare, and occurs mainly in some regions 
in Japan [24]. Several common single nucleotide polymorphisms (SNPs) in the CETP 
gene have been identified of which the TaqIB polymorphism in intron 1 (rs 708272), the 
closely associated -629C>A variant in the CETP promoter (rs 1800775) and the I405V 
polymorphism (rs 5882) have been studied most frequently [20,25,26]. The minor 
alleles of these CETP variants (A (B2), A and G alleles, respectively) are all associated 
with lower plasma CETP and higher HDL cholesterol levels [20,25,26]. Genome wide 
association studies and genetic association studies have reinforced important associa-
tions of HDL cholesterol and HDL particle size with SNPs in the CETP gene [27-29].
The best known function of CETP is its ability to transfer neutral lipids (cholesteryl 
esters and triglycerides) between plasma lipoproteins [7,8,11,18,30]. As a result of 
this neutral lipid transfer reaction, there is net loss of cholesteryl esters and net gain 
of triglycerides in HDL particles and accumulation of cholesteryl esters in triglyceride-
rich lipoproteins, particularly in hypertriglyceridemia CETP increases postprandial 
hypertriglyceridemia and delays plasma triglyceride clearance in transgenic mice 
[31]. The CETP inhibitor, torcetrapib, decreases the postprandial response after a fat 
containing meal in hyperlipidemic patients [32]. Therefore, the process of neutral 
lipid transfer will result in a more atherogenic distribution of cholesterol between 
HDL and apolipoprotein (apo) B-containing lipoproteins. Enrichment of HDL and also 
of low density lipoprotein (LDL) particles with triglycerides as a result of the activity 
of CETP is followed by hepatic lipase-mediated tryglyceride hydrolysis [8,32]. The 
combined activities of CETP and hepatic lipase will decrease HDL and LDL particle size 
[8], which may both result in higher cardiovascular risk [33,34].
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CETP-mediated transfer of cholesteryl esters from HDL towards apo B-con-
taining lipoproteins is supposed to stimulate cholesterol delivery to the liver as 
a result of hepatic uptake of these lipoproteins via the LDL receptor and the LDL 
receptor-related protein [8,11,35,36]. These pathways are facilitated by heparin 
sulphate proteoglycans [37]. Accordingly, recent experiments in CETP transgenic 
mice strongly support the notion that circulating CETP promotes macrophage re-
verse cholesterol transport via the LDL receptor pathway [38]. CETP may, therefore, 
stimulate the anti-atherogenic reverse cholesterol transport pathway, whereby 
cholesterol is transported from peripheral cells to the liver for metabolism and 
excretion in the bile [7,8,11,36,38,39].
Additionally, HDL triglyceride enrichment consequent to CETP action may con-
tribute to the generation of small, lipid poor HDL particles, designated pre-β-HDL, 
but is should be noted that other HDL-associated proteins, such as phospholipid 
transfer protein (PLTP) and apoM are also important for pre-β-HDL formation [40-
44]. Pre-β-HDL particles are regarded as initial acceptors of cell-derived cholesterol 
via the adenosine triphosphate (ATP)-binding cassette transporter (ABC) A1 (ABCA1) 
pathway [45,46]. Thus, CETP may indirectly facilitate cholesterol efflux from cells to 
the extracellular compartment, and hence may stimulate an early step in the re-
verse cholesterol transport pathway. Plasma from subjects with CETP gene variation 
that gives rise to lower CETP mass has diminished ability to stimulate cholesterol 
efflux from cultured human fibroblasts which express ABCA1 [47]. Another report 
suggested that the ability of serum from CETP deficient subjects to stimulate ABCA1-
mediated efflux is preserved [48]. Additionally, it has been shown that the capacity 
of HDL2 and HDL3 from hyperlipidemic subjects to mediate ABCA1-dependent cho-
lesterol efflux is unaffected by torcetrapib combined with atorvastatin [19]. Apart 
from a contribution of passive diffusion, cellular cholesterol efflux is also mediated 
by ABCG1-mediated transport to mature HDL particles, as well as by scavenger 
receptor BI (SR-BI) which facilitates bidirectional cholesterol transport between cells 
and mature HDL [45,46]. Increases in ABCG1-dependent cholesterol efflux have been 
documented with HDL isolated from CETP deficient patients and from torcetrapib 
treated subjects [19,49,50]. SR-B1-mediated cholesterol efflux to whole serum 
obtained from CETP deficient subjects, as well as to HDL obtained from torcetrapib 
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treated hyperlipidemic subjects may be increased as well [19,48]. CETP is present in 
foam cells from human atherosclerotic lesions [51]. CETP may stimulate cholesterol 
removal from macrophages, although the mechanism has to be defined more pre-
cisely [51]. Furthermore, CETP probably promotes hepatic uptake of HDL-derived 
cholesteryl esters, independently of transfer of cholesteryl esters to triglyceride-rich 
lipoproteins [52,53]. On the other hand, in vitro uptake of HDL-derived cholesteryl 
esters by Fu5AH model cells and HepG2 cells is stimulated after torcetrapib admin-
istration [19]. Collectively, these findings suggest that CETP may stimulate several 
steps involved in the reverse cholesterol transport pathway. Nonetheless, it is unlikely 
that administration of the CETP inhibitor, torcetrapib, results in clinically important 
adverse effects on the ex vivo ability of whole plasma/serum and of isolated HDL 
to stimulate cholesterol efflux. Additionally, fecal sterol excretion was found to be 
unaffected by torcetrapib, suggesting that the final step of the reverse cholesterol 
transport pathway is unresponsive to CETP inhibition in humans [54].
It is increasingly recognized that anti-inflammatory properties of HDL-associated 
proteins are involved in the innate immune system [55,56]. However, a potential 
role of CETP in host defense against infection and inflammatory processes in 
humans is still poorly defined. Interestingly, recent observations have shown that 
survival after endotoxemia induced by inoculation with E. coli lipopolysaccharide 
(LPS) is improved in mice expressing human CETP compared to wild type mice 
[57]. This effect of CETP could be related to attenuation of macrophage TNF-α 
and interleukin-6 responses to systemic endotoxemia [57]. In this setting, CETP 
could also promote LPS binding to HDL, thereby to some extent competing with 
LPS binding protein [57,58]. This would hinder cellular delivery of circulating LPS 
and subsequent intracellular activation of a pro-inflammatory cascade [57,58]. 
However, the CETP inhibitors torcetrapib and anacetrapib do not interfere with 
LPS binding to LPS binding protein in vitro [58]. Notably, torcetrapib administration 
enhances monocyte recruitment in APOE*3-Leiden.CETP mice [59]. In this study, 
the atherosclerotic lesion phenotype appeared to be pro-inflammatory after torce-
trapib, as reflected by a higher ratio of macrophages to collagen present in the 
lesions, whereas the lesion area was similarly reduced by torcetrapib compared to 
atorvastatin [59]. The mechanism responsible for this pro-inflammatory vascular 
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response to CETP inhibition by torcetrapib remains speculative. CETP mass is cor-
related negatively with high sensitive C-reactive protein (CRP) levels in patients 
who require coronary angiography [60], but not in healthy subjects [61]. This raises 
the possibility that decreased CETP levels could contribute to low grade chronic 
inflammation in high risk situations.
Potentially important pro-atherogenic and anti-atherogenic effects of CETP are 
summarized in Table 1.
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Inflammation
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to HDL, thereby impeding an intracellular 
pro-inflammatory cascade
*scavenger receptor BI, **adenosine triphosphate-binding cassette transporter G1
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Plasma CETP and common variations in the CETP gene: observational studies on 
cardiovascular disease in humans
Abnormalities in plasma CETP mass, CETP activity, i.e. its activity measured by an 
exogenous substrate method that is not influenced by the endogenous cholesteryl 
ester donor and acceptor lipoproteins in plasma, and CETP activity measured with 
endogenous substrates, i.e. cholesteryl ester transfer rates between endogenous 
plasma lipoproteins (designated cholesteryl ester transfer (CET)), have been re-
peatedly demonstrated in clinical conditions associations with high cardiovascular 
risk [8,62-65]. Several studies have examined the extent to which carotid intima 
media thickness (IMT), a marker of subclinical atherosclerosis, and the severity of 
coronary heart disease (CHD) is related to plasma CETP mass, CETP activity and 
CET. Carotid IMT was associated postitively with plasma CETP mass in some [66-
68], but not in other studies [69,70]. One of these reports demonstrated IMT to 
be related to plasma CET only, which in turn was determined by the concentration 
of plasma apolipoprotein B-containing lipoproteins, as well as by CETP mass [69]. 
Plasma CETP mass was unrelated to severity of coronary artery atherosclerosis 
[71], whereas CETP activity did not vary according to prevalent coronary artery 
disease in patients with and without type 2 diabetes [62,72]. In contrast, a high 
plasma CETP concentration conferred increased prevalence of a composite CVD 
estimate [70]. Moreover, high plasma CET was associated with younger age at first 
presentation of myocardial infarction [73]. Thus, these cross-sectional studies do 
not unequivocally establish a relationship of high plasma CETP mass or activity with 
(subclinical) atherosclerosis.
Two prospective studies have established relationships of progression of coro-
nary artery disease or incident cardiovascular disease with plasma CETP concentra-
tion. The Regression Growth Evaluation Statin Study (REGRESS) showed that higher 
plasma CETP concentrations predict coronary artery disease progression [74]. The 
European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk report 
also demonstrated that higher plasma CETP mass predicts incident CVD in subjects 
with higher triglycerides [75]. A nested case-control study among male participants 
from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) revealed 
that higher plasma CETP confers lower risk, but only with lower triglycerides [76]. 
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Updates from these studies reached comparable conclusions [77,78]. Among 
subjects with hypercholesterolemia and pre-existent coronary artery disease in 
whom statin treatment was initiated, low plasma CETP mass predicted increased 
incidence of recurrent cardiovascular events [79], but plasma CETP activity did not 
predict incident CVD in hemodialysis patients [80]. Two large propective studies 
have now appeared demonstrating that higher plasma CETP levels confer lower 
CVD incidence or cardiovascular mortality [60,81]. Higher plasma CETP activity 
predicted lower CVD risk among 1,978 Framingham Heart Study participants dur-
ing 15 years of follow-up [81]. The Ludwigshaven Risk and Cardiovascular Health 
Study revealed that a higher plasma CETP concentration independently predicted 
cardiovascular and even all-cause mortality during 7.75 years of follow-up in 3,256 
subjects referred for coronary angiography [60]. From these studies it obvious that 
there is no straightforward support for the idea that higher plasma CETP mass or 
CETP activity, measured with exogenous substrates, is a marker of incident CVD. 
In fact, the opposite seems to be more likely, given recent observational studies 
[60,81]. However, these findings do not exclude the possibility that CETP activity 
measured with endogenous substrates (CET) is pro-atherogenic. An overview of 
prospective studies, concerning the relation of incident CVD with plasma CETP 
concentration or CETP activity measured with exogenous substrates, is provided 
in Table 2.
As reviewed elsewhere, HDL cholesterol is considerably elevated in subjects 
with partial or complete genetic CETP deficiency [20,24,25]. Moreover, there is 
consensus that the TaqIB (rs 708272) B2 (A) allele gives rise to a per-allele increase 
in HDL cholesterol of approximately 0.06 mmol/l [20,26,82]. Nonetheless, it is un-
clear whether CETP deficiency is a determinant of increased life expectancy [20,24]. 
A meta-analysis demonstrated a lower odds ratio for coronary artery disease of 
0.89 per TaqIB B2 allele among 11,672 subjects (2,857 cases) [83], but individual 
CETP gene-cardiovascular outcome association studies have yielded markedly 
inconsistent results [20,84,85]. It was hypothesized that these discrepancies could 
in part be attributable to selection towards a lower frequency of B2B2 carriers 
in high risk populations as compared to population-based cohorts, resulting in an 
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meta-analysis comprising 51,343 subjects (19,035 cases), yielded an odds ratio of 
0.95 per TaqIB B2 allele [26], and a genome wide association study among women 
showed elevations in HDL cholesterol and decreased coronary risk in association 
with the TaqIB (B2) SNP [86]. We were unable to demonstrate consistent effects of 
variations in the CETP gene on cardiovascular outcome during lipid lowering treat-
ment in our systematic review [20]. However, a recent update from the REGRESS 
cohort revealed a TaqIB B2 allele dose-dependent increase in cardiovascular and 
total mortality during statin treatment, in marked contrast with the initial report 
[87]. These findings [87] would raise the possibility that CETP inhibitor therapy, 
mimicking lipid traits of genetically determined lower CETP levels [82], could be 
deleterious, particularly if combined with statin treatment.
Clinical studies with torcetrapib
The effect of 8 weeks administration of torcetrapib (dose range from 10 to 90 mg/
day), either alone or in combination with atorvastatin, has been determined in 
two phase 2 studies, comprising 162 and 174 subjects with low HDL cholesterol, 
respectively [88,89]. Torcetrapib in a dose of 60 mg daily resulted in an average 
placebo-adjusted increase in HDL cholesterol of 33 to 45 %, together with smaller 
increases in apo A-I [88,89]. These phase 2 studies demonstrated a clinically 
significant increase in systolic or diastolic blood pressure in 1.6 % and 2.9 % of 
subjects receiving torcetrapib alone or on top of atorvastatin, respectively [88,89]. 
The safety profile appeared otherwise reassuring. Four phase 3 clinical end-point 
studies have documented similarly large increments in HDL cholesterol, accom-
panied by smaller reductions in LDL cholesterol and triglycerides in response to 
approximately 12 to 24 months treatment with 60 mg daily torcetrapib on top 
of atorvastatin [10,90-92]. The ILLUMINATE study comprised 15,067 subjects 
at high cardiovascular risk; the primary outcome was first occurence of a major 
cardiovascular event [10]. This trial was prematurely stopped because of major 
safety issues, with a hazard ratio of the primary composite end-point of 1.25 (95 
% CI, 1.09-1.44; P = 0.001) for torcetrapib + atorvastatin compared to atorvastatin 
alone. A total of 93 deaths occured in the torcetripib + atorvastatin arm compared 
to 59 with atorvastatin monotherapy (hazard ratio 1.58 (95 % CI, 1.14-2.19; P = 
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0.006). Excess deaths included cardiovascular causes (49 vs. 35), infection (9 vs. 0), 
as well as cancer (24 vs. 14). The ILLUSTRATE trial comprised 1188 patients with 
coronary artery stenosis; the primary outcome measure was percent change in 
atheroma volume assessed by intravascular ultrasonography [90]. The RADIANCE 1 
study included 850 patients with heterozygous familial hypercholesterolemia [91]. 
RADIANCE 2 included 752 subjects with mixed dyslipidemia [92]. In both RADI-
ANCE trials the primary end-point was the change from baseline in the maximum 
carotid artery intima media thickness (IMT) for 12 carotid artery segments. None 
of these three studies demonstrated a benefit of torcetrapib in combination with 
atorvastatin compared to atorvastatin treatment alone on the primary end-point 
(P = 0.46 to P = 0.87). Blood pressure increased significantly during CETP inhibitor 
administration in all four trials. Mean increments in blood pressure attributable 
to torcetrapib ranged from 2.3 to 4.5 mmHg systolic, and from 0.7 to 2.0 mmHg 
diastolic. The ILLUSTRATE trial showed a small benefit in the change in normal-
ized atheroma volume, a secondary outcome measure, in favour of torcetrapib in 
combination with atorvastatin compared to atorvastatin alone (P = 0.02), as well 
as in patients with the greatest baseline atheroma volume (P = 0.054) [90]. That 
trial revealed an increase in atheroma volume in the torcetrapib + atorvastatin arm 
that was greater than that expected for the LDL cholesterol concentration attained 
[90]. RADIANCE 1 demonstrated a detrimental effect of torcetrapib combined with 
atorvastatin compared to atorvastatin monotherapy on the annualized change in 
mean carotid artery IMT, the secondary outcome measure of that trial (P = 0.005) 
[91]. RADIANCE 2 showed that the annual change in maximal carotid IMT in the 
torcetrapib + atorvastatin treatment arm exceeded the change that was expected 
for the HDL cholesterol concentration reached at the end of the study [92]. That 
report also reasoned that the blood pressure increment attributable to torcetrapib 
could have counteracted the beneficial drop in LDL cholesterol in response to 
this CETP inhibitor [92]. The validity of the concept that HDL cholesterol raising 
by means of pharmacological CETP inhibition could still retard atherosclerosis 
progression has been examined in post-hoc analyses from these three torcetrapib 
trials [93,94]. An explorative analysis from the ILLUSTRATE report showed some 
regression of atheroma volume in those subjects with the highest HDL cholesterol 
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levels attained and the largest increase in HDL cholesterol in response to torce-
trapib [93]. However, a secondary analysis from the RADIANCE 1 and RADIANCE 
2 trials combined did not show any relation between changes in HDL cholesterol 
after torcetrapib and changes in carotid IMT [94]. Table 3 summarizes the four 
phase 3 studies with torcetrapib.
Table 3. Characteristcs and outcome of placebo-controlled phase 3 trials with the CETP inhibi-
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15,067 1.51 first MACEc prematurely 
stopped due to 
excess adverse 
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a CVD, cardiovascular disease
bCAD, coronary artery disease
cMACE, major adverse cardiovascular event
dFH, familal hypercholesterolemia
eIMT, intima media thickness
mechanisms responsible for the failure of torcetrapib
When it became clear that prolonged torcetrapib administration resulted in a clini-
cally significant rise in blood pressure which was accompanied by a drop in serum 
potassium and increases in sodium, bicarbonate and probably also in aldosterone 
[10], it was postulated that the adverse outcome related to this drug could at least 
in part be attribitable to hitherto unappreciated off-target effects [95]. Subsequent 
studies demonstrated that torcetrapib evokes acute increases in blood pressure in 
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mice and rats, and induces arterial vasoconstriction in rabbits [96,97]. Torcetrapib 
also elevates adrenal steroids in CETP deficient rodents [96]. This blood pressure 
response was dependent on intact adrenals, but was remarkably unrelated to 
inhibition of adrenal steroid synthesis [96]. Torcetrapib is able to induce expression 
of enzymes involved in late steps of cortisol and aldosterone biosynthesis, i.e. CY-
P11B1 (11 ß-hydroxylase and CYP11B2 (aldosterone synthase), in human cultured 
adrenal carcinoma cell lines via a cellular calcium influx-dependent mechanism 
[98]. Torcetrapib is a tetrahydroquinoline (THQ) class CETP inhibitor, and no such 
effects were found with non-THQ CETP inhibitors [98]. Notably, another THQ class 
compound which has no CETP inhibitor activity also induces aldosterone [98].
While these experimental studies clearly implicate that aldosterone activation 
contributes to off-target effects of torcetrapib, uncertainty remains with respect to 
the full explanation for adverse effects related to its use in humans [99]. Reason-
ing that blood pressure is reduced in CETP transgenic Dahl salt-sensitive rats, and 
that adrenal steroid synthesis may be partly dependent on delivery of HDL-derived 
cholesterol to the adrenal cortex [100,101], we tested relationships of plasma CETP 
mass with aldosterone. In middle-aged subjects we observed an inverse relation of 
serum aldosterone with CETP mass during habitual sodium intake [102]. However, 
in young healthy men, neither plasma CETP mass nor HDL cholesterol predicted 
changes in aldosterone and in blood pressure in response to variation in sodium 
intake [103]. The systemic blood pressure response to angiotensin II infusion was 
also unrelated to the plasma CETP concentration (Figure 1; reproduced from [103]). 
More recently, a Mendelian randomization approach was applied to compare ge-
netic influences of CETP with effects of pharmacologic CETP inhibition [82]. A com-
mon CETP gene variation effect on HDL cholesterol of 0.13 mmol/l (the difference 
between B2B2 and B1B1 TaqIB allele carriers) was estimated to correspond with 
a HDL cholesterol increase elicited by a 10 mg dose of torcetrapib [82]. Despite 
concordant effects of CETP gene variation and torcetrapib on HDL cholesterol and 
several other lipid traits, systolic and diastolic blood pressure was unrelated to 
variation in the CETP gene, thus opposing significant increases in blood pressure 
in response to 10 mg of torcetrapib [82]. Taken together, these findings make it 
unlikely that blood pressure regulation is to an important extent modulated by 
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endogenous CETP in humans, although some effects of very low CETP levels cannot 
be excluded.
Figure 1. Mean arterial pressure response during incremental doses of angiotensin-II infusion 
according to increasing tertiles of plasma CETP mass during unrestricted sodium intake in 67 
healthy men. Reproduced from J.A. Krikken et al. (2008)Expert Opin Ther Targets12;1321-1328
Since the ILLUMINATE report showed that the excess mortality in the torcetrapib 
plus atorvastatin could also relate to infection and cancer [10], it is relevant to 
consider other unforeseen adverse effects of CETP inhibition. To our knowledge 
there are no clinical studies demonstrating an association of hyperaldosteronism 
with either infection or cancer, making a direct effect of aldosterone stimulation 
on these adverse outcomes unlikely. Notably, both the ILLUMINATE and the IL-
LUSTRATE studies showed small increments in CRP levels in torcetrapib-receiving 
individuals [10,90,93]. This would agree with the hypothesis that pharmacogical 
CETP inhibition by torcetrapib could stimulate inflammatory processes.
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other CetP inhibitors: dalcetrapib and anacetrapib
Two CETP inhibitors are currently being tested in placebo-controlled phase 3 tri-
als: dalcetrapib (JTT-705, RO4607381) and anacetrapib (MK-0859). Dalcetrapib 
irreversibly binds to CETP via the formation of a disulfide bond, whereas anace-
trapib, which shares structural properties with torcetrapib, reversibly increases 
CETP binding to HDL [17]. Using a mechanistic mathematic modelling approach 
it may be predicted that CETP inhibitors with irreversible binding properties and 
non-competitive inhibitors more robustly block cholesteryl ester transfer activity 
than competitive inhibitors [104]. Importantly, dalcetrapib and anacetrapib are 
non-THQ compounds with an EC50 for aldosterone induction that is more than 
40-fold higher compared to torcetrapib [98]. In vitro studies have confirmed lack 
of stimulation of aldosterone synthesis by dalcetrapib [105]. Dalcetrapib, the 
first CETP inhibitor that was tested in humans, is less potent than torcetrapib 
with increases in HDL cholesterol and apo A-I of up to 36% and 16%, respectively 
[105,106]. Pooled analyses from 4 to 12 weeks lasting phase 2 trials involving 838 
subjects showed that dalcetrapib alone and in combination with a statin does not 
raise blood pressure [105]. Frequency of adverse events was similar compared to 
placebo at a dalcetrapib dose of 600 mg daily, but was higher at the 900 mg dose, 
with diarrhoea and infection being mentioned as side effects [105]. A 48 week 
trial with dalcetrapib 900 mg daily in combination with atorvastatin involving 135 
subjects with coronary heart disease or high CVD risk confirmed that this CETP in-
hibitor does not affect blood pressure and aldosterone [107]. In subjects with type 
2 diabetes mellitus and/or metabolic syndrome, dalcetrapib in a dose of 900 mg 
daily is generally well tolerated for up to 48 weeks, and does not affect fasting glu-
cose or HbA1c [108]. Dalcetrapib in a dose of 600 mg daily is currently being tested 
in a phase 3 study, the Dal-Outcomes trial, which comprises 15,600 patients who 
have experienced an acute myocardial infarction [www.clinicaltrials.gov. Identifier 
NCT00658515 [109]]. The primary outcome measure is the time to first occurence 
of CHD death, major nonfatal coronary event or stroke. In this study, statins will 
be used to achieve an LDL cholesterol target of at least 2.6 mmol/l. Patients with 
severe hypertriglyceridemia are excluded to avoid concomitant use of niacin or 
fibrates. The trial will continue until 1,600 primary outcomes have occured dur-
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ing a follow-up of at least 2 years. Completion is expected in 2013. Stopping rule 
specifications are not mentioned in the rationale and design document [109].
A phase 1 study in 50 dyslipidemic patients showed that anacetrapib at a dose 
of 150 mg daily increases HDL cholesterol by 129 % and decreases LDL choles-
terol by 38 % after 4 weeks [110]. In 22 healthy subjects, systolic and diastolic 
blood pressure, as assessed by 24 h ambulatory blood pressure recordings, were 
unchanged after 10 days of anacetrapib at a dose of 150 mg daily [110]. A phase 
2 study in 589 hypercholesterolemic and dyslipidemic individuals again showed 
dose-dependent effects of anacetrapib on HDL cholesterol and LDL cholesterol 
after 8 weeks, comparable to those observed in the phase 1 trial [111]. Similar 
HDL cholesterol raising was observed when anacetrapib was combined with ator-
vastatin. Additionally, Lp(a) was dose-dependently decreased by anacetrapib. 
Blood pressure was unaffected, and no significant changes in CRP were noted. The 
safety profile of anacetrapib was unremarkable in the phase 1 and phase 2 studies 
[110,111]. The clinical efficacy of anacetrapib at a dose of 100 mg per day will 
be evaluated in the Determining the Efficacy and Tolerability of CETP INhibition 
with AnacEtrapib (DEFINE) trial [www.clinicaltrials. Identifier NCT0068577 [112]]. 
1,623 patients with CHD or CHD risk equivalents are enrolled in this study that 
has a duration of 18 months and includes a 3 months post-study evaluation. Pre-
study lipid modyfing treatment is maintained. Primary end-points of this study are 
the percent change from baseline in LDL cholesterol and tolerability assessments 
(including ECC changes). Interim safety analyses on key parameters, such as blood 
pressure and serum electrolytes, will be performed. Because of expected low 
numbers of cardiovascular end-points, incident CVD was not chosen as primary 
outcome measure. Instead, prespecified analyses will be carried out to interpret 
the CVD event distribution between treatment arms. Safety outcomes of this study 
are expected in 2010.
high hdl cholesterol does not always protect against atherosclerosis: relevance 
for hdl raising with CetP inhibitors
Despite apparently straight forward inverse associations of CVD with HDL cho-
lesterol, evidence is accumulating that high HDL cholesterol levels do not always 
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translate into reduced CVD risk. Analyses from the Thrombogenic Factors and Re-
current Coronary Events (THROMBO) post-infarction study showed that high HDL 
cholesterol predicts high risk for recurrent CVD in a subgroup of patients character-
ized by high total cholesterol and CRP levels [113]. Processes related closely to anti-
oxidative stress were indeed found to be important in establishing high risk despite 
high HDL-C [114]. Additionally, we were also able to identify a high HDL cholesterol, 
high CRP subgroup of individuals at increased risk for a first cardiovascular event in 
the community-dwelling PREVEND cohort [115]. Furthermore, post-hoc analyses 
from the Incremental Decrease in End Points through Aggressive Lipid Lowering 
(IDEAL) trial and the EPIC-Norfolk case-control study demonstrated that (recurrent) 
CVD risk was not reduced in subjects with the highest HDL cholesterol and the 
greatest mean HDL particle size [116].
The usually observed elevated cardiovascular risk in subjects with low HDL cho-
lesterol, but also the high CVD risk in subjects with enhanced chronic inflammation 
despite high HDL cholesterol, and the diminished cardioprotection in subjects with 
very high HDL cholesterol levels, should be interpreted in view of currently defined 
mechanisms whereby HDL particles may exert anti-atherosclerotic properties. 
HDL particles contain a large number of protein factors with anti-oxidative, anti-
inflammatory and anti-proliferative activities [6,117-120]. HDL may also attenuate 
platelet function [121,122].
Against this background we propose the concept that increased CVD risk associ-
ated with low HDL cholesterol is partly attributable to impaired anti-atherogenic 
properties of HDL particles [123]. Conversely, it is conceivable that in subjects with 
high CVD risk despite higher HDL cholesterol, the activities of HDL-associated 
anti-oxidative proteins would not be sufficiently increased to match for increased 
demands consequent to enhanced oxidative stress resulting from elevated lipids 
contained in this lipoprotein fraction [124]. Another mechanism whereby HDL 
is supposed to protect against atherosclerosis is provided by its crucial role in 
the process of reverse cholesterol transport, as delineated earlier in this review 
[7,8,11]. Unfortunately, the HDL cholesterol concentration as such does not ad-
equately reflect the dynamics of plasma cholesterol transfer between lipoproteins 
in vivo, which is difficult to measure directly in humans.
69
Cholesteryl ester transfer protein inhibition in cardiovascular risk management
3
Unfortunately, post-hoc analyses from the ILLUSTRATE and RADIANCE trials 
yielded inconsistent results regarding the association of carotid IMT progression 
with the HDL cholesterol response to CETP inhibitor treatment [93,94]. Apart from 
adverse off-targets effects of torcetrapib, it, therefore, remains uncertain whether 
the increase in HDL cholesterol resulting from CETP inhibition reflects beneficial 
changes in the anti-atherogenic properties of HDL. In addition, the effects of CETP 
inhibitors on cholesterylester content of (postprandial) triglyceride-rich lipopro-
teins has to be taken into account. We propose that epidemiological, biochemical 
and pathophysiological data, as outlined briefly here, are important for the prog-
ress of our understanding of the potential benefits and harms of currently tested 
CETP inhibitors.
ConClusions
It has long been recognized that CETP may act as a two-edged sword [125]. The car-
dinal issue whether CETP is friend or foe [126] clearly emerged again with the fail-
ure of torcetrapib. A novel class drug that doubles HDL cholesterol and at the same 
time effectively lowers LDL cholesterol seems enchanting. However, experimental 
studies have clearly shown that the reverse cholesterol transport process is stimu-
lated by CETP. Recent large observational studies disagree with the hypothesis that 
lower circulating CETP levels confer cardiovascular protection. Moreover, variation 
in the CETP gene that relates to lower plasma CETP levels could be deleterious in 
the context of statin therapy. These lines of evidence would raise serious concerns 
about the viability of pharmacological CETP inhibition, in particular if combined 
with statin treatment. We have to wait for the results of ongoing clinical trials 
with dalcetrapib and anacetrapib before making up the balance between possible 
benefits and harms related to pharmacological CETP inhibition, even if these drugs 
are devoid of adverse off-target effects.
It is beyond doubt that the results of trials with novel CETP inhibitors will 
influence current thinking about HDL cholesterol raising. Irrespective of these 
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outcomes it remains a major challenge to improve HDL’s functional properties and 
to translate novel HDL-targeted treatments into clinical practice.
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Background: The preference of the apolipoprotein (apo) B/apoA-I ratio over the 
total cholesterol/HDL cholesterol (TC/HDL-C) ratio in cardiovascular risk prediction 
is disputed. Cholesteryl ester transfer protein (CETP) is instrumental in lipopro-
tein remodelling and affects the cholesterol content in pro- and anti-atherogenic 
lipoproteins relative to their major apolipoproteins. We tested the influence of 
common CETP variations on the strength of associations of a first major adverse 
cardiovascular event (MACE) with the apoB/apoA-I ratio compared to the TC/HDL-
C ratio.
methods: A prospective case-cohort study was performed (PREVEND cohort; no 
previous cardiovascular disease and no lipid lowering drug use initially). Fasting 
serum TC/HDL-C, apoB/apoA-I, triglycerides and common CETP variations (TaqIB 
(rs708272) and -629C>A (rs1800775) polymorphisms) were measured at baseline. 
The composite endpoint was incident MACE.
results: 532 of 6780 subjects experienced a first MACE during 10.8 years follow-up. 
The age- and sex-adjusted hazard ratio (HR) was 1.31 (95 % CI, 1.23-1.41) for the 
apoB/apoA-I ratio and 1.22 (95 %, 1.26-1.39) for the TC/HDL-C ratio (both p<0.001). 
These relationships were essentially similar within each TaqIB and -629C>A CETP 
genotype group. No interactions of the apoB/apoA-I ratio and the TC/HDL-C ratio 
with the TaqIB and the -629C>A CETP variations on incident MACE were observed 
(P>0.20 for all).
Conclusion: The relationship of first MACE with the TC/HDL-C and the apoB/apoA-I 
ratio is not to an important extent dependent on common CETP variations. CETP 
variations are unlikely to affect the strength of the relationship of first MACE with 
the apoB/apoA-I ratio compared to the TC/HDL-C ratio.
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introduCtion
Abnormalities in the quantity, as well as in the quality of plasma lipoproteins have 
a major impact on the development of atherosclerotic cardiovascular disease 
[1,2]. Recent meta-analyses have established that the plasma total cholesterol/
high density lipoprotein cholesterol (TC/HDL-C) ratio is a relatively strong predictor 
of cardiovascular (CVD) risk [3,4]. Apolipoprotein (apo)B is the most important 
apolipopprotein (apo) of atherogenic low density lipoproteins (LDL), intermediate 
density lipoproteins (IDL) and very low density lipoproteins (VLDL), whereas apoA-I 
is the most abundant apolipoprotein of anti-atherogenic HDL particles. Importantly, 
the ratio of apoB/apoA-I is proposed as an alternative measure of (apo)lipoprotein-
related CVD risk [5,6], but it is still disputed if and when the apoB/apoA-I ratio may 
be preferable over the TC/HDL-C ratio in CVD risk prediction [3,7-11].
Human plasma contains cholesteryl ester transfer protein (CETP) which has a 
major role in lipoprotein remodeling, and affects the distribution of cholesterol 
between HDL and apoB-containing lipoproteins. CETP is able to transfer cholesteryl 
esters from HDL towards apolipoproteinB-containing lipoproteins in exchange for 
triglycerides [12-14]. The CETP-mediated neutral lipid transfer process is thereby 
giving rise to a net loss of cholesteryl esters in HDL particles and an increased 
cholesteryl ester content in triglyceride-rich lipoproteins [12-14]. This process also 
results in enrichment of HDL and LDL particles with triglycerides, which are subse-
quently converted into smaller particles as a result of lipase-mediated triglyceride 
hydrolysis [13]. Consequently, high plasma CETP mass and activity levels contribute 
to the generation of smaller-sized HDL and LDL particles, both of which are charac-
terized by a lower cholesterol content relative to their major apolipoproteins, i.e. 
apoA-I and apoB, respectively [15-17].
Of interest, common variations in CETP, of which the TaqIB (rs708272) and the 
CETP –629C>A (rs1800775) single nucleotide polymorphisms (SNPs) have been 
widely studied, affect the plasma lipoprotein profile in such a way that variations 
in CETP that confer higher plasma CETP levels do not only determine lower HDL-C 
levels [18,19], but also smaller-sized HDL and LDL particles [20]. Genome wide as-
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sociation studies have also revealed that HDL and LDL particle sizes associate with 
CETP variations [21,22].
The extent to which incident CVD relates to the apoB/apoA-I ratio compared to 
the TC/HDL-C ratio is proposed to be affected by compositional alterations in apoB- 
and apoA-I-containing lipoproteins [5,7-9], In view of the key role of plasma CETP 
in lipoprotein remodeling, it is relevant to test the possibility that common CETP 
variation impacts the strength of the relationship of incident CVD with the apoB/
apoA-I ratio compared to the TC/HDL-C ratio in a prospective study. The present 
study was initiated to test the influence of the CETP TaqIB and the -629C>A SNPs 
on the strength of associations of first major adverse cardiovascular events (MACE) 
with the apoB/apoA-I ratio compared to the TC/HDL-C ratio in the population-
based Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort.
mAteriAls And methods
Study population
The study cohort comprised subjects who participate in the PREVEND study, a 
prospective cohort in a predominantly Caucasian population that was started in 
1997. Details of the study protocol have been published [23; www.PREVEND.org]. 
In summary, all inhabitants of the city of Groningen, the Netherlands, aged 28 to 
75 years were sent a questionnaire and a vial to collect a first-morning-void urine 
sample (prescreening). Of these subjects, 40,856 responded (47.8%) and returned 
a vial to a central laboratory for urinary albumin and creatinine assessment. After 
exclusion of patients with insulin-treated diabetes mellitus and pregnant women, 
all subjects with a urinary albumin concentration of ≥10 mg/l (n = 7,768) were 
invited of which 6,000 participated. Furthermore, 3,394 randomly selected sub-
jects with a urinary albumin concentration of <10 mg/l were invited of which 2,592 
participated. These 8,592 subjects participated in the baseline screening and con-
stitute the actual PREVEND cohort. For the present study, we excluded participants 
who were non-fasting at the moment blood was drawn (n=428), subjects with a 
prior history of cardiovascular disease (n=426) and those who used lipid lowering 
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drugs at entry (n=238). Finally, we excluded those subjects with missing values of 
one of the following variables: cholesterol, triglycerides, HDL-C, apoA-I, apoB or 
CETP TaqIB (rs708272) genotype (n=720), leaving 6,780 subjects for the present 
analyses. The PREVEND study was approved by the institutional review board and 
is conducted in accordance with the guidelines of the declaration of Helsinki. All 
participants provided signed informed consent. Reporting of the study conforms 
to STROBE STrengthening the Reporting of OBservational studies in Epidemiology) 
and the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) 
guidelines [24].
Baseline measurements and definitions
Participants underwent two visits at the outpatient research unit for the baseline 
survey. They completed a questionnaire on demographics, cardiovascular disease 
history, smoking habits, alcohol consumption and medication use prior to their first 
visit. Height and weight were measured on the first visit. Body mass index (BMI) 
was calculated as the ratio between weight and height squared (in kg/m2). Obesity 
was defined as BMI ≥30 kg/m2. During both visits blood pressure was measured 
in the supine position for 10 min at 1 min intervals using an automatic device 
(Dinamap XL Model 9300, Johnson-Johnson Medical, Tampa, FL). Blood pressure 
values are given as the mean of the last two recordings of both visits; hyperten-
sion was defined as systolic blood pressure of at least 140 mm Hg or diastolic 
blood pressure of at least 90 mm Hg or the use of antihypertensive drugs [25]. 
The participants collected two 24h urine samples for measurement of albumin 
excretion. Microalbuminuria and macroalbuminuria were defined as mean urinary 
albumin excretion between 30 and 300 mg/24h, and > 300 mg/24h, respectively 
[26]. Participants were instructed to remain fasting for at least 8 hr before blood 
sampling which was done at the second visit. Diabetes mellitus was diagnosed by 
fasting plasma glucose ≥7.0 mmol/l, according to 1997 American Diabetes Associa-
tion criteria [27] or use of glucose lowering drugs. Furthermore, information on 
medication use was checked using pharmacy-dispensing data from all community 
pharmacies in the city of Groningen, which covers complete information on drug 




The primary endpoint of this analysis was first major adverse cardiovascular events 
(MACE), which was defined as the combined endpoint of incident cardiovascular 
morbidity and mortality that occurred during the follow-up of the study [11]. 
Information (on hospitalization) for cardiovascular morbidity was obtained from 
PRISMANT (Dutch national registry of hospital discharge diagnoses). Data on mor-
tality and cause of death was obtained by record linkage with the Dutch Central 
Bureau of Statistics. Data were coded according to the International Classification 
of Diseases, 9th revision and the classification of interventions. MACE included the 
following outcomes: acute myocardial infarction (ICD-code 410), acute and sub-
acute ischemic heart disease (411), occlusion or stenosis of the precerebral (433) 
or cerebral arteries (434) and the following procedures: coronary artery bypass 
grafting or percutaneous transluminal coronary angioplasty, and other vascular 
interventions, namely percutaneous transluminal angioplasty or bypass grafting 
of aorta and peripheral arterial vessels. Survival time was defined as the period 
from the baseline survey to the date of a first MACE. Subjects who did not develop 
MACE were censored on January first 2009 or at the date of death or moving twice 
outside the region covered by the municipal registry, whatever date occurred first.
laboratory methods
Blood samples were taken after 15 min rest. Plasma glucose was measured shortly 
after blood sampling. Serum samples for measurement of lipids, apolipoproteins 
and high-sensitive C-reactive protein (hs-CRP) were stored at-80 °C until analysis. 
Serum total cholesterol (TC) and plasma glucose were assessed using Kodak 
Ektachem dry chemistry (Eastman Kodak, Rochester, NY). HDL-C was measured 
with a homogeneous method (direct HDL, no. 7D67, AEROSET System; Abbott 
Laboratories, Abbott Park, IL) [11]. Serum triglycerides were measured enzymati-
cally. LDL-C was calculated with the Friedewald formula. If serum triglycerides were 
greater than 4.5 mmol/l (n=90), LDL-C was considered not available. Non-HDL-C 
was calculated as the difference between total cholesterol and HDL cholesterol. 
Serum apoB and apoA-I were determined by nephelometry applying commercially 
available reagents for Dade Behring nephelometer systems (BN II; Dade Behring, 
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Marburg, Germany; apo A-I test kit, code no. OUED, apo B test kit, code no. OSAN) 
[11]. Reference preparations for apoB and apoA-I were IRP SP3-07 and BCR-393, 
respectively. hs-CRP was measured by nephelometry with a threshold of 0.18 mg/l 
(BNII, Dade Behring, Marburg, Germany).
Urinary albumin concentration was determined by nephelometry (Dade Behring 
Diagnostic). The inter- and intra-assay coefficients of variations (CVs) of all these 
assays were well below 5% except for the inter-assay CV of hs-CRP which was 5.7%.
Venous blood was used for deoxyribonucleic acid (DNA) extraction. Eryth-
rocytes were removed by ammoniumchloride treatment. Genomic DNA was 
extracted from leukocytes with phenol/chloroform. Samples were stored at-80 °C 
until analysis. The TaqIB CETP (rs708272) SNP was analyzed using TaqMan-MGB 
probes and primers, designed through the Assay-by-Design service of Applied 
Biosystems (Applied Biosystems, Applera Nederland, Nieuwerkerk aan de IJssel, 
The Netherlands), as described [28] . For the TaqIB polymorphism, the forward 
primer sequence was 5′-CCCCTAACCTGGCTCAGATC, the reversed primer sequence 
was 5′-GCCAGGTATAGGGATTTGTGTTTGT, and the TaqMan-MGB probes were 
FAM-CCCTAACTTGAACCC and VIC-CCCTAACTCGAACCC. Assays were carried out 
according to the manufacturer’s recommendations on an ABI 7900HT apparatus. 
The –629C>A (rs1800775) promoter SNP was genotyped by two separate PCRs with 
allele-specific primers [29]: 5′-FAM-GCCCCAGCTGTAGGTAAAGTA was used as for-
ward primer in both reactions. Reversed primer 5′-GATATGCATAAAATAACTCTGGGT 
was used to amplify exclusively the A-allele, resulting in a 188-bp PCR product. 
Primer 5′-ttttGATATGCATAAAATAACTCTGGtG was used to amplify the C-allele. This 
latter primer has a four-5′-T-residue tail (lowercase) to generate a discriminating 
PCR product of 192 bp of the C-allele, and the second-to-last nucleotide (lowercase 
t) is a mismatch to improve specificity. After PCR cycling, using standard condi-
tions, samples were combined and separated on a MegaBACE 1000 sequencer 
(Amersham Biosciences Benelux, Roosendaal, The Netherlands). Fragments were 
analyzed with Genetic Profiler 2.0 software (Amersham Biosciences Benelux). 
The TaqIB CETP (rs708272) SNP is in close linkage disequilibrium with the CETP 




Analyses were performed using SPSS version 16.0.2 (SPSS Inc., Chicago, IL, USA) 
and Stata SE 11 (StataCorp, College Station, Tx, USA). Normally distributed values 
are presented as mean ± SD with between group differences being tested with 
Student’s t-tests. Variables with a skewed distribution are presented as median 
(inter-quartile range), and between group differences were tested with Mann–
Whitney U-tests. Differences between genotype groups were tested with one-way 
analysis of variance. Differences between categorical variables were tested using 
χ-square tests.
Event-free survival time for participants was defined as the period between 
inclusion in the study and first MACE. The associations between incidence of MACE 
and (apo)lipoprotein(s) (ratios) were analyzed by Cox proportional hazard analy-
ses. The proportional hazard assumption was assessed for each predictor using 
graphical approaches. Proportional hazard was assumed when the log–log-survival 
curve was found constant over time. The proportional hazards assumption was not 
violated in any model. Age- and sex-adjusted hazard ratios (HRs) are reported per 
1 SD change for each variable with 95% confidence intervals (95% CI). To assess 
the best fitting shape of association between (apo)lipoprotein measures and the 
risk of MACE, we introduced terms with common transformations including linear, 
quadratic, linear plus quadratic, logarithmic, squared root, and exponential in 
multivariable models. The best fit of association of each (apo)lipoprotein variable 
with MACE was found with linear transformation. Possible interactions between 
(apo)lipoprotein ratios and variations in CETP on first MACE were also determined .
Because of the design of the PREVEND study with preferential inclusion of 
subjects with elevated urinary albumin excretion, analyses were re-performed 
using a complex sample design procedure. A two-sided p<0.05 indicated statistical 
significance.
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results
Total follow up was 68,327 person-years. During a median follow-up of 10.8 (inter-
quartile range 10.5-11.1) years 532 first cases of MACE were documented (7.8 per 
1,000 person-years). Subjects who experienced an event (cases) were older, more 
likely to be male and smoked more frequently compared to subjects who did not 
experience MACE during follow-up (controls) (Table 1). Obesity, diabetes mellitus, 
hypertension as well as micro- and macroalbuminuria were more prevalent among 
cases. Serum TC, LDL-C, non-HDL-C, apoB, the TC/HDL-C ratio and the apoB/apoA-I 
ratio, as well as triglycerides and hs-CRP levels were higher, whereas HDL-C and 
apoA-I were lower in cases compared to controls (Table 1). There was no significant 
difference in TaqIB (rs708272) genotype distribution between cases and controls 
(Table 1). Event rates did not significantly differ across the 3 CETP TaqIB (rs708272) 
genotype groups (Table 2)
There were no significant differences in clinical variables between CETP Taq1B 
genotype groups (Table 3). HDL-C and apoA-I were lower in B1B1 than in B2B2 
subjects. Consequently, the TC/HDL-C and the apoB/apoA-I ratios were higher in 
B1B1 than in B2B2 carriers (Table 3).
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Table 1. Baseline clinical and laboratory characteristics and CETP TaqIB (rs 708272) geno-









men (%) 47.6 68.8 45.8 <0.001
Age (years) 48±12 59±11 47±12 <0.001
obesity (%) 15.2 23.4 14.5 <0.001
hypertension (%) 29.7 62.2 27.0 <0.001
microalbuminuria (%) 11.9 24.1 10.9 <0.001
macroalbuminuria (%) 1.3 4.3 1.1 <0.001
diabetes (%) 2.9 7.1 2.5 <0.001
Alcohol use (%) 25.6 26.7 25.5 0.554
smoking status(%) never 30.4 18.0 31.4 <0.001
former smoker 35.8 38.3 35.5
Current 33.8 43.4 33.0
tC (mmol/l) 5.65 ±1.13 6.16±1.12 5.60±1.12 <0.001
ldl-C (mmol/l) 3.65 ±1.04 4.21±1.02 3.64±1.05 <0.001
non-hdl-C (mmol/l) 4.31 ±1.22 4.96±1.19 4.25±1.20 <0.001
hdl-C (mmol/l) 1.34 ±0.40 1.20±0.38 1.35±0.40 <0.001
ApoA-i (g/l) 1.40 ±0.28 1.34±0.27 1.40±0.28 <0.001
ApoB (g/l) 1.04 ±0.30 1.18±0.30 1.02±0.30 <0.001
tC/ hdl-C 4.63 ±1.84 5.67±2.14 4.54±1.79 <0.001
ApoB/apoA-i 0.77 ±0.27 0.92±0.30 0.76±0.26 <0.001
triglycerides (mmol/l) 1.1 (0.8-1.6) 1.5 (1.0-2.2) 1.1 (0.8-1.6) <0.001
hs-CrP (mg/l) 1.2 (0.6-2.9) 1.6 (1.0-2.2) 1.1 (0.8-1.6) <0.001
CETP genotype B1B1 33.9 33.5 34.0 0.925
B1B2 47.7 47.6 47.7
B2B2 18.4 19.0 18.3
Data in mean±SD, median (interquartile range) or percentages. Apo, apolipoprotein; LDL-C, 
low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TC, total choles-
terol; hs-CRP, high sensitivity C-reactive protein.
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men (%) 47.4 47.7 47.7 0.965
Age (years) 48+12 48±12 49±13 0.116
obesity (%) 14.2 15.7 16.6 0.146
hypertension (%) 28.2 30.1 31.5 0.097
microalbuminuria (%) 11.8 11.5 13.3 0.555
macroalbuminuria (%) 1.4 1.3 1.4
diabetes (%) 2.7 3.0 2.7 0.677
Alcohol use (%) 24.8 26.1 25.9 0.522
smoking status(%) never 31.4 30.4 28.2 0.305
former smoker 34.9 35.4 37.8
Current 33.5 33.6 33.7
tC (mmol/l) 5.61+1.15 5.66±1.13 5.67±1.08 0.133
ldl-C (mmol/l) 3.70+1.04 3.70±1.17 3.64±1.03 0.217
non-hdl-C (mmol/l) 4.33+1.23 4.31±1.22 4.26±1.19 0.260
hdl-C (mmol/l) 1.28+0.37 1.35±0.40 1.41±0.42 <0.001
ApoA-i (g/l) 1.36+0.27 1.40±0.28 1.44±0.28 <0.001
ApoB (g/l) 1.03+0.30 1.04±0.31 1.03±0.31 0.662
tC/ hdl-C 4.79+1.98 4.60±1.79 4.40±1.68 <0.001
ApoB/apoA-i 0.79+0.27 0.77±0.27 0.74±0.27 <0.001
Data in mean±SD, median (interquartile range) or percentages. Apo, apolipoprotein; LDL-C; 
low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TC, total choles-
terol; hs-CRP, high sensitivity C-reactive protein.
Age-and sex-adjusted HRs for single (apo)lipoprotein measures (TC, LDL-C, non-
HDL-C, HDL-C and apos) and their ratios in the whole study population are given 
in Table 4. In the total population, first MACE was associated with all pro- and 
anti-atherogenic lipoprotein measures, apolipoproteins and their ratios (p<0.001 
for all).
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In subjects with the B1B1 genotype, MACE was associated with all pro-atherogenic 
lipoprotein variables, apolipoproteins and their ratios (p<0.001 for all) and in-
versely with HDL-C (p<0.001); the association with apoA-I was close to significance 
(p=0.052). In B1B2 carriers, first MACE was also associated with all pro- and 
anti-atherogenic lipoprotein variables, apolipoproteins and their ratios (p=0.041 
to p<0.001). In B2B2 carriers, MACE was associated with Non-HDL-C, the TC/HDL-C 
ratio, apoB and the apoB/apoA-I ratio, but not significantly so with other single 
(apo)lipoprotein measures. When the study population was split by CETP -629C>A 
(rs1800775) genotype (Table 5), it was found that all pro- and anti-atherogenic lipids 
lipoproteins and their ratios were significantly predictive of MACE in CC carriers in 
age- and sex-adjusted analyses (p<0.001 to p=0.010). In the AC carriers, MACE was 
also associated with all single (apo)lipoprotein measures and their ratios (p<0.001 
to p=0.033). In AA homozygotes, all pro-atherogenic measures except for LDL-C 
significantly predicted MACE, whereas the relation of MACE with HDL-C and apoA-I 
did not reach statistical significance. In fully adjusted models, the TC/HDL-C ratio 
(p<0.001) and the apoB/apoAI ratio (p<0.001) remained independent predictors of 
first MACE after further adjustment for conventional risk factors (obesity, smoking, 
hypertension, diabetes), triglycerides, hs-CRP and urinary albumin excretion (Table 
6). Table 6 also shows that in these fully adjusted analyses the TC/HDL-C ratio and 
the apoB/apoAI ratio were still predictive of risk in the separate CETP Taq1B and 
CETP -629C>A genotype groups, except for B2B2 and AA allele carriers.
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Of note, there were no significant interactions of the CETP Taq1B genotype with 
the TC/HDL-C ratio (p=0.986) or the apoB/apoA-I ratio (p=0.229) in predicting first 
MACE. There were also no interactions of the CETP -629C>A genotype with the TC/
HDL-C ratio (p=0.309) or the apoB/apoA-I ratio (p=0.162) in predicting first MACE.
Because of the design of the PREVEND study with enrichment of subjects with 
urinary albumin excretion >10 mg/l, the analyses were repeated using a complex 
sample design procedure. This analysis also showed that the TC/HDL-C ratio (HR 
1.29 (95 % CI, 1.19 to 1.39), p<0.001) and the apoB/apoA-I ratio (HR 1.32 (95 % 
CI, 1.19 to 1.46), p<0.001) predicted first MACE after age- and sex adjustment. 
Moreover, no interactions of the CETP Taq1B genotype with the TC/HDL-C ratio 
(p=0.324) or the apoB/apoA-I ratio (p=0.878) in predicting first MACE were ob-
served. Likewise, the CETP -629C>A genotype did not interact with the TC/HDL-C 
ratio (p=0.913) or the apoB/apoA-I ratio (p=0.956) on first MACE.
disCussion
To our knowledge the present report is the first to test whether common variation 
at the CETP locus would affect the impact of the apoB/apoA-I ratio compared to the 
TC/HDL-C ratio on cardiovascular outcome in the general population. As judged by 
age- and sex-adjusted Cox proportional hazard analyses, our report reveals that the 
strengths of the relationships of first MACE with the apoB/apoA-I and the TC/HDL-
C ratio are essentially similar within each CETP TaqIB and the -629C>A genotype 
groups. Moreover, no significant interactions of the (apo)lipoprotein ratios with 
each of the CETP SNPs tested were demonstrated. Our study, therefore, suggests 
that the strength of the relationships of the cholesterol content in pro- and anti-
atherogenic lipoproteins as compared to their major apolipoproteins on cardio-
vascular risk prediction in the general population is not to an important extent 
impacted by common variation in CETP.
The CETP TaqIB variation and the -629 C>A SNP are closely linked [19,28], and 
were selected for the present study, since they are known to be more strongly 
related to plasma CETP mass and activity levels than other common variants in 
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Caucasian populations [18,28,29]. In a subset of the PREVEND cohort we have 
shown before that CETP mass levels are on average 32 % higher in TaqIB B1B1 
carriers vs. B2B2 carriers and 37 % higher in -629C>A CC allele carriers vs. AA allele 
carriers, respectively [29,30]. In agreement, a meta-analysis reported an increase 
in CETP mass amounting to 10 % for each TaqIB B1 and -629C>A C allele present 
[18]. Of further importance, variation at the CETP locus also influences the plasma 
cholesteryl ester transfer rate between HDL and apoB-containing lipoproteins with 
30 % higher cholesteryl ester transfer rates being documented between -629C>A 
CC allele carriers and AA allele carriers [30,31]. Thus, it is plausible that associations 
of lipoprotein compositional changes with these CETP variants [20] are at least in 
part explained by effects on the plasma cholesteryl ester transfer process. Accord-
ingly, a lower HDL-C/apoA-I ratio, as an indirect measure of smaller HDL particles, 
is found to be associated with the CETP TaqIB B1 varation [19]. Although very large 
HDL particles [32], as well as high HDL-C in the context of high hs-CRP [33], may 
confer increased cardiac risk, it is generally assumed that incident CVD preferen-
tially relates to smaller sized HDL and LDL particles [34,35]. Therefore, preference 
of the apoB/apoA-I ratio over the TC/HDL-C ratio in CVD risk prediction would be 
expected among subjects carrying CETP variants that relate to higher plasma CETP 
levels. Importantly, the lack of any interactions of the (apo)lipoprotein ratios with 
the CETP variations studied on cardiovascular outcome in this large population-
based cohort makes a robust influence of CETP variations on the relative strength of 
the apoB/apoA-I ratio compared to the TC/HDL-C ratio with incident MACE unlikely. 
Furthermore, no consistent trends for any preference of apoB versus non-HDL-C 
and LDL-C, or for apoA-I versus HDL-C for CVD prediction were observed within 
the separate CETP genotype groups. It may, therefore, be suggested that effects of 
the CETP SNPs studied on plasma CETP mass and activity levels are apparently not 
profound enough to affect the relative strengths of the association of CVD risk with 
apolipoproteins as compared to lipoprotein cholesterol measures.
In the present study, the hazard ratio of CVD risk associated with the TC/HDL-C 
ratio was comparable to that associated with the apoB/apoA-I ratio in age- and sex-
adjusted analysis, in agreement with our recent report from the PREVEND cohort 
in which follow-up was three years shorter [11]. As already been documented in 
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that study [11], the risk related to the TC/HDL-C ratio and the apoB/apoA-I ratio did 
not materially change after further adjustment for hypertension, diabetes, obesity, 
smoking, urinary albumin excretion and hs-CRP. Moreover in agreement with our 
recent report [11] and the Emerging Risk Factor collaboration meta-analysis [4], 
we found no relevant preference of apoB over non-HDL-C and of apoA-I over 
HDL-C in the current analysis, irrespective of CETP variation. In contrast, another 
meta-analysis that did include the Interheart study showed benefit of the use of 
apoB compared to non-HDL-C in CVD risk prediction [7], underlining the ongoing 
controversy.
The largest meta-analysis to date has shown that there is a weak inverse as-
sociation of incident coronary heart disease with CETP SNPs that confer higher 
HDL-C [18]. Of note, evidence is accumulating that higher plasma CETP levels do 
not determine worse cardiac outcome [14], but a higher plasma cholesteryl ester 
transfer rate may predict increased coronary risk even independent of plasma lipid 
and CETP mass levels [36]. In our previous study among PREVEND participants, 
the association of coronary risk with the CETP TaqIB and the CETP -629C>A poly-
morphisms was not statistically significant, but risk was higher in combined TaqIB 
B2 allele and in -629C>A A allele carriers after adjustment for HDL-C [29]. For the 
current report with more prolonged follow-up we used incident MACE instead of 
coronary disease as composite outcome measure, and observed that the crude 
total event rate was not significantly different across the 3 CETP genotype groups. 
Within each separate cardiovascular domain there was also no significant univari-
ate difference in risk according to CETP variation.
Several methodological aspects and limitations of our study need to be consid-
ered. First, our study was not designed to carry out separate sex- and CVD domain-
specific analyses within each CETP genotype group. Second, our findings only hold 
true for subjects who were initially free of clinically manifest cardiovascular disease 
and who did not use lipid lowering drugs at baseline. Third, a complex design 
procedure demonstrated similar results with respect to the relationship of first 
MACE with the apoB/apoA-I and the TC/HDL-C ratio. This procedure again showed 
no interactions of CETP gene variations with (apo)lipoprotein ratios on incident 
MACE. Hence, relevant bias in the interpretation of the current results attributable 
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to overrepresentation of microalbuminuric subjects consequent to the focus of 
PREVEND on renal disease is very unlikely. For these reasons, we interpret our 
data to be representative for the general population. Fourth, our study was only 
focussed on variations at the CETP locus. It should, however, be noted that human 
plasma also contains phosholipid transfer protein (PLTP), which plays a crucial role 
in HDL remodelling and lipidation [13]. PLTP variations that confer higher plasma 
PLTP activity were recently found to impact on HDL particle size and to predict 
increased CVD risk [37,38].
In conclusion, it is unlikely that common variations at the CETP locus exert a 
major influence on the strength of the relationships of first cardiovascular events 
with the apoB/apoA-I and the TC/HDL-C ratio in subjects who are initially free of 
cardiovascular disease.
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High plasma cholesteryl ester transfer but not CETP 
mass predicts incident cardiovascular disease:  
A nested case-control study.





Objective: The relationship of cardiovascular disease (CVD) with plasma choles-
teryl ester transfer protein (CETP) levels is controversial. We determined whether 
plasma cholesteryl ester transfer (CET), reflecting CETP-mediated transfer of 
cholesteryl esters from endogenous HDL towards apolipoprotein B-lipoproteins, 
predicts incident CVD.
methods: A prospective nested case-control study was carried out in 114 men who 
developed CVD and 105 controls. Participants did not use lipid lowering drugs at 
baseline. Plasma CET was assayed using an isotope method.
results: Plasma CET was 19 % higher (p=0.030), whereas CETP mass was unaltered 
(p=0.30) in cases vs. controls. Plasma CET predicted CVD (age-adjusted hazard ratio 
(HR): 1.20 (95 % CI 1.02-1.46, p=0.028), but incident CVD was unrelated to CETP 
mass (HR: 0.88 (95 % CI 0.73-1.07), p=0.20). Plasma CET still predicted CVD after 
additional adjustment for total cholesterol/HDL cholesterol, triglycerides and non-
lipid risk markers (HR:1.22 (95 % CI 1.02-1.46, p=0.031).
Conclusion: Plasma CET rather than CETP mass may be a determinant of cardio-
vascular risk.
107
High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease
5
1. introduCtion
The high residual cardiovascular risk during optimal statin treatment underscores 
the need for novel pharmacological therapies [1]. In view of its anti-atherogenic 
properties, HDL has become a therapeutic target [1,2]. One approach to increase 
HDL is directed towards cholesteryl ester transfer protein (CETP), which has unique 
abilities to transfer cholesteryl esters from HDL towards apolipoprotein (apo)B-
lipoproteins [3,4]. The CETP inhibitors, dalcetrapib and anacetrapib, are currently 
being tested in clinical trials [reviewed in 4,5]. Importantly, the CETP inhibitor, 
torcetrapib, has failed to confer cardiovascular protection, despite strong increases 
in HDL cholesterol. This may challenge the concept that HDL cholesterol (HDL-C) 
raising through CETP inhibition is a valid approach to protect against cardiovascular 
disease (CVD) [4,5].
The association of plasma CETP mass or activity, measured with exogenous 
substrates (reflecting the amount of active CETP), with prevalent atherosclerosis 
[reviewed in 5], as well as the relationship of incident CVD with circulating CETP 
levels [6-13] is controversial. Remarkably little is known about the relationship 
of atherosclerosis susceptibility with plasma cholesteryl ester transfer (CET), 
as measure of the endogenous transfer of cholesteryl esters from HDL to apoB-
lipoproteins in plasma [3,14,15]. Plasma CET predicts intima media thickness [14], 
whereas a higher CET is associated with younger age at presentation of myocardial 
infarction [15].
In the absence of any data concerning the relationship of incident CVD with 
plasma CET, we set out to test the effect of CET on CVD in a prospective nested 
case-control study.
2. PAtients And methods
2.1 Study population and design
A nested case-control study was carried out among participants of the Prevention 
of REnal and Vascular ENd stage Disease (PREVEND) cohort. The study was ap-
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proved by the local medical ethics committee. Details of this nested case-control 
study which was carried out in men have been published [9,16]. Subjects without 
a history of myocardial infarction, major ischemia, percutaneous transluminal 
coronary angioplasty or coronary artery bypass graft at baseline were eligible. 
Diabetes mellitus, use of lipid lowering drugs and urinary albumin excretion > 300 
mg/ 24 h at baseline were exclusion criteria. Initial selection of cases was men who 
experienced an event during follow-up (defined below). The original time frame of 
observation included the period from enrolment (1997) until 31 December 2003 
or 31 December 2002 until which date information regarding specific causes of 
death follow up information was available [8]. For the present report, we used 
an extended follow-up, censored at 31 December 2005 [16]. The current report 
includes 114 cases and 105 controls whose CET measurements were available.
Because the matching variable may not be the confounding factor, but may 
make part of a causal pathway linking exposure to outcome, control subjects were 
not matched with cases with respect to lipids and other variables [17]. Conse-
quently, we controlled for confounding and effect modification using multivariable 
analyses.
The combined end-point was incident cardiovascular disease (CVD), defined 
as death from CVD, hospitalization for myocardial infarction, percutaneous trans-
luminal coronary angioplasty or coronary artery bypass grafting [8]. Verification 
of the vital status, causes of death and of cardiovascular end-point was done as 
described [8]. Body mass index (BMI) was calculated as the ratio between weight 
and height squared (in kg/m2). Hypertension was defined as systolic blood pressure 
≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or the use of antihypertensive 
drugs. Microalbuminuria was defined as urinary albumin excretion between 30 and 
300 mg/24h based on two 24 h urine collections.
2.2 Laboratory methods
Venous blood was obtained after an overnight fast. Plasma was prepared by cen-
trifugation at 4ºC, and the samples were stored at –80ºC until analysis. Glucose 
was measured shortly after blood sampling. Total cholesterol, HDL-C, triglycerides 
and glucose were measured as described [9]. Non-HDL cholesterol was calculated 
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as the difference between plasma total cholesterol and HDL-C. LDL cholesterol 
(LDL-C) was calculated by the Friedewald formula. Plasma cholesteryl ester trans-
fer (CET) was assayed using an isotope method exactly as detailed previously [14]. 
[3H]-cholesterol was equilibrated for 24 h with plasma free cholesterol at 4 0C fol-
lowed by incubation at 37 0C during 3 h. Thereafter, apoB-containing lipoproteins 
were precipitated with phosphotungstate/MgCl2. Lipids were then extracted from 
the precipitate, followed by separation of cholesteryl esters on silica columns and 
counting of radioactivity. CETP mass was assayed using a double antibody sandwich 
immune-sorbent assay [9]. The intra-assay coefficients of variation of the CET and 
CETP mass assays were 7.1 % and 7.8 %, respectively.
2.3 Statistical analyses
SPSS 18 was used for data analysis. Data are expressed as mean±SD or in median 
(interquartile range). Between group differences (in percentages) of variables were 
compared with Student’s t-tests, Mann-Whitney tests or χ2-analysis. Spearman’s 
correlation coefficients were determined to assess univariate relationships of 
plasma CET and CETP mass with plasma lipids. Multivariable regression analyses 
were used control for age and non-lipid risk markers in determination of differ-
ences in CET, CETP and lipids. Associations between incident CVD and plasma CET, 
CETP mass and lipids were analyzed using age-adjusted Cox proportional hazards 
models. Hazard ratios (HRs with 95 % confidence intervals (CI)) of CET and CETP 
mass were also calculated after additional adjustment for lipids, and non-lipid risk 
markers. We used Cox proportional hazard analyses, because some controls were 
lost to follow-up before census date. Since the whole PREVEND cohort consists of 
a random sample of subjects with <10 mg/l of urinary albumin concentration and 
all subjects with >10 mg/l of urinary albumin [18], risk was also estimated in a 




Median follow-up was 1072 (10th to 90th percentile, 345-2012) days in cases and 
2548 (10th to 90th percentile, 2516-2548) days in controls. Age, BMI, and prevalence 
of hypertension, smoking and microalbuminuria at baseline were higher in cases 
(Table 1). Plasma total cholesterol, non-HDL cholesterol, LDL-C, triglycerides and 
the total cholesterol/HDL cholesterol (TC/HDL-C) ratio were higher, and HDL-C was 
lower in cases. Plasma CET was on average 19 % higher in cases than in controls. 
In contrast, CETP mass was not significantly different in cases (Table 1). The differ-
ences in CET and lipids (except for LDL-C) between cases and controls remained 
significant after controlling for age, BMI, hypertension, smoking, glucose and 
microalbuminuria.
In all subjects combined, CET was correlated positively with total cholesterol, 
non-HDL cholesterol, triglycerides and TC/HDL-C, and negatively with HDL-C (Table 
2). CETP mass was correlated positively with TC/HDL-C and inversely with HDL-C. 
There was a positive relationship of CET with CETP mass. In cases, CETP mass but 
not CET was correlated with TC/HDL-C and triglycerides. In controls, CET but not 
CETP mass was correlated with non-HDL cholesterol and triglycerides.
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Table 1. Clinical characteristics, microalbuminuria, plasma glucose, lipids and lipoproteins, 
plasma cholesteryl ester transfer (Cet) and cholesteryl ester transfer protein (CetP) mass in 






Age (years) 58 ± 10 47 ± 11 < 0.001
Bmi (kg/m2) 27.4 ± 3.8 25.6 ± 3.1 < 0.001
hypertension (n, %) 62 (54 %) 32 (31 %) < 0.001
smoking (n, %) 62 (54 %) 41 (39 %) 0.033
microalbuminuria (n, %) 34 (30 %) 13 (12 %) 0.0026
glucose 5.0 ± 0.7 4.8 ± 0.6 0.071
total cholesterol (mmol/l) 6.23 ± 1.12 5.58 ± 1.04 < 0.001 0.023
non-hdl cholesterol (mmol/l) 5.19 ± 1.18 4.37 ± 1.10 < 0.001 0.003
ldl cholesterol (mmol/l) 4.33 ± 1.07 3.77 ± 0.95 < 0.001 0.092
hdl cholesterol (mmol/l) 1.04 ± 0.35 1.21 ± 0.34 < 0.001 0.005
triglycerides (mmol/l) 1.61 (1.11-2.38) 1.14 (0.81-1.60) < 0.001 < 0.001
total cholesterol/  
HDL cholesterol ratio
6.52 ± 2.26 4.99 ± 1.73 < 0.001 < 0.001
Cet (nmol/ml/h) 12.20 ± 7.39 10.32 ± 5.15 0.030 0.014
CetP mass (mg/l) 2.34 ± 0.80 2.45 ± 0.84 0.30 0.51
Data in mean ± SD or in median (interquartile range). BMI, body mass index. P-value*: ad-
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Age-adjusted incident CVD was predicted positively by plasma CET, total choles-
terol, non-HDL cholesterol, LDL-C, triglycerides and TC/HDL-C, and inversely by 
HDL-C (Table 3A). An inverse trend was observed for the association of incident 
CVD with CETP mass (Table 3A). The association of incident CVD with CET was 
essentially unaltered after additional adjustment for triglycerides and TC/HDL-C 
(the lipoprotein-related variable that showed the highest HR for incident CVD), 
as well as after further controlling for BMI, hypertension, smoking, glucose and 
microalbuminuria (Table 3B). Furthermore, CET remained predictive of incident 
CVD after controlling for CETP mass, as well as after additional adjustment for BMI, 
hypertension, smoking, glucose and microalbuminuria (Table 3C). In alternative 
analyses with non-HDL cholesterol and HDL cholesterol instead of the TC/HDL-C 
ratio, comparable associations of incident CVD with CET were observed after addi-
tional adjustment non-lipid risk markers (c.f. Table 3 B; HR 1.21 (95 % CI, 1.01-1.45, 
P = 0.040) as well as after adjustment for both non-lipid risk markers and CETP 
mass (c.f. Table 3C; HR 1.21 (95 % CI, 1.01-1.45), P = 0.043). Finally, a sensitivity 
analysis (among those subjects which were recruited from the so-called random 
sample of the cohort [18]) revealed a comparable point estimate of the hazard 
associated with CET (HR 1.26 (95 % CI, 0.94-1.68), p=0.12).
Table 3. Hazard ratios (HRs with 95 % confidence intervals, CI) of plasma cholesteryl ester 
transfer (Cet), cholesteryl ester transfer protein (CetP) mass, plasma lipids and lipoproteins 
for incident cardiovascular disease (CVD) by Cox proportional hazard analysis. All HRs are 
age-adjusted and are given per 1 sd increase.
A: Age-adjusted hazard ratios of each variable for incident CVD.
HR (95 % CI) P-value
Plasma Cet 1.20 (1.02-1.46) 0.028
Plasma CetP mass 0.88 (0.73-1.07) 0.20
total cholesterol 1.22 (1.03-1.44) 0.020
non-hdl cholesterol 1.39 (1.15-1.67) 0.001
ldl cholesterol 1.24 (1.03-1.50) 0.022
hdl cholesterol 0.64 (0.52-0.80) < 0.001
ln triglycerides 1.43 (1.19-1.71) < 0.001
Total cholesterol/HDL cholesterol ratio 1.53 (1.30-1.80) <0.001
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B: Age-adjusted hazard ratios of plasma CET and CETP mass for incident CVD after additional 
adjustment for triglycerides and the total cholesterol/HDL cholesterol ratio (*), and after ad-
ditional adjustment for triglycerides, the total cholesterol/HDL cholesterol ratio, body mass 
index, hypertension, smoking, plasma glucose and microalbuminuria (**).
HR (95 % CI) P-value
Plasma CET* 1.20 (1.00-1.45) 0.055
Plasma CETP mass* 0.82 (0.67-1.01) 0.061
Plasma CET** 1.22 (1.02-1.46) 0.031
Plasma CETP mass** 0.91 (0.73-1.13) 0.367
C: Age-adjusted hazard ratios of plasma CET for incident CVD after additional adjustment for 
plasma CETP mass (*), and after additional adjustment for CETP mass, triglycerides, the total 
cholesterol/HDL cholesterol ratio, body mass index, hypertension, smoking, plasma glucose 
and microalbuminuria (**).
HR (95 % CI) P-value
Plasma CET* 1.21 (1.02-1.45) 0.033
Plasma CET** 1.22 (1.02-1.46) 0.031
4. disCussion
This prospective nested case-control study documents that incident CVD is associ-
ated positively with plasma CET but not with CETP mass among men who did not 
use lipid lowering drugs at entry. Remarkably, CET also predicted CVD after control-
ling for TC/HDL-C, triglycerides and non-lipid risk markers. Thus, higher plasma CET 
rather than the CETP concentration may represent an independent predictor of 
incident CVD.
It is important to distinguish between plasma levels of active CETP, as mea-
sured by exogenous substrate assays that reflect CETP activity independent of the 
endogenous plasma lipoproteins, and assays that document plasma cholesteryl 
ester transfer in the context of the endogenous lipoproteins present in plasma, 
as employed in this report [3]. The isotope method that we used to assay CET 
represents an accurate measure of net mass transfer of cholesteryl esters from 
HDL towards apoB-lipoproteins [14,15]. In addition to the CETP concentration, 
the constellation of apoB-lipoproteins that accept cholesteryl esters from HDL are 
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major determinants of plasma CET [3,14,15,19]. In turn, plasma CETP mass was 
reported previously to be associated with total cholesterol in hyperlipoprotein-
emia, but not significantly in normolipidemia [20]. In cases and control subjects 
combined, we observed that plasma CET was correlated positively with non-HDL 
cholesterol, triglycerides and the TC/HDL-C ratio, and negatively with HDL-C. In 
addition, CET was also related to CETP mass. Of note, the relationship of CET with 
non-HDL cholesterol and triglycerides reached significance only in control subjects. 
On the other hand, CETP mass was correlated with the TC/HDL-C ratio and triglyc-
erides in cases but not in controls. The extent to which this finding would reflect 
that the amount of CETP becomes a limiting factor in the cholesteryl ester transfer 
process particularly in subjects who develop CVD in future, as previously observed 
in hypertriglyceridemia [21], is uncertain.
The impact of plasma CETP on incident CVD is currently debated. High CETP 
mass levels may determine higher risk in subjects with high triglycerides [7], but 
lower risk in subjects with low triglycerides [9]. More recently, plasma CETP activ-
ity, measured with exogenous substrates, was related inversely to a first CVD event 
[10]. Lower CETP mass predicted mortality among subjects referred for coronary 
angiography [12]. Decreased CETP mass also determined higher rates of recurrent 
cardiac events during (subsequently initiated) statin therapy [8,11]. This supports 
that CETP could have anti-artherogenic potential in the setting of enhanced clear-
ance of apoB-lipoproteins. The current results, obtained in subjects who did not 
use lipid lowering drugs at entry, complements these reports. Furthermore, a novel 
finding of our study is that incident CVD remained associated with CET when taking 
the TC/HDL-C ratio (or non-HDL-C and HDL-C separately), triglycerides, non-lipid 
risk markers and even CETP mass into account. This suggests that CET rates may 
still influence CVD risk in the context of the individual’s lipid and CETP levels. Of 
interest, the current report clearly suggested opposing trends of CET compared to 
CETP mass on risk, despite CET being related to CETP mass. Our study, therefore, 
suggests a paradigm in CVD risk assessment concerning plasma CET, reflecting 
transfer of cholesteryl esters between lipoproteins, and CETP mass, which is closely 
related to active CETP levels.
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Some other methodological considerations need consideration. We included 
men only, and confined case definition to cardiac end-points [9,16]. Therefore, no 
conclusion is allowed concerning possible effects of CET on CVD in women, nor 
concerning relationships of other cardiovascular risk domains with CET. More-
over, the PREVEND cohort is enriched with microalbuminuric subjects [9,16,18]. 
Controlling for microalbuminuria did not affect the association of CVD with CET, 
and a sensitivity analysis among the subset of subjects recruited from the random 
sample of PREVEND [18] revealed a comparable point estimate of CET-related haz-
ard. Therefore, bias due to preferential participation of microalbuminuric subjects 
of is unlikely.
In conclusion, plasma CET rather than CETP mass may represent a positive pre-
dictor of incident cardiovascular risk among men who did not receive lipid lowering 
drug treatment at entry.
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Carotid intima media thickness is associated 
with plasma adiponectin but not with the leptin: 
adiponectin ratio independently of metabolic 
syndrome





Purpose: A recent report showed no benefit of the leptin:adiponectin ratio (L:A 
ratio) over individual adipokine levels in CHD prediction (Karakas M et al. Athero-
sclerosis 2010;209:220-5). We determined associations of carotid intima media 
thickness (IMT) with the L:A ratio taking account of cardiovascular risk factors in a 
high risk population.
methods: IMT, plasma leptin, adiponectin and the L:A ratio were determined in 
161 middle aged men and women (45 % metabolic syndrome).
results: IMT was associated inversely with adiponectin and positively with the 
L:A ratio in age- and sex-adjusted multiple linear regression analyses (p<0.001 
for both). After controlling for metabolic syndrome, the independent association 
with adiponectin remained (p<0.001), but the relationship with the L:A ratio disap-
peared (p=0.126). Results were similar after additional adjustment for diabetes 
status or for insulin resistance.
Conclusion: This study does not support the preferential use of the leptin:adiponectin 
ratio as a marker of atherosclerosis susceptibility.
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1. introduCtion
There is considerable interest in the role of pro- and anti-inflammatory adipokines, 
such as leptin and adiponectin, in the development of atherosclerosis [1]. While 
associations of carotid intima media thickness (IMT), a well established predictor 
of cardiovascular disease, with plasma adiponectin [2-4] and in some studies also 
with leptin [5] have already been documented, the relevance of plasma leptin and 
adiponectin levels for predicting incident cardiovascular disease is less clear. The 
positive association of incident coronary heart disease (CHD) with plasma leptin is 
modest, and is to a considerable extent attenuated by obesity [6]. A meta-analysis 
demonstrated only a weak relationship of incident CHD with plasma adiponectin 
[7]. More recently, a prospective population-based case-cohort study within the 
MONICA/KORA Augsburg project demonstrated that plasma leptin and adiponectin 
levels predict incident CHD [8]. Interestingly, these associations disappeared after 
controlling for conventional risk factors and inflammatory markers [8].
The preferential use of the plasma leptin:adoponectin ratio (L:A ratio) as a 
marker of atherosclerosis susceptibility has been advocated [9,10,11]. Accordingly, 
the relationship of incident CHD with the L:A ratio was additionally assessed in 
the MONICA/KORA Augsburg studies. Importantly, no advantage of this ratio in 
CHD risk prediction could be demonstrated in this report [8]. These apparently 
contradictory findings [8-11] led us to determine the associations of IMT with the 
plasma L:A ratio and with plasma leptin and adiponectin concentrations alone, tak-
ing account of CVD risk factors as indicated by the presence of metabolic syndrome 
(MetS).
2. mAteriAls And methods
2.1 Subjects
The study was approved by the local medical ethics committee. Participants (aged 
> 18 years) were recruited by advertisement in local news papers, and provided 
written informed consent. Diabetic patients were allowed to participate. Clinically 
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manifest cardiovascular disease and renal disease were exclusion criteria. Cur-
rent smokers and subjects using lipid lowering drugs did not participate to avoid 
possible confounding effects on IMT and lipid metabolism, as outlined elsewhere 
[12]. Use of antihypertensive medication was permitted. Waist circumference was 
measured between the 10th rib and the iliac crest. Blood pressure was measured 
after 15 min rest at the left arm in sitting position using a sphygmomanometer. 
Type 2 diabetes mellitus had been previously diagnosed by primary care physi-
cians using blood glucose cut-off values as defined by the WHO. In addition to diet 
diabetic patients were treated with oral glucose lowering agent if indicated, but 
the use of insulin and of thiazolidinediones was not allowed. Three or more of the 
following criteria were required for categorization of subjects with MetS (National 
Cholesterol Education Program, ATP III 2001 criteria): waist circumference > 102 cm 
for men and > 88 cm for women; hypertension (blood pressure ≥ 130/85 mmHg or 
use of antihypertensive medication); fasting plasma triglycerides ≥ 1.7 mmol/l; HDL 
cholesterol < 1.0 mmol/l for men and < 1.3 mmol/l for women; fasting glucose ≥ 6.1 
mmol/l or known diabetes. The participants were evaluated after overnight fasting. 
Insulin resistance was determined using homeostasis model assessment (HOMAir), 
and was calculated with the equation: insulin (mU/l) x glucose (mmol/l)/22.5.
Carotid IMT was measured using high-resolution B-mode ultrasound imaging 
(ACUSON 128 XP, Mountain View, CA, USA) as detailed elsewhere [12]. Three 
arterial wall segments from both carotid arteries were imaged from a fixed lateral 
transducer angle at the far wall. The segment 1 cm proximal to the carotid dilata-
tion (common carotid artery), the segment between the carotid dilatation and 
carotid flow divider (carotid bulb) and a 1 cm segment distal to the flow divider 
(internal carotid artery) were scanned. The mean IMT of 6 carotid artery segments 
was used for analysis.
2.2 Laboratory methods
Venous blood was collected in EDTA containing tubes. Plasma samples were stored 
at -80 0C until analysis, but glucose was measured shortly after blood collection 
with an APEC glucose analyzer. Total cholesterol and triglycerides were measured 
by routine enzymatic methods. HDL cholesterol was assayed by a homogeneous 
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enzymatic colorimetric test. Leptin and total adiponectin concentrations were 
analyzed using Luminex xMAP technology with commercially available kits (Linco 
Research Inc. St. Charles, MO, USA, Lincoplex panel A and B (HADK-1-61K-A and 
HADK-2-61K-B, respectively)). Insulin was measured by microparticle enzyme im-
munoassay.
2.3 Statistical analysis
Data are given in mean ± SD or in median (interquartile range). Because of skewed 
distribution, leptin and adiponectin concentrations as well as the L:A ratio and 
HOMAir were logarithmically transformed. Between group differences were com-
pared by t-tests for unpaired observations. Chi-square analysis was used to de-
termine between group differences in frequency distribution. Pearson correlation 
coefficients were calculated to determine univariate relationships. Multiple linear 
regression analysis with a subsequent backward procedure was performed to 
disclose independent contributions between variables. In these analyses standard 
deviation (Z) scores for adiponectin, leptin and the L:A ratio were used. Two-sided 
P-values < 0.05 were considered significant.
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Table 1. Clinical characteristics, mean carotid intima media thickness (IMT), insulin resis-
tance (homAir), plasma lipids, leptin, adiponectn and the leptin:adopinectin ratio (L:A ratio) 






Age (years) 58 ± 9 56 ± 10 0.14
Sex (women/men) 32/40 36/53 0.73
diabetes history (yes/no) 53/19 26/63 <0.001
systolic blood pressure (mm hg) 145 ± 18 131 ± 20 <0.001 0.005
diastolic blood pressure (mm hg) 89 ± 9 81 ± 10 <0.001 <0.001
Body mass index (kg/m2) 29.9 ± 4.5 24.8 ± 3.2 <0.001 <0.001
waist circumference (cm) 104 ± 12 86 ± 11 <0.001 <0.001
imt (mm) 0.890 ± 0.205 0.811 ± 0.140 0.007 0.036
Fasting glucose (mmol/l) 8.5 ± 2.8 6.2 ± 1.4 <0.001 <0.001
Fasting insulin (mU/l) 11.2 (8.53-16.95) 5.2 (4.25-7.65) <0.001 <0.001
HOMAir (mU x mmol/l 2 x 22.5) 3.96 (2.80-6.58) 1.41 (1.04-2.06) <0.001 <0.001
total cholesterol (mmol/l) 5.52 ± 0.95 5.56 ± 0.96 0.81 0.37
hdl cholesterol (mmol/l) 1.17 ± 0.34 1.55 ± 0.38 <0.001 <0.001
triglycerides (mmol/l) 1.95 (1.66-2.50) 1.10 (0.84-1.52) <0.001 <0.001
Leptin (µg/l) 12.35 (5.43-31.48) 4.80 (2.95-11.2) <0.001 <0.001
Adiponectiin (mg/l) 14.7 (10.15-27.1) 18.8 (13.9-42.65) <0.001 0.005
Leptin: adiponectin ratio (µg/mg) 0.80 (0.37-1.81) 0.23 (0.10-0.91) <0.001 <0.001
Data are in mean ± SD or in median (interquartile range). P-value* adjusted for age, sex and 
diabetes history.
3. results
Seventy-two participants with MetS and 89 subjects without Mets participated 
(Table 2). Diabetes had been diagnosed more frequently in subjects with MetS. 
Of diabetic patients 57 used oral glucose lowering agents. Antihypertensives were 
used by 27 subjects with and 4 subjects without MetS. Besides expected differences 
in obesity, blood pressure, glucose, HDL cholesterol and triglycerides, IMT, insulin, 
HOMAir, leptin and the L:A ratio were higher, whereas adiponectin was lower in 
subjects with MetS compared to subjects without MetS. All differences remained 
significant after adjustment for age, sex and diabetes history. The univariate cor-
relation of HOMAir with the L:A ratio appeared to be stronger (r = 0.609, p < 0.001) 
than with leptin (r = 0.443, p < 0.001) and adiponectin alone (r = -0.458, p < 0.001).
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Table 2. Multiple linear regression models showing relationships of mean carotid artery in-
tima media thickness (IMT) with adiponectin, leptin, the leptin:adiponectin ratio (L:A ratio) 
in 161 subjects. Panel A: models without the presence of metabolic syndrome (mets) as 
covariate. Panel B: models including the presence of mets as covariate.
A model 1 model 2 model 3



















Ln leptin (Z-score) 0.098 0.252
Ln L:A ratio (Z-score) 0.187 <0.001
B model 1 model 2 model 3

























Ln leptin (Z-score) 0.000 0.99
Ln L:A ratio (Z-score) 0.123 0.126








All models are adjusted for age and sex. Models 1 include adiponectin; models 2 include leptin; 
models 3 include the L:A ratio. Adiponectin, leptin and the L:A ratio are given in standard de-
viation (Z) scores after logarithmic (Ln) transformation. Independent statistical determinants 
of IMT as assessed by subsequent backward elimination are shown in bold. β: standardized 
regression coefficient.
As shown in Table 2 (panel A) plasma adiponectin but not leptin was significantly 
associated with IMT independently of age and sex (models 1 and 2). IMT was also 
related to the L:A ratio (model 3). IMT remained independently associated with 
adiponectin in analyses that included the presence of MetS (panel B, model 1). 
However, no independent relationship of IMT with leptin and the L:A ratio was ob-
served when the presence of MetS was taken into account (models 2 and 3). When 
diabetes status was additionally included as covariate, the relationship of IMT with 
adiponectin was still significant in analyses without and with MetS as covariate 
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(p <0.01 for both). Again no association of the L:A ratio with IMT was found inde-
pendent of the presence of MetS and diabetes history (p =0.16) (data not shown). 
Alternatively, when HOMAir was added as covariate, age- and sex adjusted IMT was 
independently associated with adiponectin (p < 0.05) and with HOMAir (p< 0.02). 
IMT was also unrelated to the L:A ratio after controlling for HOMAir (p = 0.673), or 
for HOMAir and MetS together (p= 0.707) (data not shown).
4. disCussion
This study shows that IMT, as measure of subclinical atherosclerosis, is inversely 
related to plasma adiponectin independently of the presence of MetS. Although 
IMT was also related to the plasma L:A ratio, this association disappeared when 
controlling for the presence of MetS. Similar findings were observed after adjust-
ment for diabetes history or for insulin resistance. Our results, therefore, do not 
support the supposition that the L:A ratio is a preferable measure of atheroscle-
rosis susceptibility compared to plasma adiponectin alone taking conventional risk 
factors into consideration.
In overweight individuals, the plasma L:A ratio rather than leptin or adiponectin 
was found to be correlated with pulse wave velocity, as an indicator of arterial 
stiffness [9]. Subsequently, IMT was documented to be associated positively with 
the L:A ratio independently of blood pressure, plasma lipids and glycemic control 
in Japanese people with type 2 diabetes [10]. In this report, effects of the L:A ratio 
were confined to older subjects [10]. Another study in healthy middle-aged Italian 
men demonstrated a positive relationship of IMT with the L:A ratio after controlling 
for blood pressure, obesity, glucose and lipids [11]. Strong co-linearity between 
leptin, adiponectin and the L:A ratio precludes their simultaneous inclusion in 
multivariable regression analysis in our study. However, as inferred from the stan-
dardized regression coefficients in separate models, the association of IMT with 
adiponectin appeared to be stronger than that with the L:A ratio. Furthermore, 
there was no independent association of IMT with the L:A ratio after adjustment 
for the presence of MetS in this high CVD risk cohort. This lack of association of 
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IMT with the L:A ratio when taking the presence of MetS into account seems at-
tributable to its strong relationship with insulin resistance [13], as confirmed here.
We applied several selection criteria for participation to reduce confounding 
influences on IMT. This might limit extrapolation of our findings to other popula-
tions. Furthermore, since adiponectin isoforms were not measured, no conclusion 
is allowed regarding relationships of subclinical atherosclerosis with alterations 
in adiponectin oligomerization [1]. Nonetheless, this study reinforces that IMT is 
associated inversely with plasma total adiponectin, even independently of well 
established CVD risk factors. Thus, our findings would add to the concept of “re-
verse epidemiology”, possibly involving compensatory mechanisms counteracting 
metabolic stress, which might explain the emerging paradox of absent or even a 
positive association of incident CVD with adiponectin [1,14,15].
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The plasma leptin/adiponectin ratio predicts first 
cardiovascular event in men: a prospective nested 
case-control study.
P.J.W.H. Kappelle, R.P.F. Dullaart, A.P. van Beek, J.L. Hillege, B.H.R. Wolffenbuttel
on behalf of the PREVEND study group




Objective: The plasma leptin/adiponectin (L/A) ratio has been proposed as a prefer-
ential marker of atherosclerosis susceptibility compared to leptin and adiponectin 
alone. We determined the extent to which the L/A ratio predicts incident cardio-
vascular disease (CVD) taking account of clinical risk factors, microalbuminuria, 
the total cholesterol/HDL cholesterol (TC/HDL-C ratio), triglycerides, high sensitive 
C-reactive protein (hs-CRP) and insulin sensitivity (homeostasis model assessment 
(HOMAir)).
methods: A community-based prospective nested case-control study was carried 
out in 103 non-diabetic men who developed a first cardiovascular event (cases) 
and 106 male control subjects (no clinically manifest CVD and no lipid lowering 
drug use at baseline; median follow-up of 3.0 and 10.5 years, respectively). Plasma 
leptin, adiponectin, the leptin/adiponectin (L/A) ratio, as well as hs-CRP, HOMAir 
and the TC/HDL-C ratio were determined at baseline.
results: Plasma leptin levels and the L/A ratio were higher in cases vs. controls 
(p=0.002 for both), but the difference in adiponectin was not significant (p=0.10). 
Age-adjusted incident CVD was associated with plasma leptin, adiponectin and the 
L/A ratio (p=0.045 to p=0.001). The relationships of incident CVD with plasma leptin 
(p=0.19) and adiponectin (p=0.073) lost statistical significance after additional ad-
justment for smoking, waist circumference, hypertension, microalbuminuria, the 
TC/HDL-C ratio, hs-CRP and HOMAir. In this fully adjusted analysis, the L/A ratio re-
mained predictive of incident CVD (hazard ratio: 1.40 (95% CI 1.05-1.87), p=0.024).
Conclusion: This study suggests that the L/A ratio may be a preferential marker 
of a first cardiovascular event in men compared to plasma leptin and adiponectin 
levels alone.
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1. introduCtion
Leptin and adiponectin are secreted by adipose tissue, and represent the most 
abundant adipokines in human plasma [1-5]. Despite intensive study, the relevance 
of leptin and adiponectin in cardiovascular disease (CVD) prediction is still un-
settled. Although high plasma leptin levels predict incident CVD, this relationship is 
to a considerable extent attenuated by obesity [6]. A meta-analysis revealed that 
higher plasma adiponectin levels confer only a modest cardioprotective effect [7]. 
Intriguingly, pro-atherogenic effects of leptin and anti-atherogenic effects of adi-
ponectin could paradoxically disappear in people who are already suffering from 
advanced atherosclerosis [8,9].
Based on intima media thickness and other surrogate outcome measures it 
has been proposed that the L/A ratio may be preferable over separate leptin and 
adiponectin measurements in CVD risk assessment [10-13], but the advantage of 
the L/A ratio in predicting subclinical atherosclerosis is uncertain [14,15]. Informa-
tion concerning the relevance of the L/A ratio in clinical cardiovascular outcome 
prediction is limited. In the Monica/KORA Augsburg studies, incident CVD was 
related to plasma levels of leptin, adiponectin, as well as to the L/A ratio in age-, 
sex- and survey-adjusted analyses [16]. Of note, none of these adipokine measures 
predicted incident CVD after additional controlling for clinical and non-clinical risk 
factors [16].
It is well appreciated that plasma levels of high-sensitive C-reactive protein (hs-
CRP), as a marker of chronic subclinical inflammation, are correlated positively to 
plasma leptin and inversely to adiponectin [17-19]. Of further importance, various 
measures of insulin sensitivity are strongly dependent on the L/A ratio, emphasiz-
ing the role of adipocyte dysfunction in the pathogenesis of insulin resistance [20]. 
It is, therefore, relevant to take account of chronic subclinical inflammation and 
insulin sensitivity when evaluating the relationship of cardiovascular outcome with 
the L/A ratio.
In the present study, we determined the extent to which incident CVD is associ-
ated with the L/A ratio. To this end a prospective nested case-control study was 
carried out among participants of the community-based Prevention of Renal and 
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Vascular End-stage Disease (PREVEND) cohort. The set up of this study enabled us 
to take account of conventional clinical and non-clinical risk factors, microalbumin-
uria, hs-CRP and insulin sensitivity.
2. suBjeCts And methods
2.1 Study population and design
The local medical ethics committee approved the study, and all participants gave 
written informed consent. The present prospective nested case-control study was 
carried out among participants of the PREVEND cohort. Details of the PREVEND 
study have been published elsewhere [www.PREVEND.org, 21]. The PREVEND 
study comprises a prospective study in a predominantly Caucasian population 
that was started in 1997. To this end all inhabitants of the city of Groningen, the 
Netherlands, aged 28 to 75 years were sent a questionnaire and a vial to collect 
a first-morning-void urine sample (prescreening). Of these subjects, 40,856 re-
sponded (47.8%) and returned a vial to a central laboratory for urinary albumin and 
creatinine assessment. After exclusion of patients with insulin-treated diabetes 
mellitus and pregnant women, all subjects with a urinary albumin concentration 
of ≥10 mg/l (n = 7,768) were invited of which 6,000 participated. Furthermore, 
3,394 randomly selected subjects with a urinary albumin concentration of <10 
mg/l were invited of which 2,592 participated. These 8,592 subjects participated in 
the baseline screening and constitute the actual PREVEND cohort.
Men without a history of myocardial infarction, major ischemia, percutaneous 
transluminal coronary angioplasty or coronary artery bypass graft at baseline were 
eligible for the present nested case-control study, as described [21]. Diabetes mel-
litus, use of lipid lowering drugs and urinary albumin excretion > 300 mg/24 h at 
baseline were additional exclusion criteria. Initial selection of cases was men who 
experienced an event during follow-up as defined below. The original time frame of 
observation included the period from enrolment (1997) until 31 December 2003 or 
31 December 2002 until which date information regarding specific causes of death 
follow up information was available [23]. For the present study an extended follow-
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up, censored at 31 December 2008 was used. Control subjects were randomly se-
lected from the baseline sample applying similar exclusion criteria as for the cases 
[21]. The current report includes 103 cases and 106 controls in whom in addition to 
serum lipids, apolipoproteins (apos), insulin and hs-CRP, plasma adiponectin, leptin 
measurements were available.
Since the matching variable may not be the confounding factor, but may make 
part of a causal pathway linking exposure to outcome, cases were not individually 
matched with control subjects with respect to age and other clinical variables, 
thereby following the methodological approach as proposed by O.S. Miettinen 
[22]. As a consequence, we controlled for confounding and effect modification 
using multivariable analyses.
The combined end-point was incident cardiovascular disease (CVD), defined as 
death from CVD, hospitalization for myocardial infarction, percutaneous translu-
minal coronary angioplasty or coronary artery bypass grafting [21]. Verification of 
the vital status, causes of death and of cardiovascular end-point was performed 
as described [21]. Body mass index (BMI) was calculated as the ratio between 
weight and height squared (in kg/m2). Waist circumference was measured on bare 
skin between the 10th rib and the iliac crest. Hypertension was defined as systolic 
blood pressure ³ 140 mmHg or diastolic blood pressure ³ 90 mmHg or the use of 
antihypertensive drugs. Insulin resistance was estimated using homeostasis model 
assessment (HOMAir), and was calculated with the equation: fasting plasma insulin 
(mU/l) x glucose (mmol/l)/22.5. Microalbuminuria was defined as urinary albumin 
excretion between 30 and 300 mg/24h based on two 24 h urine collections.
2.2 Laboratory Analyses
Serum and ethylenediaminetetraacetic acid-anticoagulated plasma samples were 
stored at -80 0C until analysis. Plasma glucose was measured shortly after blood 
collection. Total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), tri-
glycerides and glucose were measured as described [21,23]. Non-HDL cholesterol 
(non-HDL-C) was calculated as the difference between plasma total cholesterol 
and HDL-C. Apolipoprotein (apo) B and apoA-I were determined by nephelom-
etry using commercially available reagents [23]. Plasma leptin was analyzed using 
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Luminex xMAP technology (Linco Research Inc. St. Charles, MO, USA, Lincoplex 
panel B (HADK-2-61K-B). Validation experiments have shown that leptin levels 
measured with this technology are strongly correlated with assay results obtained 
by enzyme-linked immunosorbent assay (ELISA) obtained from Linco Inc. [24; data 
provided by the manufacturer]. Total adiponectin was measured by enzyme-linked 
immunosorbent assay (Linco Research Inc., St. Charles, MO, USA, cat no EZHADP-
61k). The within-assay coefficients of variation for leptin and adiponectin were 8.9 
% and 6.4 %, respectively. Insulin was measured by microparticle enzyme immuno-
assay (AxSYM Insulin assay; Abott Laboratories, Abbott Park IL, USA). hs-CRP was 
measured by nephelometry with a threshold of 0.18 mg/l [23].
2.3 Statistical analyses
SPSS 18 was used for data analysis. Two-sided p-values £ 0.05 were considered 
significant.
Data are expressed as mean ± SD or in median (interquartile range). Differences 
in variables between cases and controls were compared with unpaired Student’s 
t-tests. Between group differences in dichotomous variables were compared by 
χ2-analysis. Because of skewed distribution, logarithmically transformed values of 
leptin, adiponectin, the L/A ratio, triglycerides, hs-CRP, insulin and HOMAir were 
used in the analysis. Between group differences in leptin, adiponectin and the L/A 
ratio were also determined after controlling for age. Univariate relationships were 
assessed by Pearson’s correlation coefficients.
Associations between incident CVD and plasma levels of leptin, adiponectin 
and the L/A ratio were determined using age-adjusted Cox proportional hazards 
analyses. The date of a first event was used to calculate duration of follow-up. The 
proportional hazards assumption was not violated in any of the models. Hazard 
ratios (HRs) are reported per SD change with 95% confidence interval (95% CI). HRs 
of adipokines and the L/A ratio were also determined after further adjustment for 
clinical variables, the TC/HDL-C ratio, triglycerides and microalbuminuria, as well 
as after additional adjustment for HOMAir and hs-CRP. We used Cox proportional 
hazard analyses, because some controls were lost to follow-up before census date.
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The whole PREVEND cohort consists of a random sample of subjects with 
urinary albumin concentration <10 mg/l and all subjects with urinary albumin 
concentration ≥10 mg/l [25]. Since enrichment for subjects with higher degrees 
of albuminuria could induce bias due to oversampling of subjects with urinary 
albumin concentration ≥10 mg/l, we also estimated risk in a sensitivity analysis. 
This sensitivity analysis was done among those subjects included in the present 
nested case-control study who made part of the so-called “random sample” of the 
PREVEND cohort, i.e. all subjects with urinary albumin concentration < 10 mg/l 
and a subset of subjects with urinary albumin concentration ≥10 mg/l, exactly as 
described previously [25].
3. results
Median follow-up was 3.0 (10th to 90th percentile, 0.9-5.8) years in cases and 
10.5 (10th to 90th percentile, 9.1-11.1) years in control subjects. Cases were older, 
more obese, smoked more frequently, had a higher prevalence of hypertension 
and microalbuminuria, had higher hs-CRP levels and were more insulin resistant 
compared to control subjects (Table 1). Plasma TC, non-HDL-C, the TC/HDL-C ratio 
and triglycerides were higher, whereas HDL-C was lower in cases. Likewise, apoB 
and the apoB/apoA-I ratio was increased, whereas apoA-I was decreased in cases. 
Plasma leptin levels and the L/A ratio were elevated in cases, although the differ-
ence in adiponectin was not significant (Table 1). In age-adjusted analyses, plasma 
adiponectin (p=0.013) and the L/A ratio (p=0.006) were different in cases compared 
to controls, but the difference in plasma leptin did not reach significance (p=0.065).
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Table 1. Clinical characteristics, microalbuminuria, plasma glucose, high sensitive C-reactive 
protein (hs-CRP), insulin sensitivity (homeostasis model assessment (HOMAir)), lipids and 







Age (years) 58±10 47±12 <0.001
Bmi (kg/m2) 27.0±3.5 25.8±3.2 0.009
waist circumference (cm) 97±10 92±9 <0.001
hypertension (n, %) 58 (56%) 31 (29%) <0.001
smoking (n, %) 57 (55%) 38 (36%) 0.005
microalbuminuria (n, %) 31 (30%) 14 (13%) 0.007
hs-CrP (mg/l) 2.09 (1.10-3.54) 0.97 (0.46-2.71) <0.001
glucose (mmol/l) 4.9±0.7 4.8±0.6 0.29
insulin (mU/l) 9.7 (6.6-13.8) 7.3 (5.4-10.3) 0.028
homAir (mU x mmol/(L2 x 22.5)) 2.0 (1.5-3.0) 1.6 (1.1-2.3) 0.002
total cholesterol (mmol/l) 6.18±1.16 5.58±1.03 <0.001
hdl cholesterol (mmol/l) 1.06±0.35 1.21±0.32 0.002
TC/HDL-C ratio 6.41±2.22 4.96±1.60 <0.001
triglycerides (mmol/l) 1.60 (1.07-2.38) 1.17 (0.84-1.55) <0.001
Apo B (g/l) 1.23±0.38 1.06±0.25 <0.001
Apo A-i (g/l) 1.24±0.27 1.33±0.0.22 0.005
ApoB/ApoA-I ratio 1.04±0.36 0.82±0.23 <0.001
Leptin (µg/l) 3.92 (2.34-7.54) 2.89 (2.01-5.00) 0.002
Adiponectin (mg/l) 15.56 (9.52-30.09) 19.97 (11.54-30.51) 0.10
L/A ratio (µg/mg) 0.26 (0.12-0.56) 0.16 (0.08-0.32) 0.002
Data in mean±SD or in median (interquartile range). BMI, body mass index; HDL, high density 
lipoproteins; TC/HDL-C ratio, total cholesterol/HDL cholesterol ratio.
In all subjects combined, leptin and the L/A ratio were correlated positively with 
waist, HOMAir, hs-CRP, albuminuria, the TC/HDL-C ratio, the apoB/apoA-I ratio and 
triglycerides (Table 2). Adiponectin was correlated inversely with waist, HOMAir, the 
TC/HDL-C ratio, the apoB/apoA-I ratio and triglycerides. Comparable relationships 
of the leptin, adiponectin and the L/A ratio with these variables were observed in 
cases and control subjects separately (Table 2). The L/A ratio was neither signifi-
cantly correlated with age in all subjects combined (r=0.108, p=0.121), nor in cases 
(r=-0.082, p=0.423) and in control subjects (r=0.092, p=0.346) separately.
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Table 3. Hazard ratios (HRs with 95 % confidence intervals, CI) of leptin, adoponectin and 
the leptin/adiponectin (L/A) ratio for incident cardiovascular disease by Cox proportional 
hazard analysis. HRs are given per 1 SD increase.
model 1 model 2 model 3
hr (95 % Ci) p-value hr (95 % Ci) p-value hr (95 % Ci) p-value
Leptin 1.25 (1.01-1.55) 0.045 1.32 (1.02-1.71) 0.037 1.21 (0.91-1.61) 0.19
Adiponectin 0.74 (0.62-0.89) 0.001 0.80 (0.65-1.00) 0.047 0.82 (0.66-1.02) 0.073
L/A ratio 1.40 (1.14-1.71) 0.001 1.50 (1.15-1.97) 0.003 1.40 (1.05-1.87) 0.024
Leptin, adiponectin and the L/A ratio values are logarithmically transformed.
Models 1: adjusted for age
Models 2: adjusted for age, smoking, waist circumference, hypertension, microalbuminuria, 
the total cholesterol/HDL cholesterol ratio and triglycerides
Models 3: adjusted for age, smoking, waist circumference, hypertension, microalbuminuria, 
the total cholesterol/HDL cholesterol ratio, triglycerides, high sensitive C-reactive protein and 
insulin sensitivity (homeostasis model assessment)
As shown in Table 2 (models 1), age-adjusted incident CVD was associated posi-
tively with leptin and inversely with adiponectin. Incident CVD was also positively 
predicted by the L/A ratio with the point estimate of the hazard ratio for CVD being 
slightly higher than that of plasma leptin alone. After additional adjustment for 
smoking, waist circumference, hypertension, microalbuminuria, the total choles-
terol/HDL cholesterol ratio and triglycerides (models 2), the relationships of inci-
dent CVD with leptin, adiponectin and the L/A ratio remained significant (models 
2). The relationships of incident CVD with leptin and adiponectin were, however, 
no longer statistically significant after further controlling for hs-CRP and HOMAir 
(models 3). Of note, the L/A ratio remained predictive of incident CVD in this fully 
adjusted model. Alternatively, in fully adjusted analyses with the apoB/apoA-I ratio 
instead of the TC/HDL-C ratio (cf. models 3) the relationships of incident CVD with 
plasma leptin (HR 1.21 (95 % CI, 0.91-1.61), p=0.19) and adiponectin (HR 0.82 (95 
% CI, 0.60-1.02), p=0.073)) were again not significant, whereas the L/A ratio still 
predicted CVD (HR 1.38 (95 % CI, 1.03-1.85), p=0.03).
A sensitivity analysis was carried out among subjects making part of the so-
called random sample of the PREVEND cohort. This analysis again revealed that 
CVD risk was associated with the L/A ratio (model 1: HR 1.35 (95 % CI 1.08-1.70), 
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p=0.009; model 2: HR 1.49 (95 % CI 1.11-2.01), p=0.009; model 3: HR 1.37 (95 % CI 
0.98-1.90), p=0.062).
4. disCussion
This prospective nested case-control study demonstrates that in age-adjusted 
analyses incident CVD is positively related to plasma leptin and the L/A ratio, and 
inversely to plasma adiponectin. Thus, in this study among men without clinically 
manifest atherosclerosis at baseline there was no evidence for a putative reverse 
epidemiology phenomenon, which has been implicated in paradoxically opposite 
relationships of these adipokines with CVD in elderly people and in subjects with 
advanced manifestations of atherosclerotic disease [8,9,26]. Moreover, after ad-
ditional adjustment for clinical risk factors, as well as for plasma lipids and micro-
albuminuria, the association of incident CVD with all these adipokine measures 
remained statistically significant. Of note, in fully adjusted models in which we also 
accounted for chronic subclinical inflammation and insulin sensitivity, only the re-
lationship of incident CVD with the L/A ratio remained statistically significant. The 
current study, therefore, suggests that the L/A ratio may be a preferential marker 
of adipokine-associated first cardiovascular events in predominantly middle-aged 
men compared to plasma leptin and adiponectin levels alone.
It is likely that leptin and adiponectin contribute to the pathogenesis of (obe-
sity-related) atherosclerosis via several interrelated metabolic pathways, including 
effects on inflammatory processes and modulation of insulin sensitivity [1-5]. In 
addition, adiponectin may directly affect the synthesis of apoA-I, the major HDL 
apolipoprotein, as well the metabolism of triglyceride-rich lipoproteins [27,28]. 
As expected, the L/A ratio was strongly correlated with the waist circumference, 
hs-CRP, HOMAir, the TC/HDL-C ratio and triglycerides [17-20]. We also observed a 
correlation with higher urinary albumin excretion, which is considered a cardio-
vascular risk marker as well [29,30]. These robust relationships underscore the 
necessity to take account of all these factors when evaluating the extent to which 
leptin, adiponectin and the L/A ratio may predict incident CVD. Indeed, we found 
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no statistically independent effects of plasma leptin and adiponectin levels alone 
on incident CVD in fully adjusted analyses.
The currently documented independent contribution of the L/A ratio to first 
cardiovascular events even in fully adjusted analysis needs to be compared with 
the results of the prospective Monica/KORA Augsburg studies that comprised 
middle aged men and women who were initially free of clinically manifest coronary 
heart disease. In that report, no independent effect of the L/A ratio on incident 
CHD could be demonstrated [16]. Although the precise reasons for the apparent 
discrepancy remain to be clarified, there are several methodological differences. 
The Monica/KORA Augsburg report had a case-cohort design and included higher 
numbers of men and women, whereas recruitment of subjects was carried out 
at multiple surveys. In the PREVEND project, in contrast, subject recruitment 
was carried out within a limited time frame. Furthermore, the current study 
had a nested case-control design, making that the number of participants in our 
study was smaller. In addition, we adjusted for hypertension and the presence of 
microalbuminuria. The Monica/KORA Augsburg report took account of physical 
activity and alcohol consumption. On the other hand, both studies used essentially 
similar clinical cardiovascular end-points, and accounted for lipoprotein-related 
risk primarily by using the TC/HDL-C ratio, which has emerged as a stronger lipid 
risk factor than single pro- and anti-atherogenic lipoprotein measures [23,31]. In 
view of the relationship of the L/A ratio with plasma triglycerides, we controlled 
for triglycerides as well. Of additional relevance, the apoB/apoA-I ratio provides 
an at least equally strong lipoprotein risk factor compared to the TC/HDL-C ratio 
[23,32,33]. Therefore, analyses with this apolipoprotein ratio instead of the TC/
HDL-C ratio were also carried out. In the current study, the L/A ratio was an inde-
pendent CVD risk predictor in apoB/apoA-I ratio-adjusted analysis as well.
Several other methodological aspects of our study require consideration. We 
included men only in the expectation that too few events would occur in women to 
allow for meaningful sex-specific analysis, as is required in view of the marked sexual 
dimorphism of leptin and adiponectin in post-pubertal subjects [24]. Furthermore, 
case definition was confined to cardiac outcomes in order to reduce heterogeneity 
among cardiovascular end-points [21]. Thus, our results do not necessarily hold 
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true for women or for other cardiovascular risk domains. Furthermore, it should be 
appreciated that the PREVEND cohort is enriched with microalbuminuric subjects 
[25]. A sensitivity analysis among the subset of subjects derived from the so-called 
random sample of the PREVEND cohort, i.e. that part of the cohort that is randomly 
selected from the Groningen city population [25], revealed essentially similar point 
estimates of the L/A ratio-associated hazard in age-adjusted as well as in fully ad-
justed analyses compared to the hazard ratios obtained in the whole current study 
group. Important bias attributable to preferential participation of microalbuminuric 
subjects is, therefore, unlikely. Finally, it should be noted that we assayed plasma 
total adiponectin, although several isoforms with different biological activity are 
present in the circulation [2].
In conclusion, the present prospective nested case-control study suggests that 
the L/A ratio may be a preferential marker of adipokine-associated first cardiovas-
cular events in predominantly middle aged men compared to plasma leptin and 
adiponectin levels alone.
leArning Points
– The plasma leptin/adiponectin (L/A) ratio has been proposed as a preferential 
marker of adipokine-related atherosclerosis susceptibility.
– This community-based prospective nested-case control study among predomi-
nantly middle-aged men who were initially free of clinically manifest cardio-
vascular disease demonstrates that the L/A ratio remains predictive of first 
cardiovascular events after controlling of clinical and non-clinical risk mrakers, 
including chronic subclinical inflammation and insulin sensitivity.
– With plasma leptin and adiponectin levels alone no such independent relation-
ships with incident cardiovascular disease were observed.
– This study suggests that the L/A ratio may be a preferential marker of adipokine-
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Atorvastatin affects low density lipoprotein and 
non-high density lipoprotein cholesterol relations 
with apolipoprotein B in type 2 diabetes mellitus: 
modification by triglycerides and cholesteryl ester 
transfer protein
P.J.W.H. Kappelle, L. Zwang, M.V. Huisman, J.D. Banga, W.J. Sluiter,  
G.M. Dallinga-Thie, R.P.F. Dullaart
for the Diabetes Atorvastatin Lipid Intervention (DALI) study group




Background: Non-HDL-cholesterol (non-HDL-C) and apolipoprotein (apo) B are 
proposed as treatment targets. The extent to which statin therapy affects relation-
ships of LDL-C and non-HDL-C with apoB was examined in type 2 diabetes.
methods: Analyses were performed in 217 hypertriglyceridemic type 2 diabetic pa-
tients (DALI cohort). Sixty-one patients randomized to placebo, 70 to atorvastatin 
10 mg daily and 65 to atorvastin 80 mg daily completed follow-up.
results: Baseline fasting LDL-C of 2.42 mmol/l and non-HDL-C of 3.69 mmol/l cor-
responded to the apoB guideline target of 0.90 g/l. During atorvastatin (10 and 80 
mg daily), the LDL-C target was achieved most frequently, and lower LDL-C (2.38 
and 2.29 mmol/l) and non-HDL-C (3.24 and 3.19 mmol/l) concentrations corre-
sponded to this apoB goal. Decreases in LDL-C during atorvastatin treatment were 
negatively (p < 0.001), whereas decreases in non-HDL-C were positively related to 
changes in triglycerides (p < 0.001), independently from decreases in apoB (p < 
0.001 for all). Decreases in LDL-C and non-HDL-C were positively associated with 
decreases in cholesteryl ester transfer protein mass (p < 0.001).
Conclusions: During atorvastatin lower LDL-C and non-HDL-C levels correspond to 
the apoB guideline target, which would favour its use as treatment target.
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1. introduCtion
It is widely appreciated that the risk of cardiovascular disease is elevated in type 
2 diabetes mellitus, and that this increased risk is in part attributable to abnor-
malities in the quantity and quality of plasma lipoproteins [1,2]. The plasma 
concentration of low density lipoprotein-cholesterol (LDL-C) is still considered 
to be the primary target for lipid lowering intervention in this patient category 
[3,4], although it is increasingly recognized that besides LDL other apoB-carrying 
lipoproteins such as intermediate density lipoproteins (IDL) and very low density 
lipoproteins (VLDL) bear atherogenic potential [5,6]. Thus, alternative or second-
ary targets for lipid lowering treatment are currently being proposed, including 
non-high density lipoprotein-cholesterol (non-HDL-C), which represents the con-
centration of cholesterol in all atherogenic lipoproteins, as well as the plasma level 
of apolipoprotein (apo) B, which reflects the number of atherogenic lipoprotein 
particles [6]. Evidence is accumulating that non-HDL-C and apoB levels may predict 
(recurrent) cardiovascular disease even better than LDL-C [7,8,9].
Present guidelines advocate early use of statin therapy for primary cardiovascu-
lar prevention in diabetic patients with recommended goals being < 2.59 mmol/l (< 
100 mg/dl) for LDL-C, < 3.37 mmol/l (, 130 mg/dl) for non-HDL-C and < 0.90 g/l for 
apoB [3,4]. Despite proven efficacy, primary and secondary prevention trials have 
shown that there is still a considerable residual cardiovascular risk during statin 
treatment [3,10]. In this regard, it is important that during statin therapy the apoB 
target is achieved less frequently than the LDL-C goal, which may at least in part be 
explained by a larger relative decrease in LDL-C during statin treatment compared 
to the decline in apoB [11]. Although a low level of high density lipoprotein choles-
terol (HDL-C) predicts incident cardiovascular disease also during intensive statin 
therapy [12], this finding [11] underscores the relevance to develop alternative 
treatment targets for reduction in atherogenic lipoproteins in high cardiovascular 
risk populations. Of note, the relationship of LDL-C with apoB may be modified 
by plasma triglycerides, because predominance of small dense LDL particles, 
consequent to hypertriglyceridemia, results in underestimation of this lipoprotein 
fraction when only its cholesterol content is measured [6,13]. Of further relevance, 
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several studies have suggested that the cholesteryl ester transfer protein (CETP)-
mediated cholesteryl ester transfer process between lipoproteins is increased in 
hypertriglyceridemic diabetic plasma [14]. This enhanced plasma cholesteryl ester 
transfer increases the cholesteryl ester content of apoB-containing lipoproteins 
with large-sized VLDL particles being preferred acceptors, and contributes to the 
formation of small dense LDL particles [15]. It is, therefore, plausible to postulate 
that plasma CETP also affects the relationships of LDL-C and non-HDL-C with apoB.
In view of a high prevalence of hypertriglyceridemia, comparison of LDL-C 
with non-HDL-C and apoB levels and their proposed target values before and 
during statin therapy appears to be particularly relevant for lipid management in 
diabetes mellitus. To our knowledge the relationships of LDL-C, non-HDL-C with 
apoB concentrations have not been compared before and during statin therapy in 
diabetic patients specifically. The present analysis was initiated to determine the 
extent to which statin treatment changes these relationships using data from the 
DALI (Diabetes Atorvastatin Lipid Intervention) trial, which comprises 217 moder-
ately hypertriglyceridaemic type 2 diabetic patients [16]. In addition, we examined 
whether the plasma triglyceride level and cholesteryl ester transfer protein (CETP) 
mass modify these relationships before and during atorvastatin treatment.
2. PAtients And methods
2.1 Participants
The DALI study is a prospective, randomized multicenter study, which is aimed to 
demonstrate the effect of low and high dose atorvastatin treatment on plasma 
lipids and lipoproteins in patients with type 2 diabetes mellitus [16]. This trial has 
been carried out in 3 centres in The Netherlands (University Medical Centres of 
Leiden, Rotterdam and Utrecht). Approval of the medical ethics committees of 
each participating center had been obtained, and all participants had provided 
written informed consent. Full details of the design of the study have been pub-
lished previously [16]. In short, men and women aged 45-75 years, with a known 
duration of type 2 diabetes of at least 1 year, hypertriglyceridemia (fasting tri-
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glycerides between 1.5 and 6.0 mmol/l and a plasma total cholesterol between 
4.0 and 8.0 mmol/l) were included. An HbA1c > 10%, a history of cardiovascular 
disease, hepatic disease, renal insufficiency, as well as malignancy, systemic inflam-
matory disease, gastrointestinal disease and excessive alcohol use were the most 
important exclusion criteria. If applicable, lipid-lowering therapy was withdrawn 8 
weeks before start of the run-in phase. Seventy-two patients were randomized to 
placebo, 73 patients to atorvastatin 10 mg daily and 72 patients to atorvastatin 80 
mg daily. Atorvastatin and matching placebo were given in the morning. In patients 
randomized to atorvastatin 80 mg daily, this statin was started at a dose of 40 mg 
daily and then increased to 80 mg daily after 4 weeks. The study lasted 30 weeks, 
and was completed in 61 placebo-randomized patients, in 70 patients treated with 
atorvastatin 10 mg daily and in 65 patients receiving atorvastatin 80 mg daily. Par-
ticipants were studied after an overnight fast of at least 12h at baseline and after 
30 weeks of follow-up.
2.2 Laboratory measurements
Venous blood was collected in EDTA containing tubes and the plasma was stored at 
–80oC until analysis. All lipid measurements were performed at the Lipid Reference 
Laboratory, Rotterdam, The Netherlands, which participates in the Centers of Dis-
ease Control and Prevention (CDC)-National Heart, Lung and Blood Institute (NHL-
BI) Lipid Standardization Program (LPS). Total cholesterol and triglycerides were 
measured by enzymatic colorimetric methods as described [16]. HDL-cholesterol 
(HDL-C) was measured by a direct enzymatic assay based on a polyethyleneglycol-
modified method (Boehringer Mannheim; Hitachi 911 analyzer) [16]. Both total 
cholesterol and HDL-C methods are standardized against the reference methods 
used in the Lipid Reference Laboratory, methods that are rigorously standardized 
to the CDC reference methods. For analytical test CDC requirements for cholesterol 
are ≤ 3% for precision and ≤ 3% for accuracy and for HDL-C requirements are ≤ 4% 
for precision and ≤ 5% for accuracy. The precision and accuracy for cholesterol were 
2.1% and 0.3% and for HDL-C precision and accuracy were 1.4% and 3.2%. LDL-C 
was calculated by the Friedewald formula [17], whereas non-HDL-C was calculated 
as the difference between total cholesterol and HDL-C. ApoB was determined with 
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an immunoturbidimetric assay (Tina-quant apoB, cat. no. 1551779, Boehringer 
Mannheim; Hitachi 917 analyzer). This method has been standardized against the 
International Federation of Clinical Chemistry SP3-07 reference standard [18,19]. 
Precision was determined with Precinorm L and Precipath L control sera. Both con-
trol sera were also used in the quality control system. Within-run and between-run 
precision for Precinorm L were 0.69 (SD 0.006) g/l (coefficient of variation (CV ) 
0.8%) and 0.80 (SD 0.008) g/l (CV 1.0%). Within-run and between-run precision for 
Precipath L were 1.52 (SD 0.008) g/l (CV 0.5%) and 1.55 (SD 0.003) g/l (CV 1.9%). 
Plasma CETP was measured using double-antibody sandwich enzyme linked immu-
nosorbent assay as described previously [20]. The CETP concentration is strongly 
related to CETP activity, as measured with excess exogenous substrates [20,21].
2.3 Statistical analysis
Statistical analyses were performed using SPSS 16. Data are given in mean ± SD, in 
median (interquartile) range and in percentage of subjects. Between group differ-
ences in (changes in) variables were determined by one-way analysis of variance. 
The Bonferroni method was used to correct for multiple comparisons. Correlation 
coefficients between variables were calculated with linear regression analysis, and 
slopes and intercepts were calculated. Multiple linear regression analysis was used 
to determine the independent contribution of variables. Two-sided p- values < 0.05 
were considered to be statistically significant.
3. results
Table 1 summarizes the baseline clinical characteristics of the participants (for 
full details see [16]). At baseline, 17 patients (5 randomized to placebo, 3 to 
atorvastatin 10 mg daily and 9 patients to atorvastatin 80 mg daily) had fasting 
plasma triglycerides > 4.5 mmol/l. Atorvastation dose-dependently decreased total 
cholesterol, LDL-C, non-HDL-C, apoB and CETP mass levels (Table 1; p < 0.01 for 
all comparisons between the two atorvastatin doses). Atorvastatin 10 mg daily as 
well as atorvastatin 80 mg daily also significantly decreased plasma triglycerides 
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(p < 0.001 for both), and increased HDL-C (p < 0.001 for 10 mg and p < 0.01 for 
80 mg), but these effects were not dose-dependent (p > 0.20 for triglycerides and 
HDL-C). Furthermore, the relative decreases in LDL-C compared to non-HDL-C 
and apoB were different during both doses of atorvastatin (p < 0.001) with the 
largest decrease in LDL-C and the smallest drop in apoB (data not shown). When 
evaluating the percentages of participants meeting the LDL-C (2.59 mmol/l), the 
non-HDL-C (3.37 mmol/l) and the apoB targets (0.90 g/l) in response to treatment 
with atorvastatin 10 mg and 80 mg daily, it was found that with the atorvastatin 
doses of 10 mg as well as 80 mg daily the apoB target was reached in fewer patients 
than the non-HDL-C and the LDL-C targets (Table 2).
As shown in Figure 1A and Table 3 there was a close correlation of LDL-C with 
the apoB concentration at baseline as well as during treatment with atorvastatin. 
Based on the regression equation between these variables, the LDL-C concentra-
tion at the guideline apoB target level and, vice versa, the apoB concentration at 
the guideline LDL-C target level were calculated (Table 3). At baseline, the esti-
mated LDL-C level at the apoB target of 0.90 g/l was lower than its guideline target 
of 2.59 mmol/l. During atorvastatin treatment the estimated LDL-C concentration 
at the guideline target apoB level of 0.90 g/l was further lowered compared to 
baseline (Figure 1B, Table 3). Conversely, the estimated apoB concentration at the 
guideline target LDL-C level of 2.59 mmol/l was higher during statin treatment 
compared to baseline. Essentially similar results were found when 17 participants 
with baseline plasma triglycerides > 4.5 mmol/l were excluded from the analysis, 
a commonly proposed value above which the Friedewald formula is considered to 
be inaccurate. As shown in Figure 1C and Table 4, the correlation coefficient of non-
HDL-C with apoB was stronger compared to that with LDL-C both at baseline as well 
as during atorvastatin treatment. The estimated non-HDL-C level at the guideline 
apoB target of 0.90 g/l was higher than its guideline target of 3.37 mmol/l. There 
was also a shift in the estimated non-HDL-C concentration at the guideline target 
apoB level of 0.90 g/l towards lower values during atorvastatin treatment (Figure 
1D, Table 4). When estimating the apoB concentration corresponding to the non-
HDL-C guideline target level of 3.37 mmol/l, it was again observed that apoB values 
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Table 2 Percentages of patients reaching guideline targets for low density cholesterol (LDL-
C) (< 2.59 mmol/l), non-high density lipoprotein cholesterol (non-hdl-C) (< 3.37 mmol/l) 
and apolipoprotein (apo) B (< 0.90 g/l) during treatment with atorvastatin.
Atorvastatin 10 mg daily
(n=70)
Atorvastatin 80 mg daily
(n=65)
ldl-C 74.3 % 93.8 %
non-hdl-C 70.0 % 87.7 %
ApoB 62.9 % 84.6 %
Figure 1 Changes in the relationships of non-high density lipoprotein cholesterol (non-HDL-
C) and low density lipoprotein cholesterol (ldl-C) with apolipopoprotein B (apoB) during 
atorvastatin treatment in type 2 diabetic patients.
A: LDLC vs. apo B at baseline.
B: LDLC vs. apo B during treatment with atorvastatin 10 mg daily (ator 10) and atorvastatin 80 
mg daily (ator 80). Green line: regression line of data during ator10; red line: regression line 
of data during ator 80.
C: Non-HDLC vs. apo B at baseline.
d: Non-HDLC vs. apo B during treatment with atorvastatin 10 mg daily (ator 10) and atorvas-
tatin 80 mg daily (ator 80). Green line; regression line of data during ator 10; red line: regres-
sion line of data during ator 80.
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Table 3 Linear regression analysis of low density lipoprotein cholesterol (LDL-C) versus apo-
lipoprotein (apo) B at baseline and after atorvastatin administration in type 2 diabetic pa-
tients. Estimated LDL-C concentrations at the guideline apoB target, and estimated apoB 
concentrations at the guideline LDL-C target are shown.
Pearson’s correlation 
coefficient
Slope Intercept LDL-C at
apoB = 0.90 g/l












0.889 3.37 -0.73 2.31 mmol/l 0.987 g/l
Table 4 Linear regression analysis of non-high density lipoprotein cholesterol (non-HDL-C) 
versus apolipoprotein (apo) B at baseline and after atorvastatin administration in type 2 
diabetic patients. Estimated non-HDL-C concentrations at the guideline apoB target, and es-
timated apoB concentrations at the guideline non-HDL-C target are shown.
Pearson’s correlation 
coefficient
Slope Intercept Non-HDL-C at
apoB = 0.90 g/l
ApoB at non-












0.964 3.99 -0.40 3.19 mmol/l 0.948 g/l
The extent to which (atorvastatin-induced changes in) plasma triglycerides and CETP 
mass modify the relationships of (changes in) LDL-C and non-HDL-C with (changes 
in) plasma apoB was determined using multiple linear regression analysis (Table 5 
and 6). This analysis demonstrated that baseline LDL-C as well as non-HDL-C were 
independently and positively related to plasma apoB after adjustment for age and 
gender. LDL-C was negatively related to plasma triglycerides, but non-HDL-C, in 
contrast, was positively related to triglycerides. Both LDL-C and non-HDL-C were 
positively related to CETP mass. Furthermore, the decreases in LDL-C and in non-
HDL-C in response to atorvastatin treatment (10 mg and 80 mg combined, n = 135) 
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were independently related to the decreases in plasma apoB (Table 6). This analysis 
also demonstrated that the changes in plasma triglycerides inversely determined 
the changes in LDL-C. Again, an opposite relation was found for the changes in 
non-HDL-C. In addition, the decrements in LDL-C and in non-HDL-C were positively 
related to the decreases in CETP mass. All relationships shown in Table 5 and 6 with 
LDL-C as dependent variable were similar when patients with plasma triglycerides 
> 4.5 mmol/l were excluded from the analyses (data not shown). Furthermore, the 
changes in HDL-C during active atorvastatin treatment (n = 135) were unrelated to 
baseline triglycerides (r = 0.11, p = 0.19), but were inversely correlated with the 
changes in triglycerides (r = -0.37, p < 0.001) in univariate analyses.
Table 5 Multiple linear regression analyses showing apolipoprotein B (apoB)-adjusted re-
lationships of low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein 
cholesterol (non-hdl-C) with triglycerides and cholesteryl ester transfer protein (CetP) mass 
after at baseline in 217 type 2 diabetic patients.
LDL-C Non-HDL-C
ß p -value ß p -value
ApoB 0.855 < 0.001 0.887 < 0.001
log triglycerides -0.355 < 0.001 0.155 < 0.001
CetP mass 0.062 0.037 0.059 0.040
All models are adjusted for age and sex. ß: standardized regression coefficient.
Table 6 Multiple linear regression analyses showing independent relationships of changes 
in low density lipoprotein cholesterol (ldl-C) and non-high density lipoprotein cholesterol 
(non-hdl-C) with changes in triglycerides and cholesteryl ester transfer protein (CetP) mass, 
adjusted for changes in apolipoprotein B (apoB) in response to treatment with atorvastatin 
10 mg or 80 mg daily in 135 type 2 diabetic patients.
changes in LDL-C changes in non-HDL-C
ß p- value ß p- value
changes in apoB 0.944 < 0.001 0.810 < 0.001
changes in triglycerides -0.349 < 0.001 0.227 < 0.001
changes in CetP mass 0.102 < 0.001 0.092 < 0.001




The present analyses from the DALI study, which enrolled moderately hypertriglyc-
eridemic type 2 diabetic patients, confirm previous findings showing that fewer 
patients meet the guideline apoB target of 0.90 g/l compared to the guideline 
LDL-C target of 2.59 mmol/l (100 mg/dl) and the guideline non-HDL-C target of 
3.37 mmol/l (130 mg/dl) during statin treatment. Our report also demonstrates 
strong linear correlations of fasting LDL-C and non-HDL-C with apoB before, as well 
as during treatment with 10 mg and 80 mg atorvastatin daily. Statin treatment 
shifted the relationships of LDL-C and non-HDL-C with apoB. Consequently, during 
atorvastatin treatment an apoB target of 0.90 g/l corresponded to lower LDL-C and 
non-HDL-C concentrations compared to baseline.
A recent analysis from the Mercury II trial comprising a large number of 
normo- and hypertriglyceridemic high risk patients with and without diabetes has 
demonstrated that before statin treatment an apoB concentration at the proposed 
target of 0.90 g/l roughly corresponds to an LDL-C level of 2.59 mmol/l and a non-
HDL-C of 3.37 mmol/l [22]. In that report, it was found that treatment with either 
rosuvastatin, atorvastatin or simvastatin decreased both the estimated LDL-C and 
non-HDL-C levels that correspond to an apoB target of 0.90 g/l by approximately 
0.78 mmol/l (30 mg/dl). In hypertriglyceridemic subjects, the decrease in the cal-
culated LDL-C cut-off level amounted to about 0.52 mmol/l, whereas the average 
decrease in the non-HDL-C cut-off value was 0.78 mmol/l [22]. The current results 
are largely in keeping with these findings, but there are also relevant differences. 
Firstly, before statin treatment, the LDL-C level at the apoB target of 0.90 g/l was 
calculated to be lower, whereas the corresponding non-HDL-C level was higher 
than their proposed goals of 2.59 and 3.37 mmol/l, respectively. This suggests 
some underestimation of cardiovascular risk by LDL-C and risk overestimation by 
non-HDL-C compared to apoB measurement in moderately hypertriglyceridemic 
diabetic patients before treatment. Secondly, the shift in the LDL-C apoB relation-
ship was smaller than that between non-HDL-C and apoB, and both shifts were less 
pronounced compared to those found in the analysis from the Mercury II trial [22]. 
This suggests that atorvastatin has only a small effect on LDL size and a larger effect 
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on other apoB-containing lipoproteins, such as VLDL and remnant particles in this 
diabetic population. Taken the predictive value of on treatment apoB levels for 
recurrent cardiovascular disease and the additional clinical benefit of aggressive 
lipid lowering treatment are into account [9,10], the data from both the Mercury II 
and the DALI study can be interpreted in favour of the use of apoB as therapeutic 
target during statin treatment.
We also analyzed whether the plasma triglyceride concentration modifies the 
relationships of LDL-C and non-HDL-C with plasma apoB. In the present study, 
LDL-C was negatively determined by triglycerides after controlling for apoB, as 
observed previously [23]. LDL-C was calculated by the Friedewald formula, which 
has a negative contribution of triglycerides in its equation [16]. Moreover, the ac-
curacy of this widely used formula for LDL-C calculation in plasma samples from 
type 2 diabetic patients has been questioned [24,25]. Despite these limitations, the 
negative relationship of LDL-C with plasma triglycerides after controlling for apoB 
is consistent with a predominance of small dense LDL over buoyant LDL at higher 
plasma triglycerides [13]. Conversely, the negative relationship of the decreases 
in LDL-C with the decreases in triglycerides when taking account of the decline in 
apoB is in keeping with partial normalization of the cholesterol content of LDL par-
ticles during statin treatment [13,25]. In contrast, positive apoB-adjusted relation-
ships of non-HDL-C with triglycerides were documented in the current study. These 
findings underscore that triglyceride-rich lipoproteins contribute to the non-HDL-C 
concentration in fasting diabetic patients with hypertriglyceridemia, even after 
controlling for the number of atherogenic lipoprotein particles. In comparison, an 
observational study that included predominantly non-diabetic subjects with lower 
triglycerides did not demonstrate a significant effect of triglycerides on the rela-
tionship of non-HDL-C with apoB [23]. Our analysis furthermore showed that the 
decrease in non-HDL-C in response to statin treatment was positively determined 
by the decline in triglycerides, independently of the drop in apoB, consistent with 
a decrease in larger VLDL and remnant particles. This opposite effect of changes in 
triglycerides on the decreases in non-HDL-C compared to the LDL-C decline is likely 
to explain why the shift in the non-HDL-C apoB relationship was more pronounced 
compared to that in the LDL-C apoB relationship in the present study.
Chapter 8
162
Plasma cholesteryl ester transfer from HDL towards apoB-containing lipopro-
teins is not only affected by the concentration and composition of cholesteryl ester 
acceptor lipoproteins but also by the amount of CETP itself [14]. In this study, both 
LDL-C and non-HDL-C at baseline were positively related to plasma CETP mass, 
in agreement with the supposed contribution of CETP to an atherogenic lipopro-
tein profile [26-28]. Although the number of DALI participants in which plasma 
CETP activity was measured was too low for meaningful inclusion in the present 
analysis [18], it is important to note that plasma CETP mass is strongly correlated 
with its activity, when measured using an exogenous substrate assay which is not 
confounded by effects of endogenous plasma lipoproteins [20,21]. Of potential 
relevance, remarkably strong relationships were found between the decreases 
in LDL-C and non-HDL-C and the drop in plasma CETP mass in response to statin 
treatment. A statin-induced decrease in plasma CETP mass and activity level has 
been found previously in other studies [14,20,29], and is probably related to down 
regulation of CETP gene expression via an effect on the sterol responsive element 
binding protein pathway, resulting in inhibition of hepatic CETP synthesis [30]. On 
the other hand, it is also plausible that lower plasma levels of active CETP as such 
will decrease cholesteryl ester transfer to apoB-containing lipoproteins in concert 
with statin-induced increased uptake of LDL and VLDL particles and reduced VLDL 
secretion by the liver. This will contribute to a decrease in the cholesterol content 
of apoB-containing lipoproteins and hence to further improvement of atherogenic 
lipoprotein abnormalities. Our findings would, therefore, provide a rationale to 
inhibit plasma levels of active CETP in diabetic dyslipidemia.
5. ConClusions
The present analysis has documented that atorvastatin treatment shifts the rela-
tionships of fasting LDL-C and non-HDL-C with apoB in hypertriglyceridemic type 
2 diabetic patients towards lower LDL-C and in particular lower non-HDL-C levels 
that correspond to the proposed apoB target of 0.90 g/l. The relationships of LDL-C 
and non-HDL-C with apoB are modified by plasma triglycerides. We, therefore, 
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consider the present data to be in favour of the use of apoB as an important treat-
ment target, provided that its measurement is well standardized and sufficiently 
available.
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Atorvastatin treatment lowers fasting remnant-like 
particle cholesterol and LDL subfraction cholesterol 
without affecting LDL size in type 2 diabetes 
mellitus: relevance for non-HDL cholesterol and 
apolipoprotein B guideline targets
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for the Diabetes Atorvastatin Lipid Intervention (DALI) study group




Background: The extent to which atorvastatin treatment affects LDL size, LDL 
subfractions levels and remnant-like particle cholesterol (RLP-C) was determined 
in type 2 diabetes. We also compared LDL size and RLP-C in relation to guideline 
cut-off values for LDL cholesterol, non-HDL cholesterol and apolipoprotein (apo) B.
methods: Changes in LDL size and RLP-C were determined in fasting plasma from 
type 2 diabetic patients after 30 weeks administration of atorvastatin (10 mg daily, 
n=65; 80 mg daily, n=62) or placebo (n=58). LDL subfraction cholesterol was mea-
sured in 74 participants.
results: Atorvastatin lowered LDL cholesterol, non-HDL cholesterol, triglycerides, 
apo B and RLP-C (p< 0.001 for all at each dose). LDL peak particle size remained 
unaffected. Cholesterol in all LDL subfractions decreased after atorvastatin (p< 
0.001 for each dose) without a shift in LDL size. RLP-C was lower in those patients 
achieving the non-HDL cholesterol or the apo B guideline targets (p< 0.01), but the 
LDL cholesterol cut-off value failed to discriminate.
Conclusions: Atorvastatin lowers fasting RLP-C and LDL subfraction cholesterol in 
diabetes. The proposed guideline cut-off levels for non-HDL cholesterol and apo B 
may be superior to the LDL cholesterol target in discriminating between higher and 
lower RLP-C levels.
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1. introduCtion
It is generally appreciated that the increased risk of cardiovascular disease in Type 
2 diabetes mellitus is in part attributable to abnormalities in the quantity as well as 
in the quality of plasma lipoproteins [1-4]. Besides elevated triglycerides and low 
high density lipoprotein cholesterol (HDL-C), diabetic dyslipidemia is also charac-
terized by a predominance of small dense low density lipoprotein (LDL) particles 
(pattern B as opposed to pattern A phenotype) [5-7]. Small dense LDL particles 
are associated with insulin resistance and high triglycerides, and have been linked 
to increased atherosclerosis susceptibility [6,7]. However, it is uncertain whether 
LDL size predicts incident cardiovascular disease when plasma levels of LDL cho-
lesterol (LDL-C), HDL-C and triglycerides are taken into account [8]. Plasma also 
contains remnant particles derived from triglyceride-rich, apolipoprotein (apo) 
B-containing lipoproteins (very low density lipoproteins (VLDL) and chylomicrons) 
which are considered to be atherogenic as well [9]. The remnant-like particle (RLP) 
cholesterol concentration, measured using an immuno-affinity technique that 
detects VLDL and chylomicron remnants, has been shown to be elevated in type 2 
diabetes [10]. Importantly, the RLP cholesterol (RLP-C) concentration may predict 
recurrent cardiovascular disease even after controlling for hypercholesterolemia, 
hypertriglyceridemia and low HDL-C [11].
A recent meta-analysis has convincingly demonstrated that statin treatment 
lowers vascular mortality in diabetic patients [12]. Current guidelines recommend 
early use of statin therapy for primary cardiovascular risk prevention in this patient 
category [13], and aggressive LDL-C lowering results in additional cardiovascular 
benefit [14]. Since there remains considerable residual risk during treatment, it is 
clinically relevant to document the extent to which LDL particle size, LDL subfrac-
tion cholesterol levels and RLP-C concentration is affected by statin treatment in 
diabetic subjects. Equivocal effects of statin therapy have been reported on LDL 
size and subfraction distribution in diabetes [15-21], whereas limited data are 
available with respect to the effect of this treatment on RLP-C [17,19]. Moreover, 
although the triglyceride lowering by statin treatment may be dose-dependent in 
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hypertriglyceridemic subjects [22], effects on LDL quality and RLP-C have not been 
compared between usual and high dose statin administration in diabetes mellitus.
The present study was carried out to determine the effect of usual and high 
dose atorvastatin treatment on LDL size and LDL subfraction cholesterol levels, 
as well as on RLP-C in type 2 diabetic patients participating in the DALI (Diabetes 
Atorvastatin Lipid Intervention) trial. It has been advocated recently to use non-
HDL cholesterol (non-HDL-C) and apo B as primary treatment targets in addition to 
LDL-C with plasma triglycerides being a secondary goal [13,23]. We, therefore, also 
compared LDL size and RLP-C in relation to the guideline cut-off values for LDL-C, 
non-HDL-C, apo B and triglycerides.
2. PAtients And methods
2.1. Participants
The DALI study is a prospective, randomized multicenter study, which is aimed to 
demonstrate the effect of low (10 mg daily) and high dose (80 mg daily) atorvastatin 
treatment on plasma lipids and lipoproteins in patients with type 2 diabetes mel-
litus [24]. This trial has been carried out in 3 centers in The Netherlands (University 
Medical Centers of Leiden, Rotterdam and Utrecht). Approval of the medical ethics 
committees of each participating center had been obtained, and all participants 
had provided written informed consent. Full details of the design of the study 
have been published previously [24]. In short, men and women aged 45-75 years, 
with a known duration of type 2 diabetes of at least 1 year, hypertriglyceridemia 
(fasting triglycerides between 1.5 and 6.0 mmol/l) and a plasma total cholesterol 
between 4.0 and 8.0 mmol/l were included. An HbA1c above 10%, a history of 
cardiovascular disease, hepatic disease, renal insufficiency, as well as malignancy, 
systemic inflammatory disease, gastrointestinal disease and excessive alcohol use 
were the most important exclusion criteria. If applicable, lipid-lowering therapy 
was withdrawn 8 weeks before start of the run-in phase. Atorvastatin and matching 
placebo were given in the morning. In patients randomized to atorvastatin 80 mg 
daily, this statin was started at a dose of 40 mg daily and then increased to 80 mg 
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daily after 4 weeks. The present study included 58 patients randomized to placebo, 
65 to atorvastatin 10 mg daily and 62 randomized to atorvastatin 80 mg daily who 
completed follow-up and from whom RLP measurements were available. LDL sub-
fraction isolation and cholesterol measurements were carried out in 74 patients 
who were randomly selected from the cohort. Participants were studied after an 
overnight fast of at least 12h at baseline and after 30 weeks of follow-up. Of the 
study subjects 2% were treated with diet alone, 44% with oral glucose lowering 
drugs, 28% with insulin and 26% with combination therapy. Treatment for diabetes 
was equally distributed among the 3 randomized groups.
2.2. Laboratory measurements
Venous blood was collected in EDTA containing tubes. Plasma was obtained by 
centrifugation at 3000 rpm for 15 min at 4°C and the samples were stored at -80oC 
until analysis. Total cholesterol and triglycerides were measured by enzymatic colo-
rimetric methods as described [24]. HDL-cholesterol (HDL-C) was measured by a di-
rect enzymatic assay based on a polyethyleneglycol-modified method (Boehringer 
Mannheim; Hitachi 911 analyzer). LDL-C was calculated by the Friedewald formula 
[25] and non-HDL-C was calculated as the difference between total cholesterol and 
HDL-C. Apo B was determined with an immunoturbidimetric assay (Tina-quant apo 
B, cat. no. 1551779, Boehringer Mannheim; Hitachi 917 analyzer) with calibration 
according to International Federation of Clinical Chemistry standards [26]. LDL 
particle size was measured by polyacrylamide gradient gel electrophoresis [27]. 
Standardization was achieved by inclusion of LDL samples with known size donated 
by Ronald M. Krauss. Based on their peak size, particles were divided into two 
classes: particles > 25.5 nm (pattern A) reflects the presence of predominantly 
large, buoyant LDL particles, and particles < 25.5 nm (pattern B) with a predomi-
nance of small LDL particles.
LDL subfractions were isolated by density gradient ultracentrifugation using a 
six-step, discontinuous salt gradient. Twenty 500 ml aliquots were collected after 
centrifugation in a Beckman SW40 rotor for 24 h, 40.000 rpm at 4 °C as described 
by Griffin et al. [28]. The LDL fractions were recovered from the tube by upward dis-
placement. Major LDL subfractions were identified according to their density and 
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divided into three LDL categories: 1.020-1.029 g/ml (LDL1: fraction 6-10), 1.030-
1.040 g/ml (LDL2: fraction 11-13), or 1.041-1.061 g/ml (LDL3: fraction 14-17). The 
isolated fractions were frozen immediately at -80 °C for subsequent cholesterol 
measurement using a colorimetric assay (ABX Diagnostics, Montpellier, France) on 
a Cobas Mira S autoanalyzer
RLPs were prepared using an immuno-separation technique as described 
[29,30]. This assay detects apo E-rich VLDL remnants that contain apo B 100 to-
gether with chylomicron remnants containing apo B 48. In brief, 5 μl of plasma was 
added to 300 μl of mixed immunoaffinity gel suspension containing monoclonal 
anti-human apo A-I (H-12) and anti-human apo B 100 (JI-H) antibodies (Japan 
Immunoresearch Laboratories, Takasaki, Japan). The reaction mixture was gently 
shaken for 120 min at 21°C followed by standing for 15 min. Subsequently, 200 μl of 
the supernatant was used for measurement of RLP cholesterol (RLP-C). Cholesterol 
in RLP was analyzed enzymatically in duplicate using a Cobas Mira S auto-analyzer. 
(JIMRO, Japan). The upper normal limit of the RLP-C concentration in fasting plasma 
from non-diabetic subjects is 0.51 mmol/l for women (n = 649) and 0.71 mmol/l 
for men (n = 219), as derived from the nutrient-gene interactions in human obesity 
project [31].
2.3 Statistical analysis
Statistical analyses were performed using SPSS 16. Data are given in mean ± SD, 
median (interquartile) range and numbers of subjects. Within group changes in 
variables were evaluated by paired t-tests or Wilcoxon tests. Between group differ-
ences in (changes in) variables were determined by one-way ANOVA. The Bonfer-
roni method was used to correct for multiple comparisons. Correlation coefficients 
between variables were calculated with linear regression analysis. Two-sided P 
values < 0.05 were considered to be statistically significant.
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3. results
Baseline clinical characteristics of the participants are summarized in Table 1 (for 
full details see [24]). The decreases in LDL-C, non-HDL-C and apo B in response 
to atorvastatin administration were dose-dependent (Table 1; p< 0.05 for all 
comparisons between the two atorvastatin doses), whereas the drop in plasma 
triglycerides was not significantly different between the atorvastatin 10 mg and 80 
mg groups (P > 0.20).
As shown in Table 2, 30% of the 185 participants showed LDL pattern B at 
baseline. The size distribution pattern was not significantly different between the 
three groups, and was unaffected by atorvastatin treatment. Consequently, 23% 
of patients receiving atorvastatin 10 mg and 32% of patients receiving atorvastatin 
80 mg showed an LDL size pattern B at the end of the study (Table 2). LDL subfrac-
tions were determined in a subset of patients. As shown in Table 3, LDL1, LDL2 and 
LDL3 cholesterol decreased in response to atorvastatin. These effects were dose-
dependent for LDL1 (p< 0.01) and LDL2 (p< 0.05), but not for LDL3 (P > 0.20). The 
effect of atorvastatin treatment is illustrated in Figure 1. No shift towards larger, 
more buoyant LDL particle size was observed. RLP-C decreased in response to both 
atorvastatin doses, although this effect was not dose-dependent (P > 0.40) (Table 
2). At baseline RLP-C was elevated in 28% of participants, but only 6% of patients 
treated with atorvastatin 10 mg and 5% of patients treated with atorvastatin 80 mg 
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Figure 1. Low density lipoprotein (LDL) subfraction cholesterol distribution after 30 weeks 
of placebo administration (red line), treatment with atorvastatin 10 mg daily (green line) 
and atorvastatine 80 mg daily (black line) in type 2 diabetic patients. Three different LDL sub-
fractions are defined based on their density (see laboratory methods) : LDL1 1.020-1.029 g/
ml (fraction 6-10); LDL2 1.030-1.040 g/ml (fraction 11-13); LDL3 1.041-1.061 (fraction 14-17).
LDL size and RLP-C during atorvastatin treatment were also compared according to 
whether the patients had attained the guideline targets for LDL-C (< 2.59 mmol/l), 
non-HDL-C (< 3.37 mmol/l), apo B (< 0.90 g/l) and triglycerides (< 1.70 mmol/l) 
(combined data at doses of 10 and 80 mg daily, n = 127, Table 4). LDL size was not 
different in patients who did and patients who did not achieve the LDL-C, non-
HDL-C or apo B targets, but was decreased in subjects reaching the triglyceride 
target. RLP-C was also not significantly different in patients who met the LDL-C 
target compared to those who did not (Table 4). In contrast, RLP-C was lower in 
patients attaining either the non-HDL-C target, the apo B or the triglyceride target 
compared to those who did not (Table 4).
Chapter 9
176 177




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Univariate regression analysis demonstrated that the decreases in RLP-C were 
correlated with the decreases in triglycerides, non-HDL-C and apo B in response 
to atorvastatin treatment (combined data at doses of 10 and 80 mg daily, n = 127, 
Table 5). However, except for a positive relationship with the changes in triglyc-
erides, the individual changes in LDL size were not significantly correlated with 
changes in any of these variables. Neither the changes in RLP-C nor in LDL size were 
related to the changes in LDL-C (Table 5).
Table 5. Relationships between changes in low density lipoprotein cholesterol (LDL-C), non-
high density lipoprotein cholesterol (non-hdl-C), apolipoprotein (apo) B and triglycerides 
with changes in remnant like particles cholesterol (RLP-C) and LDL size in response to atorv-
astatin treatment in 127 diabetic patients (10 mg daily: n = 65 ; 80 mg daily: n = 62).
Δ RLP-C Δ LDL particle size
Δ LDL-C 0.08 0.02
Δ Non-HDL-C 0.49* -0.11
Δ Apo B 0.29* -0.04
Δ Triglycerides 0.79* -0.29*
Linear regression coefficients are shown. * p< 0.001
4. disCussion
The present study has demonstrated that atorvastatin treatment dose-dependently 
lowers LDL-C, non-HDL-C and apo B in moderately hypertriglyceridemic type 2 dia-
betic patients. A potentially important novel observation is that atorvastatin also 
considerably lowered RLP-C in conjunction with a drop in triglycerides, although 
this effect was not significantly different between the 2 atorvastatin doses. In con-
trast, neither usual nor high dose atorvastatin affected LDL mean peak diameter. As 
a result, the proportion of subjects with predominance of small sized LDL (pattern 
B) remained unchanged. Atorvastatin decreased the cholesterol content of all 3 
LDL subfractions, as determined by density gradient ultracentrifugation, with the 
effect on LDL3, the most dense subfraction, being unrelated to the atorvastatin 
dose. Taken together, our findings suggests that in moderately hypertriglyceride-
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mic type 2 diabetic patients aggressive statin treatment largely normalizes fasting 
RLP-C, but does not have a major effect on LDL particle distribution.
Reasoning that all apo B-containing lipoproteins have pro-atherogenic proper-
ties, it has been proposed to use additional treatment targets besides LDL-C for 
subjects at high cardiovascular risk [13,23]. Applying the proposed guideline cut-off 
values of for LDL-C, non-HDL-C and apo B (< 2.59 mmol/l, < 3.37 mmol/l and < 0.90 
g/l, respectivley) to high risk subjects without clinically manifest cardiovascular 
disease [13], it has been reported that LDL-C treatment goals are reached more 
readily during statin treatment than the non-HDL-C and apo B targets [32,33]. The 
current analysis, showing that the LDL-C target is achieved most frequently among 
those treatment goals, is in keeping with these earlier findings. The present report 
also demonstrates that upon division according to these proposed cut-off levels, 
the RLP-C concentration was lower in subjects who met the non-HDL-C or the apo 
B target compared to those who did not. In contrast, the LDL-C cut-off value failed 
to discriminate significantly between higher and lower RLP-C levels. In view of the 
potential role of RLP-C for atherosclerosis development [11], the present findings 
support the relevance to apply additional treatment targets besides LDL-C in type 
2 diabetic patients.
During statin treatment the relationships of non-HDL-C and of LDL-C with apo B 
are shifted towards lower non-HDL-C and LDL-C levels that correspond to the same 
plasma apo B concentration [33]. Since VLDL, LDL and remnants contain one apo 
B molecule per particle, this shift may be attributable to changes in the concentra-
tion and/or composition of all apo B-containing lipoproteins. Our study showing 
a drop in RLP-C in response to statin therapy strongly suggests that the altered 
relationship of non-HDL cholesterol with apo B [33] is at least in part attributable 
to a decrease in the number or in the cholesterol content of remnant particles. 
Furthermore, the reduction in apo B together with a lack of change in LDL subfrac-
tion distribution in response to atorvastatin is in agreement with the hypothesis 
that this treatment predominantly decreases the number of LDL particles. Such a 
phenomenon would favor apo B as a preferable treatment target.
The present study has demonstrated positive relationships of the drop in RLP-C 
with decreases in triglycerides, non-HDL-C and apo B in response to statin therapy, 
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in keeping with expected effects of statin therapy on hepatic LDL receptor upregu-
lation and possibly also on attenuated apo B production by the liver [34,35]. How-
ever, there was only a modest inverse relationship between the individual changes 
in LDL mean peak diameter and the decrease in triglycerides, despite the fact that 
LDL size was smaller in those patients who did achieve the guideline triglyceride 
target level of 1.70 mmol/l [13].
Our findings are in agreement with the well documented negative relation of the 
triglyceride level with small dense LDL [5-7], but the mechanisms involved in LDL 
size regulation in response to statin treatment are still incompletely understood. 
Cholesteryl ester transfer protein (CETP) contributes to the formation of small 
dense LDL particles by a preferential cholesteryl ester transfer from HDL to these 
LDL particles, as well as through an indirect mechanism involving an enhanced cho-
lesteryl ester transfer from HDL to large VLDL1 [36], which are regarded as precur-
sors of small dense LDL [6,7]. Moreover, plasma CETP mass as well as cholesteryl 
ester transfer out of HDL decrease in response to statin treatment [37,38]. Changes 
in this process clearly favor an increase in LDL diameter and a density shift towards 
more buoyant LDL in response to statin therapy. Nonetheless, the inconsistent ef-
fects on LDL size and subfraction distribution reported so far [15-21], and the lack 
of change in small dense LDL even upon combined administration of statins with 
other lipid lowering drugs [39] supports the contention that other factors may also 
govern LDL size regulation during lipid lowering treatment. Notably, genetic factors 
contribute to the LDL size pattern with estimates of heritability being approximately 
40% [40]. This suggests that it may be rather difficult to modify the LDL size pattern, 
although the total load of circulating LDL particles is ameliorated by statin therapy. 
In the presently studied cohort, 30% of diabetic patients showed LDL size pattern 
B at baseline. This prevalence appears to be somewhat lower compared to that 
reported in other diabetic patients [5,18], and is only modestly higher compared 
to previous reported prevalences in non-diabetic adults [40]. Importantly, it has 
been proposed recently that hyperglycemia-driven hepatic overproduction of large 
VLDL1 represents a central feature of diabetic dyslipidemia [40]. It is, therefore, 
conceivable that persistent hyperglycemia attenuates LDL size changes in response 
to statin administration in diabetic patients. Consequently, these findings [41] 
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would provide a rationale to determine effects of strict metabolic control com-
bined with aggressive lipid lowering on LDL size distribution and subfraction levels.
In conclusion, the present study demonstrates that usual and high dose atorv-
astatin treatment lowers fasting RLP-C without affecting LDL size and changing LDL 
subfractions towards more buoyant LDL in type 2 diabetic patients. The proposed 
guideline cut-off levels for non-HDL-C and apo B may be superior to the LDL-C 
target in discriminating between higher and lower RLP-C levels.
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Plasma apolipoprotein M responses to statin and 
fibrate administration in type 2 diabetes mellitus
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Purpose: Plasma apolipoprotein M (apoM) is potentially anti-atherogenic, and has 
been found to be associated positively with plasma total, LDL and HDL cholesterol 
in humans. ApoM may, therefore, be intricately related to cholesterol metabolism. 
Here, we determined whether plasma apoM is affected by statin or fibrate admin-
istration in patients with diabetes mellitus.
methods: Fourteen type 2 diabetic patients participated in a placebo-controlled 
crossover study which included three 8-week treatment periods with simvastatin 
(40 mg daily), bezafibrate (400 mg daily), and their combination.
results: ApoM was decreased by 7 % in response to simvastatin (p< 0.05 from 
baseline and placebo), and remained unchanged during bezafibrate and combined 
simvastatin+bezafibrate administration. Plasma apoM concentrations correlated 
positively with apoB-containing lipoprotein measures at baseline and during pla-
cebo (p<0.02 to p<0.001), but these relationships were lost during all lipid lowering 
treatment periods.
Conclusions: This study suggests that, even though plasma apoM is lowered by 
statins, apoM metabolism is to a considerable extent independent of statin- and 
fibrate-affected pathways involved in cholesterol homeostasis.
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1. introduCtion
Apolipoprotein (apo) M is a recently identified apolipoprotein which is mainly ex-
pressed in liver and kidney [1,2]. ApoM binds to lipoproteins via its retained signal 
peptide which serves as a lipophilic anchor [1]. Circulating apoM is present in a 
small proportion of HDL and of apoB-containing lipoprotein particles [3]. In human 
populations, plasma apoM levels are correlated positively with total cholesterol, 
LDL cholesterol and HDL cholesterol [4-8].
Interestingly, it has been shown that apoM retards atherosclerosis develop-
ment in murine models [1,9,10]. Atheroprotective effects of apoM could possibly 
be attributed to the ability of this apolipoprotein to generate lipid poor pre-ß par-
ticles which serve as early acceptors of cellular cholesterol in the anti-atherogenic 
reverse cholesterol transport pathway, as well as to its anti-oxidative properties 
[1,3,7].
Experimental evidence is accumulating that apoM regulation may be intricately 
related to LDL cholesterol homeostasis. ApoM overexpression and apoM defi-
ciency increase and decrease plasma cholesterol, respectively [10]. Recently, an 
increasing effect of apoM on VLDL+ LDL cholesterol was found to be dependent 
on an intact LDL receptor [11]. Moreover, plasma apoM is increased in murine 
models of LDL receptor deficiency [11]. These findings raise the possibility that 
plasma apoM levels may be decreased in response to administration of cholesterol 
lowering drugs. Nevertheless, the effects of pharmacological cholesterol lowering 
on human plasma apoM are still unexplored.
In this study we tested the extent to which statin and fibrate administration, 
alone and in combination, affect plasma apoM levels in type 2 diabetic patients.
2. mAteriAls And methods
2.1. Subjects
The medical ethics committee of the University Medical Center Groningen approved 
the study. Written informed consent was obtained from all subjects. Non-smoking 
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male patients, aged > 18 years, with previously diagnosed type 2 diabetes mellitus 
participated. Diabetes treatment consisted of diet alone or combined with oral 
glucose lowering agents. Patients using lipid lowering drugs, insulin, thiazolidin-
ediones and/or anti-hypertensive medication were excluded. None of the subjects 
had a cardiovascular disease history, hypertension (blood pressure > 140 mm Hg 
systolic and/or 90 mm Hg diastolic), severe hyperlipidemia (fasting plasma total 
cholesterol > 8.0 mmol/l and/or triglycerides > 4.5 mmol/l), thyroid disease, liver 
function abnormalities or elevated urinary albumin excretion (urinary albumin > 20 
mg/l). Maximal alcohol allowance was 3 beverages daily. Participants were studied 
after an overnight fast on all occcasions. BMI was calculated as weight (kg) divided 
by height (m) squared. Blood pressure was measured after15 min. rest at the left 
arm in sitting position using a sphygmomanometer.
We performed a double blind, placebo-controlled cross-over study. Active 
medication and placebos were taken at 18.00 h. After baseline measurement, each 
patient first received either simvastatin 40 mg or bezafibrate 400 mg + matching 
placebo daily for a period of 8 weeks, followed by a double placebo period of 8 
weeks. This double placebo period was followed by alternative treatment with 
bezafibrate 400 mg daily or simvastatin 40 mg daily + matching placebo. Thereafter, 
participants received simvastatin 40 mg daily + bezafibrate 400 mg daily for another 
8 weeks. Combined treatment with simvastatin + bezafibrate was given at the end 
of the study to avoid possible carry-over effects. Participants were instructed to 
continue their usual diet as well as their oral glucose lowering medication during 
the study.
2.2 Laboratory methods
Venous blood was collected into EDTA-containing tubes (1.5 mg/mL). Plasma 
samples were prepared by centrifugation at 1400 g for 15 min at 4 0C. Glucose 
and glycated hemoglobin (HbA1c) were measured shortly after blood collection. 
Samples for other assays were stored at -80 oC until assay.
Plasma cholesterol and triglycerides were assayed by routine enzymatic meth-
ods (Roche/Hitachi cat nos 11876023 and 11875540 respectively, Roche Diagnostics 
GmbH, Mannheim, Germany). HDL cholesterol was measured using a homogeneous 
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enzymatic colorimetric test (Roche/Hitachi cat. no. 03030024). Non-HDL choles-
terol was calculated by subtracting HDL cholesterol from plasma total cholesterol. 
LDL cholesterol was calculated by the Friedewald formula. Apolipoprotein (apo) 
A-I and B were assayed by immunoturbidimetry (Roche/Cobas Integra Tina-quant 
cat no. 03032566 and 033032574, respectively, Roche Diagnostics). ApoM was as-
sayed using a sandwich ELISA based on two highly specific monoclonal antibodies 
as described [4]. The procedure involves >1000 fold predilution of plasma samples 
and the use of detergent buffer (Triton X-100) to avoid interference with lipids and 
other plasma components in the assay. The concentration of apoM in the calibrator 
was determined using a standard with known apoM concentration. The interassay 
coeffficient of variation (CV) was 4.9 %. Glucose was analyzed with an APEC glucose 
analyzer (APEC Inc., Danvers, MA). HbA1c was measured by high performance liquid 
chromatography (Bio-Rad, Veenendaal, The Netherlands; normal range 4.6-6.1%).
2.3 Statistical analysis
Data are given in mean±SD or median (interquartile range). Changes in variables 
were evaluated by two-way ANOVA. Duncan’s test was applied to correct for 
multiple comparisons. Differences in relative changes in variables were tested by T-
tests. Univariate relationships were calculated by Pearson correlation coefficients. 
Two-sided P-values <0.05 were taken as statistically significant.
3. results
Fourteen type 2 diabetic patients (mean age 55±8 years, diabetes duration 4±2 
years) participated. Their BMI, systolic blood pressure and diastolic blood pres-
sure were 28.3±4.7 kg/m2, 127±10 mm Hg and 80±7 mm Hg, respectively. Two 
patients were treated with diet only, 6 patients used metformin and 3 patients 
used sulfonylurea derivates alone; 3 patients used both drugs. These medications 
were continued during the study. BMI and blood pressure were unchanged dur-
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All (apo)lipoprotein measures were similar at baseline and during placebo admin-
istration (Table 1). Plasma total cholesterol and non-HDL cholesterol decreased 
during treatment with simvastatin, bezafibrate and their combination (Table 1). 
LDL cholesterol dropped during treatment with simvastatin alone and during sim-
vastatin + bezafibrate. Plasma triglycerides decreased, whereas HDL cholesterol 
increased after bezafibrate and simvastatin + bezafibrate. Plasma apoB decreased 
during treatment with simvastatin alone and simvastatin + bezafibrate, whereas 
apoA-I increased during combined treatment (Table 1). The HDL cholesterol/non-
HDL cholesterol ratio increased from 0.32±0.13 at baseline to 0.61±0.27 during 
combined treatment (p<0.001).
Plasma apoM decreased by 7 % during simvastatin monotherapy, but remained 
unchanged during bezafibrate and simvastatin + bezafibrate combined (Table 1). 
Baseline plasma apoM was correlated rather strongly and positively with baseline 
plasma total cholesterol, LDL cholesterol, non-HDL cholesterol and apoB (Table 2, 
Figure 1). These relationships were lost during all active treatment periods, but 
reappeared during placebo administration. In contrast, apoM was not significantly 
associated with HDL cholesterol and apoA-I at baseline, but a positive correlation 
of apoM with HDL cholesterol and apoA-I appeared during combination therapy 
(Table 2, Figure 1). Changes in apoM from baseline in response to simvastatin, 
bezafibrate and combination therapy were not positively correlated with changes 
in LDL cholesterol, non-HDL cholesterol and apoB during treatment (P>0.05 for all). 
Consequently, the LDL cholesterol, non-HDL cholesterol and apoB levels attained 
during administration of simvastatin, bezafibrate and simvastatin + bezafibrate 
combined were still correlated with baseline apoM (r=0.574, P=0.032 to r=0.684, 
P=0.008, data not shown).
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Figure 1. Relationships of plasma apolipoprotein M (apoM) with LDL cholesterol and HDL 
cholesterol at baseline (A,B) and during administration of simvastatin + bezafibrate com-
bined (C,d).
Table 2. Pearson correlation coefficients of apolipoprotein M with LDL cholesterol, non-HDL 
cholesterol and apolipoprotein B (apoB) in 14 type 2 diabetic patients at baseline and during 
administration of simvastatin (40 mg daily), bezafibrate (400 mg daily), placebo and simvas-
tatin + bezafibrate combined.
Baseline Simvastatin Bezafibrate Placebo Simvastatin+ 
bezafibrate
total cholesterol 0.737** 0.238 0.043 0.880*** 0.234
ldl cholesterol 0.649* 0.073 -0.167 0.813*** 0.212
non-hdl 
cholesterol
0.680** 0.095 -0.165 0.814*** 0.217
ApoB 0.687** 0.206 -0.190 0.770*** 0.125
hdl cholesterol -0.054 0.247 0.461 -0.410 0.669**
ApoA-i 0.088 0.019 0.442 -0.216 0.802***
*p<0.02; **p<0.01; ***p<0.001.
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4. disCussion
This placebo-controlled study demonstrates that plasma apoM is decreased by 
simvastatin administration in type 2 diabetes. However, apoM remained unchanged 
during combined simvastatin and bezafibrate administration, contrasting expect-
edly large reductions in apoB-containing lipoproteins [12]. Our report thus shows 
that pharmacological lowering of apoB-containing lipoproteins does not decrease 
plasma apoM when obtained with an HDL-raising therapy.
We determined effects of statin and fibrate administration on apoM in type 2 
diabetic patients in view of current recommendations that favour early lipid lower-
ing drug intervention [13]. ApoM was found to be 9 % lower in type 2 diabetes, but 
this difference was attributable to diabetes-associated obesity [7]. Furthermore, 
statins are equally effective in cholesterol lowering in diabetic compared to non-
diabetic subjects. Therefore, it is likely that the presently observed apoM response 
to statin treatment can be extrapolated to non-diabetic subjects.
Statins lower LDL cholesterol at least in part by increasing hepatic LDL catabo-
lism via stimulation of LDL receptor-mediated lipoprotein uptake in response to 
cholesterol synthesis inhibition, and these effects are possibly accompanied by a 
decrease in apoB production [14,15]. We observed recently that complete absence 
of LDL-receptors in mice approximately doubles plasma apoM, and found that even 
HDL-associated apoM is affected by the LDL-receptor most likely in an apoE-depen-
dent manner [11]. The modest lowering of apoM during simvastatin monotherapy, 
as demonstrated in the present study, is consistent with the hypothesis that the 
LDL receptor also has some effect on plasma apoM levels in humans.
Fibrates decrease hepatic triglyceride synthesis, increase the catabolism and 
delipidation of large VLDL particles, and stimulate apoA-I synthesis [15]. In our 
study, plasma apoM was unaffected when bezafibrate was administered alone or 
in combination with simvastatin. As in an earlier report [6], plasma apoM before 
treatment was not significantly related to HDL cholesterol and apoA-I in type 2 
diabetic subjects, suggesting that the diabetic state could weaken the strength of 
the relationship of HDL cholesterol with plasma apoM. Notably, apoM became cor-
related positively with HDL-cholesterol and apoA-I in response to combined fibrate 
+ statin administration, which represented the treatment regimen that resulted in 
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the lowest HDL cholesterol/non-HDL cholesterol ratio. The responsible mechanism 
for this appearance of a relation between apoM and HDL cholesterol in response 
to treatment is unknown at present, but could involve a shift in apoM distribution 
between apoB-containing lipoproteins and HDL. ApoM exchanges rapidly between 
lipoproteins in vivo [11], and a shift in apoM lipoprotein distribution has been 
observed in murine models of LDL receptor and apoE deficiency [16]. Of further 
importance, apoM is decreased in apoA-I deficient mice [16]. Conversely, plasma 
apoM levels may predict apoA-I metabolism in obese individuals [8]. Altogether, it 
would seem possible that a decreasing effect of statins on total plasma apoM levels 
in association with LDL lowering is counteracted by an HDL and apoA-I increasing 
effect of fibrates.
Unlike animal studies which strongly suggest that apoM exerts anti-atherogenic 
properties [1,9,10], the relationship between apoM and cardiovascular disease in 
humans is unestablished at present [4,7,17]. It is, therefore, uncertain whether 
the small drop in plasma apoM in response to statin treatment would translate 
in cardiovascular risk modification. Of potential clinical relevance, higher apoB-
containing lipoproteins levels during lipid lowering treatment were correlated with 
higher baseline apoM concentrations. Hence, future studies may reveal the validity 
of plasma apoM measurement in predicting the extent to which lipid targets are 
reached during pharmacological intervention.
In conclusion, regulation of human plasma apoM seems largely independent 
from statin and fibrate affected pathways involved in cholesterol homeostasis.
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Relationship of plasma apolipoprotein M with 
proprotein convertase subtilisin-kexin type 9 levels in 
non-diabetic subjects





Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine 
models, and may be regulated by pathways involved in LDL metabolism. Proprotein 
convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor process-
ing. We determined whether plasma apoM is related to PCSK9 levels in subjects 
with varying degrees of obesity.
methods: We sought correlations between plasma apoM and PCSK9, measured 
using recently developed ELISAs, in 79 non-diabetic subjects (42 subjects with body 
mass index (BMI) ≥25 kg/m2).
results: ApoM and PCSK9 levels were both correlated positively with total choles-
terol, non-HDL cholesterol, LDL cholesterol and apoB (p<0.05 to p<0.001). ApoM 
correlated positively with PCSK9 in lean subjects (r=0.337, p=0.041; ß=0.413, 
p=0.021 after BMI and apoB adjustment), but not in subjects with BMI≥25 kg/m2 
(r=0.099, p=0.53).
Conclusions: The PCSK9 pathway may contribute to plasma apoM regulation in 
humans. The influence of PCSK9 on circulating apoM appears to be modified by 
adiposity.
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1. introduCtion
Interest in the regulation of apolipoprotein (apo) M comes from the observation 
that apoM retards atherosclerosis development in murine models [1-3]. Its plasma 
level is related positively with HDL cholesterol and apoA-I [4-5]. ApoM is also 
correlated positively with plasma total cholesterol and LDL cholesterol [4-6], al-
though only a minor proportion is located in the LDL fraction [7]. ApoM deficiency 
decreases whereas apoM overexpression increases plasma cholesterol [3]. This 
effect is more pronounced in the setting of LDL receptor deficiency [8]. Conversely, 
plasma apoM is increased in murine models of LDL receptor deficiency [3]. Recently, 
plasma apoM was found to decrease after statin treatment in humans [9]. Taken 
together, these findings favour an intricate relation between apoM regulation and 
LDL cholesterol homeostasis.
Proprotein convertase subtilisin-kexin type 9 (PCSK9) provides a key regulatory 
pathway for LDL receptor processing [10,11]. The mechanisms whereby PCSK9 pro-
motes LDL receptor degradation involve intracellular targeting of internalized LDL 
receptors towards the lysosomal compartment. PCSK9 is a secreted protease and 
binds to the extracellular domain of the LDL receptor, where it acts as a chaperone 
targeting the LDL receptor towards intracellular degradation and preventing LDL 
receptor recycling to the cell surface. This implies that circulating PCSK9 is physi-
ologically relevant [10,11]. Indeed, the LDL apoB fractional catabolic rate correlates 
inversely with plasma PCSK9 levels in humans [12]. Human studies have now shown 
that plasma apoB-containing lipoproteins levels are correlated positively with the 
PCSK9 concentration [12,13].
Against this background we hypothesized that apoM is positively related to the 
PCSK9 level. Here we determined the extent to which plasma apoM correlates with 
PCSK9 levels in non-diabetic subjects with varying degrees of obesity.
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2. mAteriAls And methods
2.1. Subjects
The medical ethics committee of the University Medical Center Groningen, The 
Netherlands, approved the study. Participants (aged>18 years) were recruited by 
advertisement and provided written informed consent. Physical examination did 
not reveal abnormalities. Previously diagnosed diabetes mellitus, cardiovascular 
disease, renal insufficiency, hypertension, thyroid disorders, liver disease and 
pregnancy were exclusion criteria. Smokers and subjects who used >3 alcoholic 
drinks per day were also excluded. BMI was calculated as weight divided by height 
squared (in kg/m2). Overweight and obesity were defined as BMI≥25 kg/m2 and 
≥30 kg/m2, respectively. Homeostasis model assessment (HOMAir) was used to as-
sess insulin sensitivity, and was calculated with the formula: fasting plasma insulin 
x glucose/22.5. The subjects were studied after an overnight fast.
2.3. Laboratory analyses
Venous blood samples were collected into EDTA-containing tubes (1.5 mg/mL). 
Plasma samples were stored at -800C until analysis. Glucose was measured shortly 
after blood collection. Cholesterol and triglycerides were assayed by routine en-
zymatic methods. HDL cholesterol was measured with a homogeneous enzymatic 
colorimetric test. Non-HDL cholesterol was calculated as the difference between 
total cholesterol and HDL cholesterol. LDL cholesterol was calculated with the Frie-
dewald formula. ApoA-I and apoB were measured by immunoturbidimetry. ApoM 
was assayed using a sandwich ELISA based on two highly specific monoclonal 
antibodies as described [4]. Plasma PCSK9 was measured using a sandwich ELISA 
exactly as described [12]. The inter-assay coefficients of variation were 4.9 % and 
5.6 %, respectively
2.4 Statistical analysis
Data are given in mean±SD or in median (interquartile range). Univariate relation-
ships were calculated using Spearman’s rank correlation. Multivariable regression 
analysis was performed to the independent contribution of variables. Two-sided 
p-values <0.05 were considered significant.
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3. results
Seventy-nine non-diabetic Caucasian subjects participated (Table 1). BMI ranged 
from 19.4 to 40.4 kg/m2. Forty-two subjects (53 %) were overweight (n=32) or 
obese (n=10). Plasma insulin and HOMAir were higher (p<0.001), but glucose was 
similar (p=0.81) in subjects with BMI≥25 kg/m2vs. lean subjects (not shown).
Table 1. Clinical characteristics, plasma glucose, insulin, homeostasis model assessment 
(homAir), plasma lipids, apolipoproteins (apos), proprotein convertase subtilisin-kexin type 
9 (PCSK9) levels, and correlation coefficients with apoM and PCSK9 in 79 non-diabetic sub-
jects
Variable Correlation coefficient of 
variable with
apom PCsk9
Age (years) 55 ± 10 0.028 -0.120
Sex (m/f) 44/35
systolic blood pressure (mm hg) 131 ± 19 -0.115 0.022
diastolic blood pressure (mm hg) 82 ± 11 -0.133 -0.079
Bmi (kg/m2) 25.9 ± 3.9 -0.298** -0.021
glucose (mmol/l) 5.6 ± 0.7 0.174 -0.141
insulin (mu/l) 6.7 (4.3-8.4) 0.014 0.245*
homAir (mU x mmol/(l2 x 22.5)) 1.57 (1.03-2.20) 0.042 0.219*
total cholesterol (mmol/l) 5.72 ± 1.00 0.365*** 0.357***
non-hdl cholesterol (mmol/l) 4.25 ± 1.06 0.303** 0.398***
ldl cholesterol (mmol/l) 3.54 ± 0.88 0.273** 0.292**
hdl cholesterol (mmol/l) 1.46 ± 0.40 0.132 -0.130
triglycerides (mmol/l) 1.27 (0.88-1.91) 0.210* 0.337**
ApoB (g/l) 0.96 ± 0.24 0.253* 0.278**
ApoA-i (g/l) 1.42 ± 0.22 0.216* 0.034
ApoM (μmol/l) 1.09 ± 0.25 0.149
PCSK9 (μg/l) 155 ± 58
Data in mean (SD) or in median (interquartile range). BMI, body mass index. Spearman’s cor-
relation coefficients are shown. *P≤0.05; **P≤0.01; ***P≤0.001.
In the whole group, plasma apoM ranged from 0.53 to 1.95 μmol/l, and PCSK9 
ranged 43 from to 339 μg/l. ApoM was lower in subjects with BMI≥25 kg/m2 
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(1.04±0.26 μmol/l) compared to lean individuals (1.14±0.22 μmol/l, p=0.046). In 
contrast, PCSK9 levels were not decreased in overweight or obese subjects (BMI≥25 
kg/m2: 162±62 µg/l vs. BMI<25 kg/m2: 146±52 µg/l, p=0.22).
Plasma apoM was correlated inversely with BMI, but was unrelated to insulin 
and HOMAir. PCSK9 was correlated positively with insulin and HOMAir but was 
not correlated with BMI (Table 1). ApoM as well as PCSK9 levels were correlated 
positively with total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB. 
Additionally, apoM was related positively with apoA-I and PCSK9 correlated posi-
tively with triglycerides. Despite relationships of both apoM and PCSK9 with apoB-
containing lipoproteins, the correlation of apoM with PCSK9 was not significant in 
the whole group (p=0.19; Table 1).
Since the presence of overweight could confound the putative relationship 
between PCSK9 and apoM, we determined relationships of apoM with PCSK9 in 
subjects with BMI<25 kg/m2 and ≥25 kg/m2 separately. In subjects with BMI<25 kg/
m2, apoM did correlate positively with PCSK9 (r=0.337, p=0.041; Fig. 1). Multivari-
able regression analysis showed that apoM was correlated positively with PCSK9 in 
these subjects (ß=0.413, p=0.021) after adjustment for BMI and apoB. In contrast 
in subjects with BMI ≥25 kg/m2, apoM was unrelated to PCSK9 (r=0.099, p=0.53), 
and multivariable regression analysis did not demonstrate a relationship of apoM 
with PCSK9 (ß=0.011, p=0.94) after controlling for BMI and apoB either.
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Figure 1 Scatterplot showing relationship of plasma apolipoprotein M (apoM) with propro-
tein convertase subtilisin-kexin type 9 (PCSK9) concentrations in 37 lean subjects (body mass 
index (BMI) <25 kg/m2)
4. disCussion
Here we demonstrate that plasma apoM is correlated positively with the PCSK9 
level in lean subjects without diabetes mellitus. No such relationship was present 
in overweight and obese individuals. Our findings support the hypothesis that the 
PCSK9 pathway may be involved in apoM regulation in humans, and suggest that 
effects of PCSK9 on apoM may be modified by adiposity.
Both plasma apoM and PCSK9 concentrations were correlated positively with 
total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB, as expected [4-
6,12,13]. In lean individuals, the positive relationship of apoM with PCSK9 levels 
was independent of BMI and apoB-containing lipoproteins. PCSK9 facilitates LDL 
receptor degradation [10,11]. The present findings, therefore, agree with the con-
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cept that the clearance of circulating apoM is affected by the LDL receptor-pathway 
in humans [3,8].
Relevant differences were found for the association of apoM and PCSK9 with 
obesity and insulin sensitivity. ApoM was correlated inversely with BMI, in accord 
with other data [5,6]. The relationship apoM with insulin and insulin sensitivity 
was not significant. Plasma PCSK9 was not significantly related to BMI, but was 
correlated positively with plasma insulin and HOMAir. Using a different ELISA posi-
tive relationships of plasma PCSK9 with insulin and HOMAir were reported recently 
[13]. Plasma PCSK9 levels ranged 100-fold in that study [13], exceeding the range 
of values that was currently observed. That report also showed a positive relation-
ship of PCSK9 with BMI, but this correlation was weaker than that with insulin and 
HOMAir [13]. In vitro studies have suggested that insulin decreases apoM [14], but 
increases PCSK9 expression [15]. These contrasting effects of insulin could in part 
be responsible for the differences in associations of apoM compared to PCSK9 with 
insulin and insulin sensitivity. Although the precise mechanisms responsible for 
a modifying effect of adiposity on the contribution of PCSK9 to apoM regulation 
are unknown, metabolic factors related to insulin-regulated pathways could be 
involved.
In conclusion, the present study suggests that PCSK9, which plays a key role in 
LDL receptor degradation, may affect apoM regulation in lean individuals.
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Chapter 1 describes the purpose of the studies presented in this thesis. The 
first part concerns the role of pro-and anti-atherogenic (apo)lipoproteins in the 
development of cardiovascular disease and the prediction thereof. In this section 
we also considered cholesteryl ester transfer protein (CETP) and the role of CETP 
inhibitors in cardiovascular disease prevention. In addition, this section evaluates 
the association of adipose tissue-derived hormones, so-called adipokines, with 
(sub)clinical atherosclerosis.
Chapter 2 describes a study in which we determined which lipoprotein or 
apolipoprotein measure best predict first cardiovascular events in the general 
population. To this end different parameters were measured in the Prevention of 
Renal and Vascular ENd-stage Disease (PREVEND) cohort. The PREVEND study is a 
large population-based prospective study aimed to determine the role of elevated 
urinary albumin excretion in progression of renal and cardiovascular disease. We 
observed that all pro- and anti-atherogenic (apo)lipoprotein measures predicted 
the incidence of major adverse cardiovascular events (MACE). The relationship of 
the total cholesterol/high density lipoprotein (HDL) cholesterol ratio and the apoB/
apoA-I ratio with first MACE was at least as strong as the associations found with 
single (apo)lipoprotein measures. In a direct comparison of the total cholesterol/
HDL-cholesterol and the apoB/apoA-I ratio there appeared to be a higher hazard 
ratio attributable to the apoB/apoA-I ratio; however, this difference disappeared 
after correction for age and sex. Additional adjustment for traditional risk factors, 
triglycerides, as well as albuminuria and high sensitivity C-reactive protein yielded 
only marginally lower hazard ratios for both these ratios. We, therefore, concluded 
that the incidence of first MACE is equally predicted by both the apoB/apoA-I 
ratio and the total cholesterol/HDL-cholesterol ratio, even when taking account 
of traditional and novel risk markers. The results of our study furthermore sug-
gest that low density lipoprotein (LDL) cholesterol (calculated by the widely used 
Friedewald formula, which is derived from total cholesterol, HDL cholesterol and 
triglycerides) does not add to total cholesterol and HDL cholesterol measurement 
in MACE prediction
Chapter 3 is a review on cholesteryl ester transfer protein (CETP) and pharma-
cological CETP inhibition. We provide an overview of the functions of CETP, and 
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evaluate the cardioprotective potential of CETP inhibitors, a new class of drugs. In-
hibition of CETP primarily raises HDL cholesterol to a considerable extent. Although 
CETP inhibitors also lower the cholesterol content in apoB-containing lipoproteins, 
such as LDL, this class of drugs essentially tests the hypothesis that HDL cholesterol 
raising per se beneficially reduces cardiovascular risk. The first CETP inhibitor that 
was tested in a large scale phase 3 clinical trial (ILLUMINATE ) was torcetrapib [1]. 
In contrast to expectation, there was an increase in cardiovascular events in the 
group receiving torcetrapib in addition to conventional lipid lowering treatment 
compared to conventional lipid lowering treatment alone. It has been suggested 
that an unforeseen increase in blood pressure induced by torcetrapib may have 
outweighed the benefits of a higher HDL cholesterol and a lower LDL cholesterol. 
More recently, other CETP inhibitors, like anacetrapib, dalcetrapib and evacetrapib, 
have been or are being tested in large trials. These compounds do not appear to 
increase blood pressure as observed with torcetrapib. Dalcetrapib studies have 
been halted for lack of efficacy [2,3]. The ACCELERATE trial in which evacetrapib 
was studied has also been halted due to lack of efficacy [4]. The results of the 
REVEAL trial with the third compound, anacetrapib will demonstrate whether 
pharmacological CETP inhibition could still be regarded as a viable therapeutic 
option in the prevention of cardiovascular disease [5]. Very recently, a new CETP 
inhibitor, known as TA-8995, has been developed. In a recent phase 2 trial this 
compound demonstrated the greatest increase in HDL cholesterol and the largest 
reduction in LDL cholesterol of all CETP inhibitors studied to date [6,7]. However, at 
this moment the possible cardiovascular benefit of this CETP inhibitor is unknown.
The influence of common CETP polymorphisms on prediction of MACE is de-
scribed in chapter 4. Using data from the PREVEND study, we observed that the 
incidence of a first major cardiovascular events did not differ significantly between 
TaqIB (rs708272) and –629C>A (rs1800775) genotype groups. These polymor-
phisms affect the plasma lipoprotein profile in such a way that variations in CETP 
that confer greater plasma CETP levels do not only determine lower HDL cholesterol 
levels, but also smaller-sized HDL and LDL particles [8]. No significant interactions 
between the total cholesterol/HDL cholesterol ratio and the apoB/apoA-I ratio and 
each of the CETP SNPs on incident cardiovascular risk was observed. This finding 
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suggests that risk prediction of MACE by plasma lipids, apolipoproteins and their 
ratios in the general population is not to an important extent influenced by com-
mon CETP polymorphisms.
Chapter 5 concerns a nested case-control study among 219 men (114 cases) 
within the PREVEND cohort. The aim of this study was to compare the associa-
tion of incident cardiovascular disease with plasma CETP mass levels and plasma 
cholesteryl ester transfer (CET). We found that plasma CET was associated with 
incident cardiovascular disease, whereas plasma CETP mass did not predict car-
diovascular events. The association of plasma CET with incident cardiovascular dis-
ease remained statistically significant when the total cholesterol/HDL cholesterol 
ratio, body mass index, hypertension, smoking, plasma glucose, albuminuria and 
even plasma CETP mass were taken into account. This suggests that the process 
of plasma cholesteryl ester transfer, whereby cholesteryl esters are transferred 
from HDL towards apoB-containing lipoproteins, may be more important for the 
development of atherosclerosis than the plasma concentration of this lipid transfer 
protein per se.
Chapter 6 concerns the association of the degree of subclinical atherosclerosis 
with two adipocyte-derived hormones, leptin and adiponectin. Leptin mainly has 
potentially pro-atherogenic effects, including induction of endothelial dysfunction, 
stimulation of inflammatory reaction, oxidative stress and migration, hypertrophy 
and proliferation of vascular smooth muscle cells [9]. In contrast, adiponectin is 
known to inhibit the process of atherosclerosis by inhibition of foam cell formation, 
the proliferation and migration of smooth muscle cells and by inhibiting the expres-
sion of adhesion molecules [10]. Circulating levels of adiponectin are decreased 
in obesity and diabetes mellitus. High leptin levels are known to increase the risk 
of first cardiac events in men, a relationship which is to a considerable extent at-
tenuated by obesity [11]. Adiponectin is known to have a modest cardioprotective 
effect [12, 13]. We studied 72 participants with and 89 subjects without metabolic 
syndrome. We measured carotid artery intima media thickness (c-IMT) as a marker 
of subclinical atherosclerosis. In this cross-sectional study we observed an inverse 
association of the adiponectin level and a positive association of the leptin/adipo-
nectin ratio with c-IMT after adjustment for age and sex. However, after additional 
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adjustment for the presence of the metabolic syndrome the inverse association of 
the adiponectin level with c-IMT remained present but the statistical significance 
of relationship between c-IMT and the leptin/adiponectin ratio was lost. This cross-
sectional study suggested that the leptin/adiponectin ratio might not be preferable 
to the adiponectin level alone in determining atherosclerosis susceptibility when 
taking conventional risk markers into account.
Chapter 7 describes a nested case-control study among male PREVEND par-
ticipants in which we determined the predictive value of the leptin/adiponectin 
ratio in cardiovascular disease development compared to plasma levels of leptin 
and adiponectin alone. We found that plasma leptin, adiponectin and their ratio 
all predicted a first cardiovascular event. After correction for conventional risk fac-
tors, plasma lipids and albuminuria the associations of incident MACE with leptin, 
adiponectin and the leptin/adiponectin remained statistically significant. Of note, 
after additional correction for insulin resistance and high sensitivity C-reactive pro-
tein only the leptin/adiponectin ratio remained positively associated with incident 
cardiovascular disease. We concluded from this prospective study that the leptin/
adiponectin ratio may be a preferable predictor of a first cardiovascular event 
compared to adiponectin or leptin alone.
The apparent discrepancy between these two studies concerning the value of 
the leptin/adiponectin ratio over leptin and adiponectin alone may at least in part 
be ascribed to differences in study design. The former study was cross-sectional 
in design, and a subclinical surrogate marker was used as an endpoint, while the 
latter study was a prospective clinical endpoint study. Furthermore, the second 
study included men only, and we additionally adjusted for other risk markers, such 
as insulin resistance, albuminuria and high sensitivity C-reactive protein.
The second part of this thesis focuses on the effects of lipid lowering treatment 
on various (apo)lipoproteins.
In Chapter 8 we describe a study performed in the diabetes atorvastatin lipid 
intervention (DALI) study cohort which comprises 217 moderately hypertriglyceri-
daemic patients with type 2 diabetes mellitus. We studied the relationships of LDL 
cholesterol, estimated by the Friedewald formula and non-HDL cholesterol with 
apoB concentrations before and during statin therapy. We found that there is a 
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shift in the regression lines of the relationships between of LDL cholesterol and 
non-HDL cholesterol with apoB after administration of atorvastatin. On treatment 
values of both LDL cholesterol and non-HDL cholesterol corresponded to higher 
apoB values compared to baseline. This could imply a predominance of small dense 
LDL in plasma or less large-sized VLDL particles and/or VLDL remnants after initia-
tion of statin treatment. Considering the predictive value of on-treatment apoB 
levels for recurrent cardiovascular disease and the additional clinical benefit of 
aggressive lipid lowering treatment are taken into account [14,15], the data from 
this study might be interpreted in favour of the use of apoB as a therapeutic target 
during statin treatment.
Chapter 9 concerns another analysis in the DALI cohort. Given the pro-athero-
genic role of cholesterol-rich remnant particles [16] and small-dense LDL particles 
[17] we studied changes in lipoprotein remnants and LDL size during atorvastatin 
administration. We found that atorvastatin considerably lowered remnant lipo-
protein cholesterol in conjunction with a reduction in triglycerides. In contrast, 
atorvastatin did not affect LDL mean peak diameter. As a result, the proportion of 
subjects with predominance of small sized LDL (also known as pattern B) remained 
unchanged. In summary, we found that atorvastatin largely normalizes fasting 
remnant lipoprotein cholesterol, decreases the cholesterol content in all LDL sub-
fractions, but does not have a major effect on LDL subfraction distribution. Taken 
together, the shift in the relationship of non-HDL cholesterol and apoB might thus 
be explained by a predominant decrease in cholesterol-rich VLDL remnants with-
out affecting LDL particle size. The apparent discordance of a shift in the relation 
between apoB and LDL cholesterol without affecting particle size might in part be 
due to inaccuracy in the Friedewald formula for the estimation of LDL cholesterol 
in diabetic patients on statin treatment [18].
Chapter 10 describes a study concerning apolipoprotein M (apoM). ApoM 
is mainly expressed in liver and kidney. In human plasma, apoM is associated 
predominantly with the HDL fraction and to a lesser extent with LDL. In murine 
models, apoM may retard atherosclerosis development by facilitating the forma-
tion of preβ-HDL and cell cholesterol efflux to HDL, thereby putatively inhibiting 
the formation of atherosclerotic lesions [19]. Intriguingly, murine models showed 
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that in the setting of LDL receptor deficiency the antiatherogenic effect of apoM 
might be blunted which could be attributable to the pro-atherogenic effect of rais-
ing LDL and VLDL. Importantly, plasma apoM is increased in murine models of LDL 
receptor deficiency [20]. However, despite a positive relationship of apoM with LDL 
cholesterol, it is still uncertain whether apoM is regulated by LDL receptor abun-
dancy in humans. In chapter 10 we showed that simvastatin treatment moderately 
lowers apoM, consistent with experimental findings that LDL receptor expression 
contributes to apoM regulation. Remarkably, the combination of simvastatin and 
bezafibrate did not significantly lower plasma apoM. Furthermore, during statin-
fibrate combination the normally present positive relationship of apoM with LDL 
cholesterol disappeared, whereas apoM became positively related with HDL cho-
lesterol and apoA-I. Since apoM is rapidly exchanged between lipoproteins in vivo 
[20], this phenomenon might be ascribed to a shift in apoM distribution between 
apoB-containing lipoproteins and HDL. Altogether, it would seem possible that a 
decreasing effect of statins on total plasma apoM levels in association with LDL 
lowering is counteracted by an HDL and apoA-I increasing effect of fibrates.
Chapter 11 describes the relationship of apoM with proprotein convertase 
subtilisin-kexin type 9 (PCSK9) levels. PCSK9 is plays an important role in directing 
the LDL receptor towards intracellular degradation. PCSK9 action, thereby, leads 
to increased plasma LDL cholesterol levels. We found the level of apoM and PCSK9 
to be positively correlated in lean individuals. Such a relationship could not be 
found in overweight and obese subjects. We conclude that PCSK9 may affect apoM 
regulation in lean individuals. Our findings support the contention that the LDL 
receptor pathway may be involved in the metabolism of apoM. The mechanism 
responsible for the influence of adiposity on this effect is unknown, but differential 
effects insulin on apoM and PCSK9 regulation could possibly be involved [21-24].
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future PersPeCtiVes
the role of apolipoproteins in cardiovascular risk management
The focus of lipid management in daily practice is currently focused on plasma lev-
els of lipoproteins or lipoprotein ratios and the risk of cardiovascular disease they 
infer. (Apo)lipoprotein levels are then taken as specific treatment targets. However, 
there might be a role for a more integrated approach to lipoprotein management. 
From an epidemiological perspective, models of cardiovascular risk prediction do 
not seem to benefit from the use of apolipoprotein measures over or alongside 
of lipoprotein measures [25-27]. This is in keeping with our findings that the total 
cholesterol/HDL-cholesterol and the apoB/apoA-I ratio equally predict first MACE. 
Whether the inclusion of triglycerides in these models provides any advantage is 
debated, and some experts have even proposed that there is no requirement to 
measure triglycerides on a routine basis [28].
From a clinical perspective the classification of a more specific dyslipoprotein-
aemic phenotype is of importance. In this regard the measurement of triglycerides 
and apoB could be instrumental in establishing a more detailed classification of 
dyslipidaemia [29]. Since each apoB-containing lipoprotein particle contains one 
apoB molecule, the apoB concentration is indicative of the number of atherogenic 
particles instead of the cholesterol content in apoB-containing lipoproteins, the 
latter being measured as non-HDL cholesterol. By defining the specific dyslipo-
proteinaemic phenotype a more (patho)physiological approach could be utilized, 
thereby possibly facilitating to define treatment targets depending on the specific 
lipoprotein abnormality. There are six major apoB dyslipoproteinaemias, which 
are classified on the basis of which one or which ones of the apoB containing 
lipoprotein particles, chylomicrons, VLDL, VLDL remnants, and LDL are elevated. 
Changes in these lipoproteins all have a distinct pathophysiological background 
[30]. The atherogenicity of these different phenotypes might vary considerably. 
An approach to characterize the different apoB dyslipoproteinaemias using plasma 
apoB, triglycerides and total cholesterol has been proposed [29]. At this moment 
evidence for a clinical benefit of this phenotype-centered approach awaits further 
study. More research is required to establish whether this approach results in more 
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adequate prediction of clinically manifest atherosclerotic cardiovascular disease. 
Equally important, it is still unclear whether this leads to a better decision making 
on the need for, the type of and the intensity of the therapeutic regimen to employ 
to adequately reduce cardiovascular risk.
Of further interest is the ongoing discussion of the usefulness of lipoprotein 
subfraction measurements [31]. An elevated concentration of small-dense LDL is 
associated with an increased risk of cardiovascular events and has even been found 
to be more predictive of cardiovascular risk than the LDL cholesterol concentra-
tion [32,33]. In one prospective study in women no benefit of LDL subfraction 
measurement when added to a model which included the total cholesterol/HDL 
cholesterol was found [34]. Whether this holds true in men, or in other populations 
like subjects with diabetes is not yet clear. In this regard it is also important that 
measurement of “remnant cholesterol”, i.e. cholesterol in triglycerde-rich remnant 
particles, may add to cardiovascular risk prediction [16,35].
The utility of measurement of HDL subfractions has not been unequivocally 
established either. In some studies, no effects of HDL subfraction distribution was 
found [36]. In other studies, small-sized HDL was positively predictive of cardiovas-
cular events [37,38]. In one of these studies this association was largely attenuated 
when traditional lipid measures were included in the model. [37]
HDL cholesterol concentration versus HDL functionality
When it was first discovered that a low HDL cholesterol concentration is highly 
prevalent in subjects with cardiovascular disease, it was postulated that HDL was 
able to stimulate the clearance of cholesterol from the arterial wall, thereby puta-
tively protecting against atherosclerotic manifestations [39]. More recently, it has 
been documented that HDL executes a myriad of functions: it is a key player in the 
reverse cholesterol transport pathway whereby HDL promotes efflux of cholesterol 
from macrophages, and delivers it to the liver for metabolism and excretion in 
the bile. In a recent study, the capacity of HDL cholesterol to stimulate efflux from 
macrophages, was inversely associated with incident atherosclerotic cardiovascu-
lar disease even after correction for the HDL cholesterol concentration and particle 
number [40]. Another prospective study also showed that efflux from a macro-
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phage cell system to apoB-depleted serum was inversely associated with incident 
coronary heart disease [41]. This association remained present after adjustment 
for HDL cholesterol or apoA-I, and also after taking conventional cardiovascular 
risk factors into account [41]. These results suggest that HDL function is important 
in reducing atherosclerosis development and/or progression independent from 
the HDL particle number or the cholesterol content. However, another study in 
which efflux was measured from fibroblasts to whole plasma failed to show such a 
relationship [42]. Also in a prospective study, cholesterol efflux from macrophages 
to apoB-depleted serum was paradoxically associated with an increased cardio-
vascular risk [43]. Remarkably, in a recent report in renal transplant recipients, 
cholesterol efflux from macrophages predicted graft failure but not cardiovascular 
events independent of HDL cholesterol levels [44].
Secondly, HDL exerts a number of other atheroprotective functions [45,46]. 
HDL is able to directly inhibit the oxidation of LDL particles resulting in reduced 
atherogenicity of these lipoproteins [47-49]. Furthermore, HDL exhibits anti-
inflammatory functions by downregulating inflammatory cytokines and vascular 
cell adhesion molecules. This is an important function because inflammation is 
a key component of atherosclerosis [48]. HDL also has anti-thrombotic functions 
by inhibiting platelet aggregation and by promoting prostacyclin and nitric oxide 
production which in turn decrease local proliferation of vascular smooth muscle 
cells. [48,50]
Randomized controlled trials and meta-analyses of the use of HDL cholesterol-
raising drugs, including CETP inhibitors and niacin, have, thus far, been unable to 
underscore the hypothesis that HDL cholesterol should be regarded as therapeutic 
target per se [51-53]. The CETP inhibitors, anacetrapib and TA-8995, not only have 
a large impact on HDL cholesterol but also lower LDL cholesterol to a considerable 
extent. If one or both of these substances proves to lower cardiovascular risk, this 
could very well be at least in part a result of the lowering of LDL cholesterol instead 
of the raising HDL cholesterol.
Central in future research is to determine whether measurement of different 
functions of HDL will facilitate better prediction of cardiovascular risk compared to 
either HDL cholesterol concentration or of the measurement of HDL subfractions. 
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To assess the issue of HDL function as a potential therapeutic target, reproducible, 
standardized and high-throughput analytical methods are required.
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hoofdstuk 1 beschrijft het doel van de studies die deel uit maken van dit proefschrift. 
Het eerste deel betreft de rol van pro- en anti-atherogene (apo)lipoproteïnen in 
de ontwikkeling van hart- en vaatziekten en het voorspellen hiervan. Hier wordt 
ook cholesterylester transfer protein (CETP) en de rol van CETP remmers in het 
voorkomen van cardiovasculaire incidenten behandeld. In dit deel wordt ook de 
associatie geëvalueerd tussen door vetweefsel afgegeven hormonen, zogenaamde 
adipokines, en (sub)klinische atherosclerose.
In hoofdstuk 2 wordt een studie beschreven waarin we hebben bepaald welke 
lipoproteïne of apolipoproteïne parameter het ontstaan van een eerste cardiovas-
culair incident het beste voorspelt in de algemene bevolking. Om dit te bepalen 
werden verschillende parameters gemeten in het Prevention of Renal and Vascular 
end-stage Disease (PREVEND) cohort. De PREVEND studie is een grote populatie 
gebaseerde prospectieve studie, welke is opgezet om de rol van een verhoogde 
albumine excretie in de urine in de ontwikkeling van nier en hart- en vaatziekten te 
bepalen. We hebben gevonden dat alle door ons geteste pro- en anti-atherogene 
variabelen het voorkomen van eerste cardiovasculaire incidenten voorspelden. 
De associatie van de totaal cholesterol/ high density lipoprotein (HDL) cholesterol 
ratio en de apoB/apoA-I ratio was minimaal zo sterk als die van de verschillende 
individuele (apo)lipoproteïne maten. In een directe vergelijking van de totaal cho-
lesterol/HDL-cholesterol en de apoB/apoA-I ratio leek er een grotere hazard ratio 
te bestaan bij de apoB/apoA-I ratio; dit verschil verdween echter na correctie voor 
leeftijd en geslacht. Verdere correctie voor traditionele risicofactoren, triglyceri-
den en albuminurie en high sensitivity C-reactive protein verlaagden de hazard 
ratios van beide ratios slechts in geringe mate. Wij hebben geconcludeerd dat het 
voorkomen van een eerste cardiovasculair incident in de algemene bevolking even 
goed wordt voorspeld door de totaal cholesterol/HDL cholesterol ratio en de apoB/
apoA-I ratio. Verder suggereert deze studie dat het gebruik van een berekende 
waarde van low density lipoprotein (LDL) cholesterol geen toegevoegde waarde 
ten opzichte van totaal cholesterol en HDL cholesterol heeft in de voorspelling van 
cardiovasculaire incidenten.
hoofdstuk 3 is een review over cholesteryl ester transfer proteïne (CETP) en 
de farmacologische inhibitie hiervan. We beschrijven de functies van CETP en we 
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behandelen het cardioprotectieve effect van CETP remmers, een nieuwe klasse 
medicijnen. Het remmen van CETP geeft een forse verhoging van het HDL choles-
terol. Hoewel CETP remmers ook de hoeveelheid cholesterol in apoB-bevattende 
lipoproteïnen verlaagt, wordt door deze medicijnen in essentie bepaald of het ver-
hogen van HDL cholesterol op zich het cardiovasculaire risico verlaagt. De eerste 
CETP remmer die in fase 3 onderzoek is getest was torcetrapib[1]. In tegenstelling 
tot wat werd verwacht was er een toegenomen incidentie van cardiovasculaire 
incidenten in de met torcetrapib behandelde groep. Er is gesuggereerd dat een 
verhoging van de bloeddruk door torcetrapib het voordeel van een hoger HDL 
cholesterol en een lager LDL cholesterol teniet heeft gedaan. Sinds het falen van 
torcetrapib zijn of worden de CETP remmers anacetrapib, evacetrapib, dalcetrapib 
en het met de code aangeduide TA-8995 in klinische studies onderzocht. Deze 
middelen hebben in tegenstelling tot torcetrapib geen bloeddruk verhogend ef-
fect. De onderzoeken met dalcetrapib en evacetrapib zijn voortijdig gestaakt in 
verband met een gebrek aan effectiviteit [2-4]. De resultaten van de onderzoeken 
met anacetrapib en TA-8995 [5-7] zullen aantonen of het farmacologisch remmen 
van CETP nog als een reële optie kan worden beschouwd in het voorkómen van 
cardiovasculaire incidenten.
Het effect van verschillende CETP polymorfismen op de voorspelling van car-
diovasculaire incidenten komt aan bod in hoofdstuk 4. Gebruik makend van de 
data in de PREVEND studie hebben wij gevonden dat de incidentie van eerste car-
diovasculaire incidenten niet werd beïnvloed door Taq1B (rs708272) en -629C>A 
(rs1800775) genotypen. Deze polymorfismen beïnvloeden het plasma lipoproteïne 
spectrum op dusdanige wijze dat variaties in CETP die samengaan met hogere 
plasma CETP activiteit niet alleen leiden tot een lager HDL cholesterol maar ook 
kleinere HDL en LDL deeltjes veroorzaken [8]. Er werden geen significante inter-
acties gevonden tussen de totaal cholesterol/HDL cholesterol ratio en de apoB/
apoA-I ratio enerzijds en elk van de polymorfismen anderzijds op de incidentie van 
cadiovasculaire incidenten. Deze bevindingen suggereren dat risicovoorspellingen 
van cardiovasculaire incidenten in de algemene bevolking niet in belangrijke mate 
worden beïnvloed door deze veelvoorkomende variaties in CETP.
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hoofdstuk 5 beschrijft een prospectieve nested “case-control” studie onder 
219 mannen, waarvan 114 met nieuw vastgestelde hart- en vaatziekten, binnen 
het PREVEND cohort. Het doel van deze studie was om de associatie van het optre-
den van cardiovasculaire incidenten met plasma CETP massa en plasma cholesteryl 
ester transfer (CET) te vergelijken. Wij hebben gevonden dat plasma CET geas-
socieerd was met het optreden van cardiovasculaire incidenten, terwijl de CETP 
massa dit niet voorspelde. De associatie van plasma CET met het optreden van 
cardiovasculaire incidenten bleef statistisch significant na correctie voor de totaal 
cholesterol/HDL cholesterol ratio, body mass index, hypertensie, roken, plasma 
glucose, albuminurie en zelfs de plasma CETP concentratie. Dit suggereert dat 
het proces van cholesterylester transport, waarbij cholesteryl esters van HDL naar 
apoB-bevattende lipoproteïnen worden getransporteerd, belangrijker zou kunnen 
zijn dan de plasma concentratie van dit eiwit op zich voor het optreden van hart- en 
vaatziekten.
hoofdstuk 6 gaat over de associatie van de mate van subklinische atherosclerose 
met twee in vetweefsel geproduceerde hormonen (adipokinen), te weten leptine 
en adiponectine. Leptine heeft een aantal pro-atherogene effecten, waaronder het 
induceren van endotheel dysfunctie, het stimuleren van een inflammatoire reactie, 
oxidatieve stress, alsmede migratie, hypertrofie en proliferatie van gladde spiercel-
len in de vaatwand [9]. Adiponectine heeft daarentegen juist eigenschappen welke 
het optreden van atherosclerose kunnen tegengaan. Dit effect komt voort uit het 
remmen van de vorming van schuimcellen, de proliferatie en migratie van gladde 
spiercellen en door het blokkeren van de expressie van adhesie moleculen [10]. 
De concentratie van circulerend adiponectine is verlaagd bij obesitas en type 2 
diabetes mellitus. Een hoge leptine spiegel is een bekende risicofactor voor het 
ontstaan van cardiovasculaire incidenten bij mannen. Deze relatie neemt voor een 
aanzienlijk deel af wanneer rekening gehouden wordt met obesitas [11]. Adipon-
ectine is waarschijnlijk mild cardioprotectief [12,13]. Wij hebben 72 deelnemers 
bestudeerd met en 89 mensen zonder metabool syndroom. Als uitkomstmaat 
gebruikten we de intima media dikte van de arteria carotis (c-IMT) als maat voor 
subklinische atherosclerose. In dit transversale onderzoek zagen we een negatieve 
associatie van de adiponectine spiegel en een positief verband van de leptine/
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adiponectine ratio met c-IMT na correctie voor leeftijd en geslacht. Na verdere 
correctie voor de aanwezigheid van metabool syndroom verdween de associatie 
met de leptine/adiponectien ratio maar bleef de associatie met de adiponectine 
spiegel bestaan. Deze studie suggereert derhalve dat de leptine/adiponectine ratio 
mogelijk niet de voorkeur verdient in het bepalen van het risico op atherosclerose 
wanneer met conventionele risicofactoren rekening wordt gehouden.
In hoofdstuk 7 beschrijven we een “nested case-control” studie onder manne-
lijke deelnemers van het PREVEND onderzoek. In deze studie hebben we de voor-
spellende waarde van de leptine/adiponectine ratio ten opzichte van de plasma 
spiegels van leptine en adiponectine op zich voor het ontstaan van cardiovasculaire 
incidenten bepaald. Zowel plasma adiponectine en leptine als de ratio tussen beide 
voorspelde het optreden van een cardiovasculair incident. Na correctie voor con-
ventionele risicofactoren, plasma lipiden en albuminurie bleven de verbanden van 
leptine, adiponectine en de leptine/adiponectine ratio statistisch significant. Na 
verdere correctie voor insuline resistentie en C-reactief proteïne bleef alleen de 
leptine/adiponectine ratio geassocieerd met de kans op het voorkomen van een 
cardiovasculair incident. Wij hebben geconcludeerd dat de leptine/adiponectine 
ratio mogelijk de voorkeur verdient boven leptine en adiponectine op zich.
De ogenschijnlijke discrepantie tussen hoofdstuk 6 en 7 wat betreft de waarde 
van leptine/adiponectine ten opzichte van leptine en adiponectine op zich kan ten 
dele worden geweten aan verschillen in studieopzet. De eerste studie is transver-
saal van opzet en gebruikt een subklinische surrogaat marker als eindpunt, terwijl 
de tweede studie een prospectieve studie was met een klinisch eindpunt. Verder 
bestond de laatste studie alleen uit mannen en hebben we in deze studie voor 
meerdere factoren gecorrigeerd.
Het tweede deel van dit proefschrift richt zich op de effecten van lipiden verla-
gende therapieen op verschillende (apo)lipoproteïnen.
In hoofdstuk 8 beschrijven we een studie welke is verricht in het diabetes ator-
vastatin lipid intervention (DALI) studie cohort. Deze populatie omvat 217 matig 
hypertriglyceridemische patiënten met type 2 diabetes mellitus. We hebben de 
relatie tussen LDL cholesterol, berekend met de Friedewald formule, en non-HDL 
cholesterol met de apoB concentratie voor en tijdens statine therapie bestudeerd. 
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Wij hebben vastgesteld dat er sprake is van een verschuiving is van de regressielij-
nen van de relatie tussen LDL cholesterol en non-HDL cholesterol met apoB tijdens 
behandeling met atorvastatine. Tijdens behandeling correspondeerden waardes 
van zowel LDL cholesterol als non-HDL cholesterol met hogere apoB waarden dan 
voorafgaand aan atorvastatine toediening. Dit zou kunnen impliceren dat er sprake 
is van meer kleine LDL deeltjes of dat er sprake is van minder grote “very low density 
lipoproteïne” (VLDL) deeltjes of VLDL “remnants” tijdens behandeling met een sta-
tine. Als rekening wordt gehouden met de voorspellende waarde van apoB spiegels 
tijdens behandeling voor het opnieuw optreden van cardiovasculaire incidenten en 
als de toegevoegde klinische waarde van agressieve lipiden verlagende therapie in 
ogenschouw wordt genomen[14,15] pleiten de gegevens uit deze studie voor het 
gebruik van apoB als therapeutisch doel tijdens behandeling met een statine.
hoofdstuk 9 beschrijft een andere studie in het DALI-cohort. Gezien de pro-
atherogene rol van cholesterolrijke “remnant” deeltjes [16] en van kleine LDL 
deeltjes [17] hebben we de veranderingen in LDL grootte en lipoproteïne “rem-
nants” tijdens behandeling met atorvastatine bestudeerd. Er bleek een duidelijke 
vermindering van het “remnant” cholesterol op te treden tezamen met een da-
ling in de hoeveelheid triglyceriden. Atorvastatine had echter geen invloed op de 
gemiddelde piek diameter van LDL. Hierdoor bleef het aandeel deelnemers met 
overwegend klein LDL (ook wel bekend als patroon B) gelijk. Samenvattend hebben 
we gevonden dat atorvastatine het nuchtere “remnant” cholesterol grotendeels 
normaliseert, de hoeveelheid cholesterol in alle LDL subfracties vermindert, maar 
geen beduidend effect heeft op LDL-subfractie distributie. Beide voorgaande 
hoofdstukken samennemend zou de verschuiving van de relatie tussen non-HDL 
cholesterol en apoB verklaard kunnen worden vanuit een met name grote afname 
in cholesterolrijke VLDL “remnants” zonder dat daarbij een effect optreedt bij de 
LDL deeltjes grootte. De discordantie van de verschuiving in de relatie tussen LDL 
cholesterol en apoB zonder dat daarbij de LDL deeltjes grootte verandert zou deels 
verklaard kunnen worden door een verminderde accuratesse van de Friedewald 




hoofdstuk 10 betreft een studie over apolipoproteïne M (apoM). ApoM wordt 
met name in de lever en in de nier tot expressie gebracht. In humaan plasma is 
apoM met name geassocieerd met de HDL fractie en in mindere mate met LDL. In 
muismodellen lijkt apoM het ontstaan van atherosclerose te vertragen door het fa-
ciliteren van de vorming van preβ-HDL en cel cholesterol efflux naar HDL, waarmee 
vermoedelijk het vormen van atherosclerotische laesies wordt geremd [19]. Verder 
blijkt er uit muismodellen dat het anti-atherogene effect van apoM verminderd lijkt 
te worden indien er sprake is van LDL-receptor deficiëntie. Dit kan mogelijk worden 
toegeschreven kan worden aan het pro-atherogene effect van het verhogen van 
VLDL en LDL. Bovendien is er sprake van een verhoging van de apoM spiegel in 
muismodellen van een LDL-receptor deficiëntie [20]. Ondanks een positieve relatie 
tussen apoM en LDL cholesterol blijft het onduidelijk of de LDL-receptor bijdraagt 
aan de regulatie van apoM. In hoofdstuk 10 hebben wij aangetoond dat behandeling 
met simvastatine de apoM concentratie in plasma verlaagt, hetgeen strookt met 
experimentele bevindingen dat LDL-receptor expressie bijdraagt aan de regulatie 
van apoM. Opvallend was dat de combinatie van simvastatine met bezafibraat het 
plasma apoM niet verlaagde. Daarnaast verdween de normaal gesproken positieve 
correlatie tussen apoM en LDL cholesterol tijdens behandeling met de statine-
fibraat combinatie, terwijl apoM in die situatie positief gecorreleerd was met HDL 
cholesterol en apoA-I. Omdat apoM snel uitgewisseld wordt tussen verschillende 
lipoproteïnen in vivo [20], zou dit fenomeen verklaard kunnen worden door een 
verschuiving in de apoM verdeling tussen apoB bevattende lipoproteïnen en HDL. 
Alles samengenomen lijkt het mogelijk dat een verminderend effect van statines op 
totaal plasma apoM tijdens LDL verlagende therapie tegengewerkt wordt door een 
HDL en apoA-I verhogend effect tijdens therapie met fibraten.
hoofdstuk 11 beschrijft de relatie van apoM met proproteine subtilisine-kexine 
type 9 (PCSK9) spiegels. PCSK9 speelt een belangrijke rol in het bewegen van de 
LDL receptor richting intracellulaire afbraak. de activiteit van PCSK9 leidt hierdoor 
tot verhoogde plasma LDL cholesterol spiegels. We zagen dat de spiegels van 
apoM en PCSK9 positief gecorreleerd zijn in slanke individuen. In mensen met 
overgewicht of obesitas kon een dergelijk verband niet worden aangetoond. We 
hebben geconcludeerd dat in slanke personen PCSK9 van invloed zou kunnen zijn 
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op het metabolisme van apoM. Onze bevindingen ondersteunen het idee dat de 
LDL receptor pathway betrokken zou kunnen zijn bij het metabolisme van apoM. 
Het mechanisme dat verantwoordelijk is voor de invloed van overgewicht op dit 
effect is niet bekend, maar verschillende effecten van insuline op apoM en PCSK9 
zouden hierbij betrokken kunnen zijn [21-24].
toekomst PersPeCtief
de rol van apolipoproteïnen in cardiovasculair risicomanagement
Op dit moment ligt de focus van lipiden management in de klinische praktijk op 
plasmaconcentraties van (apo)lipoproteïnen of lipoproteïne ratios en het hiervan 
afgeleide risico op cardiovasculaire incidenten. (Apo)lipoproteïne spiegels worden 
dan als specifieke behandeldoelen gesteld. Mogelijk is er een plaats voor een meer 
integrale benadering van management van lipoproteïnen. Vanuit epidemiologisch 
perspectief lijken modellen voor het voorspellen van het risico op cardiovasculaire 
incidenten niet te verbeteren door het gebruik van apolipoproteïne spiegels naast 
of in plaats van lipoproteïne spiegels. [25-27]
Dit strookt met onze bevindingen dat de totaal cholesterol/HDL-cholesterol 
ratio en de apoB/apoA-I ratio cardiovasculaire incidenten even goed voorspellen. 
Of het toevoegen van triglyceriden aan deze modellen voordelen biedt is een 
onderwerp van discussie; er zijn experts die zelfs hebben voorgesteld dat er geen 
noodzaak is om triglyceriden routinematig te bepalen [28].
Vanuit klinisch perspectief is de classificatie van meer specifieke dyslipopro-
teïnemische fenotypes belangrijk. In dit opzicht zou het meten van triglyceriden 
en apoB van belang kunnen zijn voor een nauwkeurige classificatie van de dysli-
pidemie [29]. Gegeven dat ieder apoB bevattend lipoproteïne deeltje één apoB 
molecuul bevat is de plasma apoB spiegel een maat voor het aantal partikels, 
in plaats van de hoeveelheid cholesterol in deze apoB-bevattende deeltjes. Dat 
laatste wordt gemeten als het non-HDL-cholesterol. Door het definiëren van het 
specifieke dyslipoproteïnemische fenotype zou een aanpak die meer gebaseerd 
is op de onderliggende (patho)fysiologische afwijking kunnen worden gebruikt. 
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Hierdoor zou het mogelijk gemaakt kunnen worden om behandeldoelen te stel-
len gebaseerd op de specifieke lipoproteïneafwijking. Er zijn zes belangrijke apoB 
dyslipoproteïnemieën welke geclassificeerd worden op basis van welk of welke 
van de lipoproteïnedeeltjes, chylomicronen, VLDL, VLDL “remnants” of LDL, ver-
hoogd zijn. Veranderingen in deze lipoproteïnen hebben elk een kenmerkende 
pathofysiologische achtergrond [30]. De atherogeniciteit van deze verschillende 
fenotypes is mogelijk zeer verschillend. Een benadering om een onderscheid te 
kunnen maken tussen de verschillende apoB dyslipoproteïnemieën op basis van 
apoB, triglyceriden en totaal cholesterol is recent voorgesteld [29]. Op dit moment 
is er nog geen onderzoek dat een klinisch voordeel aantoont van deze aanpak op 
basis van deze fenotypische karakterisering. Er is meer onderzoek nodig om vast te 
stellen of deze aanpak resulteert in een betere voorspelling van klinisch manifeste 
atherosclerotische aandoeningen. Daarnaast is het nog onduidelijk of dit leidt 
tot een betere beslissing wat betreft de noodzaak tot, het type en de intensiteit 
van een therapeutisch regime om het risico op cardiovasculaire aandoeningen te 
verlagen.
Er bestaat een discussie over het nut van het meten van lipoproteïne subfrac-
ties [31]. Een verhoogde concentratie kleine LDL deeltjes is geassocieerd met een 
verhoogd risico op cardiovasculaire incidenten en is zelfs beter voorspellend voor 
het risico op cardiovasculair risico dan de LDL cholesterol concentratie [32,33]. In 
een prospectieve studie bij vrouwen werd geen toegevoegde waarde gevonden 
van LDL subfractie metingen t.o.v. een model met totaal cholesterol/HDL choleste-
rol [34]. Of dit ook voor mannen geldt is nog niet duidelijk. Van belang is ook dat 
het meten van het zogenaamde “remnant cholesterol” oftewel het cholesterol in 
triglyceride-rijke “remnant” deeltjes bijdraagt aan het voorspellen van cardiovas-
culaire incidenten [16,35]
De bruikbaarheid van HDL subfracties staat ook niet onomstotelijk vast. Er zijn 
studies waarin geen effect wordt gevonden van het meten van HDL subfractie 
distributie [36]. In andere studies bleek een kleine HDL grootte voorspellend voor 
het optreden van cardiovasculaire incidenten [37,38]. In een van deze studies 
verdween deze associatie grotendeels indien traditionele lipidenwaarden aan het 
model werden toegevoegd [37].
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HDL cholesterol versus HDL functionaliteit
Toen voor het eerst werd vastgesteld dat een lage concentratie HDL cholesterol 
frequent voorkomt bij mensen met hart- en vaatziekten is gepostuleerd dat HDL 
in staat is om het verwijderen van cholesterol uit de vaatwand te stimuleren en 
daardoor vermoedelijk in staat is om tegen atherosclerotische manifestaties te 
beschermen [39]. Recentelijk is bekend geworden dat HDL een scala aan functies 
vervult: het vervult een sleutel rol in het “reverse cholesterol transport”. Hierbij 
faciliteert HDL de efflux van cholesterol van macrofagen, waarna cholesterol wordt 
getransporteerd naar de lever voor verdere metabolisering en excretie via de gal. 
In een recente studie was de HDL cholesterol efflux capaciteit vanuit macrofagen 
omgekeerd geassocieerd met het optreden van atherosclerotische cardiovasculaire 
incidenten, zelfs na correctie voor de HDL cholesterol concentratie en het aantal 
HDL deeltjes [40]. Een andere prospectieve studie heeft eveneens laten zien dat 
efflux vanuit een macrofagen celsysteem naar apoB-depleet plasma omgekeerd ge-
associeerd was met het optreden van cardiovasculaire incidenten [40]. Dit verband 
bleef bestaan wanneer gecorrigeerd werd voor HDL-cholesterol of apoA-I [40]. In 
een andere studie daarentegen waarin efflux werd gemeten vanuit fibroblasten 
naar plasma werd een dergelijke relatie niet gevonden [42]. Daarnaast werd in een 
prospectieve studie gevonden dat de cholesterol efflux vanuit macrofagen naar 
apoB-depleet serum, paradoxaal geassocieerd was met een verhoogd risico op 
cardiovasculaire incidenten [43]. Opmerkelijk genoeg werd in een recente studie 
onder niertransplantatie patiënten gevonden dat cholesterol efflux vanuit macro-
fagen voorspellend was voor falen van het transplantaat onafhankelijk van HDL 
cholesterol concentratie, maar niet voor cardiovasculaire incidenten [44].
HDL heeft een aantal andere atheroprotectieve functies [45,46]. HDL is in 
staat om de oxidatie van LDL deeltjes te remmen waardoor deze deeltje minder 
atherogeen worden [47-49]. Verder vertoont HDL anti-inflammatoire functies door 
de afgifte van inflammatoire cytokines en vasculaire cel adhesie moleculen te rem-
men. Dit is een belangrijk aspect want inflammatie vervult een sleutelrol bij het 
ontstaan van atherosclerose [48]. HDL heeft ook anti-trombotische functies zoals 
blijkt uit het inhiberen van plaatjesaggregatie en het stimuleren van de productie 
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van prostacyclines en stikstofoxide, hetgeen leidt tot een verminderde lokale proli-
feratie van gladde spiercellen in de vaatwand [48, 50].
De huidige stand van zaken is dat gerandomiseerde en gecontroleerde studies 
en meta-analyses van HDL cholesterol verhogende medicamenten, waaronder 
CETP-remmers en nicotinezuur, de hypothese dat het verhogen van het HDL cho-
lesterol op zich als therapeutisch doel moet worden beschouwd nog niet hebben 
kunnen ondersteunen [51-53]. De CETP remmers, anacetrapib en TA-8995, hebben 
naast een robust effect op de HDL cholesterol concentratie een beduidend LDL 
cholesterol verlagend effect. Als deze middelen het cardiovasculair risico blijken te 
verlagen kan niet worden uitgesloten dat dit effect aan het verlagen van het LDL in 
plaats van het verhogen van het HDL moet worden toegeschreven.
Een centrale plaats in toekomstig onderzoek zal moeten worden vervuld door 
het bepalen of het meten van verschillende functies van HDL leidt tot een betere 
voorspelling van cardiovasculair risico vergeleken met het meten van HDL choles-
terol concentraties of het meten van HDL subfracties. Om de bruikbaarheid van het 
meten van HDL functie als mogelijk behandeldoel vast te stellen is het noodzakelijk 
dat er reproduceerbare en gestandaardiseerde analysemethoden beschikbaar 
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